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ABSTRACT 
The mutations E361G and E99K in the cardiac actin gene cause dilated 
and hypertrophic cardiomyopathy respectively. Transgenic mouse models have 
been developed that over-express these mutations in their hearts. Mutant 
protein was expressed at 50% of to tal actin. Thin filaments were reconstituted 
with mouse actin, human cardiac tropomyosin and troponin, and studied by in 
vitro motility assay.   
Phosphorylated E361G and non-transgenic thin filaments were 
indistinguishable at all Ca2+-concentrations (EC50 NTg/E361G =1.07±0.11, 
p=0.59). E361G-actin reconstituted with dephosphorylated troponin had a lower 
Ca2+-sensitivity than non-transgenic (EC50 NTg/E361G = 0.47±0.09, p=0.01). 
When we compared E361G thin filaments containing phosphorylated and 
dephosphorylated troponin, the Ca2+-sensitivity was indistinguishable  (EC50 
E361G/E361G.dp = 1.03±0.08, p=0.74). This is in contrast to non-transgenic 
actin, where the EC50 of the phosphorylated thin filament was 3-times greater 
than dephosphorylated (p=0.003). The major functional change induced by the 
E361G mutation was therefore the abolition of the response to troponin 
phosphorylation. This would blunt the inotropic response in vivo and be the 
cause of the E361G DCM phenotype. The in vitro motility technique was 
extended to measure α-actinin binding affinity. The E361G mutant actin had a 
5.3-fold reduced affinity for α-actinin, indicating a weaker attachment of 
filaments at the Z-line. 
Investigation of the DCM-causing mutation TNNC1 G159D in troponin 
isolated from human muscle showed a higher Ca2+ sensitivity with native 
phosphorylation levels (EC50 NF/G159D = 4.67±1.87) and upon 
dephosphorylation (EC50 NF/G159D = 1.77±0.29). G159D thin filaments also 
blunted the change in Ca2+-sensitivity when dephosphorylated (EC50 
G159D/G159D.dp =1.24±0.17). 
The E99K mutation produced a strikingly different pattern of results to 
DCM mutations of an increased Ca2+-sensitivity and faster cross-bridge cycling 
rate, with phosphorylated (EC50 NTg/E99K = 2.54±0.64, p=0.07) and 
dephosphorylated troponin (EC50 NTg/E99K =1.2). The E99K mutation also 
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produced a reduced but not completely suppressed response to troponin 
phosphorylation (EC50 E99K/E99K.dp = 1.14±0.06, p=0.12). 
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Time: 
1. INTRODUCTION 
 
1.1 Cardiac Physiology  
The cardiovascular system is composed of two major circulatory systems: 
the pulmonary system (pumps blood from the right side of the heart to the 
lungs), and the systemic system (pumps blood from the left side of the heart to 
the rest of the body). The heart is divided into four chambers: the right and left 
atria and the right and left ventricles. The upper two are the atria and the lower 
chambers are the ventricles. The sequence of events that occur when the heart 
beats is referred to as the cardiac cycle (Figure 1.1). There are two phases: 
diastole, where the ventricles are relaxed and fill with blood, and systole, where 
the ventricles contract and blood is ejected from the ventricles.  
 
Figure 1.1 Pressure and Volume Changes during a Cardiac 
Cycle 
 
 
 
 
 
 
 
  
 
 
(A): Plot of left ventricular volume (LVV), left ventricular pressure (LVP), left atrial pressure 
(LAP) and aortic pressure (AoP) as a function of time. (B): A ‘pressure-volume’ loop for one 
cardiac cycle, the cycle proceeds in an anti-clockwise direction (Lionel, 2005). 
 
The cardiac cycle can be divided further into four phases: (a) ventricular 
filling, (b) isovolumetric contraction, (c) ejection (systole), (d) isovolumetric 
relaxation (Figure 1.1b). Point A is at the end of diastole and represents the 
end-diastolic pressure and maximum end-diastolic volume for the ventricle. As 
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the ventricle begins to contract (A - B), the LVP increases but the LV remains 
the same. When the LVP exceeds the aortic diastolic pressure, the ejection 
phase (B - C) begins. The LV volume decreases as the LVP increases at 
almost constant pressure and then decreases as the ventricle begins to relax 
(point C). When the LVP falls below the LAP (point D), the mitral valve opens 
and the ventricle fills to reach the maximum end-diastolic pressure at phase A 
(Wilcken, 2003). 
 
1.2 The Cardiac Myocyte Structure 
 Cardiac myocytes are the contractile cells of the heart and constitute 
about 75% of the ventricular mass. They are large elongated cells, 
approximately 100-120µm long and 20-35µm wide (Sugden et al., 2003). The 
close attachment of myocytes to their neighbours and also to the extra cellular 
matrix allows for the efficient transmission of force. Each individual myocyte 
makes contact with approximately 10 adjacent myocytes, through a 
characteristic area of the plasma membrane called the intercalated disc. Gap 
junctions and adherens junctions on the surface of the intercalated disc allow 
ions to pass through and electrical impulses to pass between myocytes (Figure 
1.2 A and B). 
 
Figure 1.2 Cardiac Muscle and an Isolated Myocyte  
 
 
 
 
 
 
 
 
 
[A] Cardiac myocytes are cut in longitudinal section showing the striated appearance.  
Intercalated discs can also be seen. [B] An isolated rat ventricular myocyte. The myofibrils have 
been visualised by immunostaining of α-actinin and viewed by confocal microscopy (Severs, 
2000). 
Myocyte Intercalated 
discs 
A B 
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It has been known for some decades that the contractile apparatus of 
muscle cells are highly ordered, and contraction involves the sliding of the thick 
and thin filaments of the sarcomere (Huxley and Hanson, 1954). The alignment 
and overlap of thick and thin filaments gives the myofibril its striated 
appearance. Figure 1.3 illustrates the structure of the sarcomere. Thick 
filaments consist mainly of the protein myosin-II (named myosin for the purpose 
of this thesis). Thin filaments consist of a helical polymer of approximately 300 
globular actin subunits, in association with the regulatory proteins tropomyosin 
and the troponin complex. Thin filaments are linked at the Z-line, which is 
mainly composed of the actin cross-linking protein α-actinin. The Z lines are 
associated with T-tubules and costameres. The M line lies at the centre of 
sarcomere and contains the protein myomesin (crosslinks thick filaments to 
maintain them in regular array). Titin is also present in this area, connecting the 
Z-line to the M-line in the sarcomere and contributing to the passive stiffness of 
the muscle (Severs, 2000). 
 
Figure 1.3 Structure of the Sarcomere 
 
 
 
 
 
 
 
 
 
 
 
 
 
[A] Thin section electron micrograph showing the structure of cardiac muscle myofibrils. The 
sarcomeres of two myofibrils are shown with a row of mitochondria between. Note the greater 
concentration of mitochondria with cardiac muscle. [B]: Representation of the arrangement  of 
the thick and thin filaments in relation to the striated pattern shown in [A]. Figure kindly provided 
by Prof. Nick Severs (Imperial College London). 
A 
B 
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Sarcomere length 
Much of our understanding of the mechanism of muscle contraction has 
come from biochemical, mechanical and structural studies performed over 
several decades since the 1950s, during which methods for isolating specific 
muscle proteins were developed as well as the methods for measuring their 
specific properties (Huxley and Hanson, 1954, Huxley, 1957, Eisenberg and 
Moos, 1968, Weeds and Lowey, 1971, Lymn and Taylor, 1971b, Rayment et 
al., 1993b, Kabsch et al., 1990). Thick and thin filaments slide past each other 
due to the force generated when myosin heads interact with F-actin. This 
interaction is due to conformational changes in the acto-myosin cross-bridge 
that is coupled to ATP hydrolysis in the myosin head. 
The isometric force produced by a muscle depends upon the sarcomeric 
length. Optimal force is produced at 2-2.25µm, where the overlap of thick and 
thin filaments is such that all myosin cross-bridges can interact with actin 
(Figure 1.4, point 2-3). In the heart, the sarcomere is optimally stretched at 2.1 
µm at the end of diastole and shortens to 1.6µm during systole. The increase in 
stretch during diastole produces an increase in the force of the next contraction. 
In dilated cardiomyopathy (DCM), sarcomeres may be stretched beyond 2.3µm 
which reduces the force of contraction (Sugden et al., 2003). 
 
Figure 1.4 The Length-Tension Relationship In Cardiac Muscle 
 
 
 
 
 
 
 
 
 
 
 
 
 
[A]: Diagram of the tension-sarcomere length relationship.  [B]: Schematic representation of 
myofilament sliding. The range of sarcomere lengths during a normal cardiac cycle is shown in 
blue. Figure based on a diagram from (Gordon et al., 1966). 
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1.3 Actin: Structure and Function 
The sequence of actin is amongst the most conserved of all proteins. It 
was first discovered by Straub in an extract of muscle tissue (Straub, 1942) and 
has a variety of structural and motile functions in the cytoplasm. Monomeric 
actin (G-actin) polymerises under physiological salt concentrations to form F-
actin. Actin performs many biological functions in the filamentous form, 
including muscle contraction, cell motility, morphological changes, cell division 
and intracellular movements (Hennessey et al., 1993). Although not essential 
for contractile function, all actins undergo post-translational modifications, 
including the methylation of His73 and the modification of the N-terminus by 
removal of two residues followed by acetylation of the new N-terminus (Pollard 
and Cooper, 1986, Sheterline et al., 1998). 
Actin filaments are anchored at the Z-line by α-actinin, which has distinct 
binding sites on adjacent actin monomers within residues 112-125 and 360-372 
(McGough et al., 1994, Broderick and Winder, 2005, Borrego-Diaz et al., 2006). 
The anti-parallel cross-linking of actin with α-actinin forms the Z-disc and allows 
force to be propagated along the myofibril. The opposite orientation of actin on 
either side of the Z line is necessary for the sliding filaments.  
The structure of G-actin was first published as a complex with DNase I in 
1990 using X-ray crystallography (Kabsch et al., 1990). Several structures have 
been reported since then in other complexes (Schutt et al., 1993, McLaughlin et 
al., 1993). Otterbein et al. have most recently published a crystal structure of 
uncomplexed actin in the ADP state (Otterbein et al., 2001). The actin molecule 
has a maximum dimension of 9-10nm and consists of 2 domains, the smaller of 
which contains both N and C termini (Holmes et al., 1990). The G-actin crystal 
structure reported by Kabsch et al. revealed that the actin monomer could be 
further divided into 4 sub domains, the inner domains 3 and 4 and outer 
domains 1 and 2 (Figure 1.5).  
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Figure 1.5 Molecular Model of the Actin Monomer  
 
 
 
 
 
 
 
 
 
 
 
 
Ribbon representation of the structure of uncomplexed actin (1J6Z.pdb file). Subdomain 1 is 
shown in blue, subdomain 2 in gold, subdomain 3 in green, and subdomain 4 in red. ADP is 
shown in red. Molecular graphic image was drawn from atomic coordinates published by 
(Otterbein et al., 2001), using the USSF Chimera package (Pettersen et al., 2004). 
 
ATP or ADP and Ca2+ or Mg2+ bind between the 2 domains of the actin 
monomer. The inner and outer domains are linked by two polypeptide chains 
(Kabsch et al., 1990). ATP hydrolysis may cause a conformational change in 
the monomer, since slight structural differences are apparent between ADP-
actin (Otterbein et al., 2001) and ATP-actin (bound to DNase1) (Kabsch et al., 
1990). In the same year as the G-actin crystal structure was proposed, a 
structure of the F-actin helix at the atomic level was derived by fitting a helix of 
G-actin structures to low resolution X-ray fibre diffraction patterns of the filament 
(Holmes et al., 1990). The structure was further refined by Lorenz et al. (Lorenz 
et al., 1993, Lorenz et al., 1995). F-actin has 13 molecules arranged as a 
double-helix which repeats every 36nm (Figure 1.6). The rise in subunit is 
2.75nm (Geeves and Holmes, 1999). Along each of the helices, the actin 
monomers are spaced by 5.5nm.  
DNAase I 
binding loop 
N 
Subdomain 3 
Subdomain 4 Subdomain 2 
Subdomain 1 
C 
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Figure 1.6 Molecular Model of F-Actin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The F-actin filament, as established from the helical parameters of the standard Homes model 
(Holmes et al., 1990). Figure prepared using the USSF Chimera package (Pettersen et al., 
2004). 
 
The structure of F-actin derived by Holmes et al. (Holmes et al., 1990) 
gives a good indication of the monomers orientation within the filament. F-actin 
is highly flexible and each monomer can make contact with 4 other monomers 
in the helix (dos-Remedios and Moens, 1995). Subdomains 1 and 2 are 
orientated on the outside and subdomains 3 and 4 are in the centre (Rayment 
et al., 1993a). Interactions occur both between strands and along the actin 
filament in each strand. The highly flexible nature of both G-actin and F-actin is 
36nm 
5.5nm 
2.75nm 
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important during its interaction with myosin and subsequent force generation 
along the actin filament, as well as in regulation. 
 
1.4 Myosin Structure  
Myosin is probably the most important molecule that binds to actin, 
forming the motor essential for muscle contraction. Ventricular human cardiac 
thick filaments are mainly composed of b-myosin II with 5% α-myosin II. Myosin 
belongs to a large family of motor proteins and consists of two structurally and 
proteolytically defined domains (Weeds and Lowey, 1971): sub fragment 1 (S1), 
which is a globular domain that contains the motor domain, and the rod which is 
a long α-helix. The rod domains form a coiled-coil dimer that makes up the shaft 
of the myosin filament with the S1 domains protruding (Figure 1.7).  
 
Figure 1.7 Structure of the Myosin Molecule 
 
 
 
 
 
 
 
Figure obtained from (Voet et al., 1995). Proteolysis can occur at the S1-S2 junction to yield S1 
and the rod, or the LMM-S2 junction to yield HMM and LMM. 
 
S1 comprises the first 843 residues of the heavy chain together with two 
light chains (essential and regulatory of 19KDa and 25KDa each). This domain 
forms the motor domain that drives muscle contraction. Tryptic cleavage has 
resulted in the identification of 3 sub-domains of S1. These included the N-
terminal 25kDa nucleotide domain (Szilagyi et al., 1979), the central actin-
binding 50kDa domain, and the C-terminal 20kDa actin-binding domain (Mornet 
et al., 1981, Sutoh, 1982). The C-terminal end of the heavy chains forms two 
long α-helices that are wound around together in a coiled-coil, forming the shaft 
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of the thick filament (S2). The S2 domain of the myosin molecule is linked to the 
LMM domain that forms the bipolar thick filaments (Spudich, 2001). 
In the crystal structure, S1 appears as a globular domain with a long 
single α-helix forming a ‘tail’. The two light chains are bound to the tail, 
stabilising the α-helix and forming a ‘lever arm’. The current hypothesis for the 
mechanism of force generation by actin-myosin-ATP involves the rotation of the 
lever arm relative to the globular domain (Geeves and Holmes, 1999). During 
ATP-binding and subsequent ATP-hydrolysis, the nucleotide binding site of S1 
undergoes subtle conformational changes and the lever arm is believed to 
swing through an angle of ~90°. The rotation of the lever arm that is thought to 
occur in force production is illustrated in Figure 1.8.  
 
Figure 1.8 Actomyosin Interaction Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three-dimensional atomic model of F-actin combined with myosin subfragment 1. From Geeves 
et al. (Geeves and Holmes, 1999). The ribbon on the left corresponds to myosin S1; an F-actin 
double helix consisting of 5 actin subunits is shown on the right. Figure A illustrates the lever 
arm’s position in the pre-power-stroke state of actomyosin. Figure B illustrates the lever arm’s 
position in the post-power-stroke state of actomyosin.  
CHAPTER 1 
 28
The solubility of S1 and HMM has enabled their use for in vitro 
investigations of contractile proteins. Several functional assays have been 
developed that recreate the basic unit of contractile muscle and allow the action 
of the myosin motor to be studied. The in vitro motility assay devised by Kron 
and Spudich (Kron and Spudich, 1986, Kron et al., 1991) is one such valuable 
technique, and allows actin-myosin interactions to be studied at the molecular 
level. Rabbit fast skeletal muscle HMM can act as a motor on silicone-treated 
glass, with actin labelled with TRITC-phalloidin on the surface (Marston, 2003). 
The movement of actin filaments over HMM is initiated by addition of ATP, and 
can be visualised by epifluorescence microscopy and detected by a s ilicon-
intensified video camera. This assay can measure the unloaded shortening 
velocity of muscle. The movement of actin over myosin is random but occurs at 
a uniform speed (Marston, 2003). Experiments that have used pure populations 
and mixtures of fast skeletal myosin, cardiac myosin, phosphorylated and 
unphosphorylated smooth muscle myosin, have shown that actin filament 
velocity is proportional to actin-activated ATPase activities of the myosins 
(Sheetz and Spudich, 1983) and the unloaded shortening velocity of muscle 
(Malmqvist et al., 2004). 
 Another in vitro technique, the “optical tweezer” or “optical trap”, has 
allowed measurements of the force and step size of single myosin molecules 
(Sleep et al., 2006). It uses the effect by which a laser beam focused by the 
strong objective lens of a microscope can trap microscopic objects in an energy 
well. A single actin filament can be stretched between two plastic beads held in 
optical tweezers, and the myosin can then bind to the filament allowing its 
working stroke to be detected from positions of the two trapped beads. It is 
therefore possible to recreate under the microscope the basic unit of contractile 
muscle and investigate how a single myosin molecule responds to an external 
force applied to actin via the optical trap. Measurements suggest that the 
displacement of actin from a single myosin molecule is approximately 10nm 
(Sleep et al., 2006).  
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1.5 The Mechanism of Contraction: The Cross-bridge Cycle  
Following the proposal of the sliding filament theory of muscle contraction 
(Huxley and Hanson, 1954), A.F Huxley devised mathematical equations for the 
operation of multiple independent force generations, later identified as myosin 
“cross-bridges” that generate the sliding forces between actin and myosin 
filaments (Huxley, 1957). This causes the contraction of muscle. Eisenberg and 
Moos studied the kinetics of activation of myosin- ATPase by actin (Eisenberg 
and Moos, 1968). Subsequent test-tube enzyme kinetic studies of purified actin 
and S1 showed the kinetic pathway of actin activation of myosin ATPase, which 
was interpreted as being the biochemical equivalent of the structural cycle 
(Lymn and Taylor, 1971a). 
Our current understanding of how the actin activated enzymatic 
breakdown of ATP drives the cross-bridge cycle is shown in Figure 1.9. ATP 
binding to myosin heads either at rest (c) or when myosin heads are under a 
load (b), results in conformational changes occurring which cause the very rapid 
(500sec-1) and almost irreversible dissociation of myosin from actin (Geeves 
and Holmes, 2005). This detachment from actin is followed by the hydrolysis of 
ATP to ADP and Pi, which remain tightly bound to the myosin head (e). 
Hydrolysis is rapid (10sec-1), reversible (Keq = 10), and is accompanied by a 
major conformational change (the ‘priming’ stroke) (Geeves and Holmes, 1999). 
The myosin-ADP-Pi complex can bind to actin and this is followed by the 
powerstroke, in which the lever arm of myosin moves and Pi is released. If the 
muscle is placed under load, the movement satisfies an elastic element in the 
cross-bridge and produces force. Isometric crossbridges release ADP slowly. If 
the muscle is unloaded, the power stroke causes the rapid release of ADP. This 
results in the sliding of thin filaments past thick filaments, which causes the 
sarcomere to shorten and force to be generated. ATP then binds and 
dissociates actin from myosin.  
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Figure 1.9 Myosin Cross-bridge Cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
Actin monomers are shown in orange, the myosin head in green, light chains in yellow, myosin 
S2 and the thick filament in black. ATP/ADP is shown in blue/pink, and Pi is pink/yellow. Figure 
provided by S.Weiss and M.A Geeves, (www.kent.ac.uk/geeves/Research). 
 
1.6 The Regulation of Cardiac Contraction  
1.6.1 Excitation-Contraction (EC) Coupling  
The Ca2+ ion is the physiological regulator of muscle contraction (Ebashi 
et al., 1968, Yasui et al., 1968, Fuchs and Briggs, 1968). EC coupling refers to 
the coupling of the electrical excitation of the heart to the production of 
contractility by Ca2+ ions (Sugden et al., 2003). It involves the interaction of a 
number of proteins involved in Ca2+ homeostasis. Within the cell, each myofibril 
is surrounded by an intracellular membranous structure called the sarcoplasmic 
reticulum (SR). At multiple sites, swellings called junctional SR cisternae form, 
which press tightly against peripheral plasma membrane and invaginations of 
the surface called transverse tubules (T-tubules). During diastole, Ca2+ is 
sequestered by calsequestrin within the junctional SR. Depolarisation of the cell 
membrane causes the influx of Ca2+ through L-type Ca2+ channels of the T-
tubules and plasma membrane. This triggers the opening of Ca2+ release 
channels in the junctional SR membrane  (Ca2+-induced Ca2+-release), and 
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Ca2+ is released into the cytoplasm (Severs, 2000). The release of Ca2+ from 
the SR activates the contractile apparatus of the sarcomere (Figure 1.9). An 
increase in the Ca2+ concentration causes an increase in the force of 
contraction. The regulatory effect of Ca2+ on isometric force is shown in Figure 
1.10, where contraction of demembranated cells requires only ATP as a 
substrate and Ca2+ as an activator. The Ca2+ switch of muscle is located in the 
thin filaments. 
 
Figure 1.10 Ca2+ Sensitivity of Isometric Force 
 
 
 
 
 
 
 
 
 
 
The Ca2+ sensitivity of isometric force, as measured in chemically skinned cardiac myocytes 
from human ventricular muscle (van der Velden et al., 1998). Force-pCa relations have been 
fitted to a Hill Equation. 
 
1.7 Contraction and Regulation by Thin Filaments 
Thin filaments of the sarcomere are composed of tropomyosin and the 
troponin complex (troponin I, C, T) in association with F-actin (Figure 1.11). 
Troponin is the Ca2+ ion receptor that regulates contraction through interactions 
with tropomyosin and actin (Ebashi and Endo, 1968). Regulatory Ca2+ binds to 
troponin at the amino-terminal domain of the troponin C sub unit with an affinity 
of about 106M-1 (Greaser and Gergely, 1971).  
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Figure 1.11 Atomic Model of the Thin Filament 
 
One repeat of the actin filament is coloured in white and tropomyosin in blue. Only a single 
troponin molecule is shown. There should be one on each tropomyosin strand. Troponin I is 
pink, troponin C is yellow, and troponin T is red. Figure prepared with MacPyMOL using the pdb 
files of (Pirani et al., 2006). 
 
 Numerous functional assays (in vitro motility, ATPase assays, and 
isometric force measurements) have enabled the thin filaments of cardiac 
muscle and their regulation to be studied. The in vitro motility assay is a 
particularly useful technique that allows several parameters of movement to be 
studied at once (Marston, 2003). It enables thin filaments to be assembled from 
pure proteins and the functionality of each to be assessed.  This has provided 
useful information about the structure-function relationship of each thin filament 
protein. The addition of tropomyosin and troponin (at comparable 
concentrations), along with TRITC-labelled actin on a surface of HMM, allows 
the movement of actin filaments to be regulated (Fraser and Marston, 1995a, 
Marston, 2003). Inhibitory concentrations of troponin added to 
actin.tropomyosin reduce the fraction of filaments that are moving. Regulated 
filaments are therefore in a two-state system of movement and non-movement, 
and the transition depends upon troponin and the Ca 2+ concentration. The 
equilibrium is entirely reversible. Troponin stops movement at pCa9 (low Ca2+), 
but filaments move again when a high Ca2+ buffer (pCa5) is infused. At 
intermediate Ca2+ concentrations (pCa6.4), filaments can switch between states 
of moving at the same speed as at pCa5, not moving at all, and a few that stop 
and start. Therefore the primary role of troponin in the thin filament is in the 
control of the myosin cross-bridge binding to actin.tropomyosin, rather than 
controlling the cross-bridge turnover rate (Marston, 2003). 
Measurements at 28°C into the effect of cardiac tropomyosin on the actin 
sliding speed have shown that movement is enhanced with increasing 
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concentrations, which saturated at approximately 40nM (Marston, 2003). Since 
actin dissociates from tropomyosin conventionally at 100-200nM, the lower 
concentrations needed in the in vitro motility assay illustrate that once 
tropomyosin has joined up end-to-end with actin, the rate of dissociation is 
slowed (Fraser and Marston, 1995a, Vilfan, 2001). Tropomyosin is composed of 
two α-helical chains arranged as a coiled-coil that spans 7 actin filaments 
(Lorenz et al., 1995). This arrangement is important for the cooperative 
activation of the thin filament by Ca2+ and myosin. Information is carried along 
the actin filament by the lengths of repeating tropomyosin molecules. The 
position of tropomyosin relative to actin plays a key role in switching thin 
filament activity. During activation, tropomyosin moves away in a stepwise 
fashion, first by Ca2+ binding to troponin and then myosin binding to actin (Pirani 
et al., 2005). 
 
1.7.1 Ca2+ Regulation and Co-operativity 
The contraction of muscle and its regulation involves co-operative and 
allosteric interactions between actin, myosin, tropomyosin and troponin (Lehrer 
and Geeves, 1998). Geeves and Halsall proposed that the binding of 
tropomyosin alone to actin induces two states (open and closed) (Geeves and 
Halsall, 1987). McKillop and Geeves subsequently proposed that in the 
presence of troponin and the absence of Ca2+, a third state (blocked) is present 
(McKillop and Geeves, 1993). The three-state model of the thin filament as 
proposed by McKillop and Geeves is shown in Figure 1.12. Cross-bridge 
cycling only occurs when actomyosin is in the open state. The regulation of the 
equilibrium between states regulates contractility. 
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Figure 1.12 Three-State Model of the Thin Filament 
 
 
 
 
 
 
 
 
The actin.Tm.Tn structural unit is shown as seven open circles, connected via a line 
representing the tropomyosin. The equilibrium between the three states is represented by the 
different positions of tropomyosin. The blocked state occurs when no S1 binding can occur (in 
the absence of Ca2+ when troponin is tightly bound to the filament). The closed state occurs 
when only weak binding can occur, and the open state occurs when isomerisation of the S1 to 
the rigor state is allowed. KB is the equilibrium constant that defines the ratio between the 
blocked and closed states, and KT is the equilibrium constant which defines the ratio between 
the closed and open states. Image adapted from (Maytum et al., 1999).  
 
The blocked state can only be detected in kinetic experiments. In steady 
state experiments like the in vitro motility assay, we only ever see evidence for 
the ‘closed’ and ‘open’ states. The blocked state may be present but it cannot 
be distinguished from the closed state. The correct terminology for the states 
measurable by steady state methods is ON (moving filaments) and OFF (non-
moving filaments), with OFF corresponding to the blocked and closed state.  
 
1.7.2 Troponin and Ca2+ Regulation 
In vitro motility measurements have also been used to determine the 
distinct functional roles of the three individual subunits in whole troponin and the 
functional effects in native thin filaments (Bing et al., 1997). The switch off at 
pCa9 is caused by troponin I. The interaction of troponin I and troponin C 
controls the inhibitory activity of troponin I and is controlled by Ca2+ binding to 
troponin C. Ca2+ binding to troponin C strengthens the troponin I-troponin C 
interaction, releases it from actin and removing the inhibition. Filament velocity 
is also controlled by Ca2+ but this is due to the presence of troponin T and its 
interaction with troponin C, since no such effect has been seen in the absence 
of troponin T (Bing et al., 1997, Potter et al., 1995). 
blocked 
closed
open 
S1 binds to form A state Isomerisation to R state only 
possible for open filament 
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In vitro motility studies correlate with biochemical studies that indicate the 
regulatory role of troponin T-troponin C interactions, in addition to troponin I-
troponin C interactions (Potter et al., 1995, Malnic et al., 1998, Perry, 1998, 
Perry, 1999, Vinogradova et al., 2005).  
 
Figure 1.13 Conformational Changes occurring in Troponin in 
response to Ca2+  
 
 
 
 
 
 
 
Figure adapted from (Vinogradova et al., 2005). Troponin T is coloured in cream, troponin I in 
blue, troponin C in red. Ca2+ ions are shown as black circles. 
 
Figure 1.13 illustrates the conformational changes that occur in the 
troponin complex in response to Ca2+. In relaxed muscle, the Ca2+ concentration 
is low and the C-terminus of the inhibitory region of troponin I binds to sites on 
actin which prevents cross-bridge cycling. In response to Ca2+, Ca2+ binds to 
troponin C and the N-terminus of troponin C binds to the C-terminal regulatory 
sequence of troponin I. This restores the helical conformation of troponin C and 
removes the troponin I inhibitory segment from actin. Troponin I modulates the 
Ca2+ binding properties of troponin C through PKA phosphorylation of the 
troponin I-specific N terminus (Ray and England, 1976, Solaro et al., 1976). The 
C-terminus of troponin T binds both to troponin I (in a double α-helix) and the 
troponin C C-terminus and modulates the interactions of both with each other. 
The N-terminal half of troponin T is α-helical and binds the troponin complex to 
tropomyosin, anchoring troponin onto the thin filament. The publishing of the 
high resolution X-ray structure of the core domains of chicken skeletal muscle 
and human cardiac troponin has allowed the precise molecular arrangement of 
+ Ca2+ 
TnI switch 
Segment 
TnI switch 
Segment 
Hydrophobic 
pocket of TnC N-
lobe  
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the troponin complex to be visualised (Takeda et al., 2003, Vinogradova et al., 
2005) (Figure 1.14).  
 
Figure 1.14 Crystal Structure of the Core Domain of Troponin in 
the Ca2+ Saturated Form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ribbon representation of the structure of the core domain, comprising troponin C (blue), 
troponin I (red) and troponin T (green). Note the Ca2+ ions are shown in black. Molecular 
graphic image was drawn from atomic coordinates published by (Takeda et al., 2003) (pdb file 
1J1E), using the USSF Chimera package (Pettersen et al., 2004). 
 
1.8 Adrenergic Regulation of Contractility 
In the normal human heart, the activation of the sympathetic nervous 
system (e.g. through exercise, fight-or-flight response) causes an increase in 
cardiac output by increasing myocyte contractility (inotropy) (Houser and 
cTnC N lobe 
cTnC C 
lobe 
cTnT  
N terminal 
cTnT C terminal 
cTnI N terminal 
cTnI C 
terminal 
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Margulies, 2003). The changes that occur in ventricular inotropy are unique to 
cardiac muscle, and are accomplished by changes in the stroke volume (refer 
to cardiac cycle depicted in Figure 1.1). The inotropic response is the heart’s 
mechanism for increasing the force generation that is independent of preload 
(i.e. sarcomere length). In heart muscle, inotropy is manifested as a change in 
Vmax, i.e. a change in maximal fibre velocity shortening to zero afterload. An 
increased rate of fibre shortening leads to an increase in the rate of ventricular 
pressure development. The altered rate of force and pressure development by 
the ventricle can change the rate of ejection and the ejection fraction (refer to 
PV loops depicted in Figure 1.1). Increased inotropy increases the ejection 
fraction and decreased inotropy decreases the ejection fraction. The ejection 
fraction of the heart is therefore used as a clinical index for evaluating the 
inotropic state of the heart. In heart failure, the decrease in inotropy leads to a 
decreased stroke volume, an increased preload, and a decreased ejection 
fraction (Towbin and Bowles, 2002, Houser and Margulies, 2003).  
The inotropic state of the heart is mediated by b-adrenergic stimulation. It 
involves the binding of adrenergic amines to b-adrenergic receptors, which 
activates adenylate cyclase and increases the production of cAMP. Protein 
kinase A (PKA) becomes activated, binds to A-kinase anchoring proteins 
(AKAP’s), and phosphorylates numerous Ca2+ regulatory proteins 
(phospholamban, L-type Ca2+ channels, ryanodine receptors, myosin binding 
protein C and troponin) (Houser and Margulies, 2003). Additionally, PKA can 
affect enzymes involved in energy metabolism and can increase the production 
of ATP. b-adrenergic stimulation results in an increase in Ca2+ influx and 
storage by the SR. The increased Ca2+ release and faster kinetics increases the 
rate and magnitude of force generation and relaxation by the contractile 
apparatus. Phosphorylation of myosin binding protein C and troponin I adjusts 
the contractile regulatory system to do this. For the necessary background to 
the experiments undertaken in this thesis, only the regulation of contraction by 
alterations in cardiac troponin I phosphorylation by PKA will be reviewed. 
Phosphorylation of cardiac troponin I occurs at residues Ser23/24 
(reviewed in (Metzger and Westfall, 2004, Solaro and Rarick, 1998)), which 
forms part of a 27-33 amino acid N-terminal domain unique to cardiac troponin I 
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(Layland et al., 2005). The physiological relevance of Ser23/24 phosphorylation 
has been extensively studied using transgenic animals, force measurements 
from skinned cardiac muscle preparations, as well as from biochemical studies 
using intact and skinned cardiac muscle preparations. Collectively, these 
studies have shown that the PKA phosphorylation of cardiac troponin I reduces 
myofilament Ca2+ sensitivity, increases the cross-bridge cycling rate and 
enhances unloaded shortening velocity (Hoh et al., 1988, Saeki et al., 1990, 
Fentzke et al., 1999, Kentish et al., 2001, Herron et al., 2001). The reduced 
Ca2+ sensitivity is due to an increase in the rate of Ca2+ dissociation from 
troponin C, which is crucial in speeding up relaxation and allowing the heart rate 
to increase. However, in this tissue troponin I is already about 50% 
phosphorylated. PKA treated non-failing human donor cardiomyocytes show a 
minor decrease in the Ca2+ sensitivity of isometric force (van der Velden et al., 
2003). Similarly using non-failing human donor tissue, Messer et al. reported 
that the Ca2+ sensitivity of the troponin in the in vitro motility assay (TnI 
2.1molPi/mol TnI) was increased upon dephosphorylation by phosphatase 
treatment (TnI 0molPi/mol TnI) (Messer et al., 2006). These functional studies 
have provided strong evidence that myofilament properties can become 
modified by alterations in troponin I phosphorylation and under physiological 
conditions these modifications play an important role in achieving an optimal 
cardiac output.  
The failing heart has a reduced contractile reserve and a reduced 
responsiveness to b-adrenergic stimulation (Houser and Margulies, 2003). The 
abnormal contractile properties are characterised by a decrease in the rate of 
maximally activated cross-bridge cycling, decreased contraction and relaxation 
rates and an increase in Ca2+ sensitivity. Collectively, these features could 
reduce the rate of relaxation in diastole, leading to incomplete relaxation so 
work output in systole may be decreased (Pagani et al., 1988, Wolff et al., 
1996, Alpert et al., 2002). 
Studies of human heart muscle by in vitro motility assay indicate that 
there is a defect in the thin filaments but not the thick filaments (Purcell et al., 
1999, Knott et al., 2002, Noguchi et al., 2003). Using the in vitro motility assay, 
Messer et al. reported that changes in troponin function alone could account for 
the contractile abnormality in failing heart muscle (Messer et al., 2006). The 
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critical difference between non-failing and failing troponin was the very low level 
of troponin I phosphorylation in the failing heart. In fact, the Ca2+ sensitivity and 
maximum velocity was shown to correlate with the level of troponin I 
phosphorylation. Van der Velden et al. similarly showed reductions in troponin I 
phosphorylation by PKA in end-stage human cardiomyocytes (van der Velden 
et al., 2003). This was associated with an increased Ca2+ sensitivity. Myosin 
binding protein C and myosin light chain-2 are also less phosphorylated in 
failing heart muscle (El-Armouche et al., 2007, Palmer, 2005). Reduced PKA 
activity and increased α-PKC and phosphatase activity may work together to 
dephosphorylate troponin I and other regulatory proteins. 
 
1.9 The Cardiomyopathies: Hypertrophic and Dilated 
 Cardiomyopathies are a group of cardiac disorders in which the 
structure and function of the myocardium deteriorates for any unexplained 
reason. They have been divided into four different diagnostic groups, based on 
World Health Organisation guidelines: dilated cardiomyopathy (DCM), 
hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and 
arrythmogenic right ventricle cardiomyopathy (ARVC) (Richardson et al., 1996) 
(Figure 1.15). Many of the conditions are hereditary (Mestroni et al., 1999b, 
Hamid et al., 2002, Richard et al., 2003), and thus provide a unique resource for 
studying the genetic basis of disease. 
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Figure 1.15 Cardiac Remodelling Patterns and Histopathology 
 
 
 
 
 
 
 
 
 
 
 
 
 
[A] HCM heart showing an increase in left ventricular wall thickness (top), with enlargement and 
disarray of myocytes (red) wi th increased interstitial fibrosis (blue) (below). [B] Healthy heart 
showing normal left ventricular wall thickness and chamber volume (top), with an orderly 
alignment of myocytes and minimal interstitial fibrosis in the healthy ventricular myocardium 
(below). [C] DCM showing a marked increase in left ventricular chamber volumes and atrial 
enlargement (top), with hypertrophy and degeneration of myocytes (dark red) without disarray 
and increased interstitial fibrosis (pale pink) (below). Figure adapted from (Seidman and 
Seidman, 2001). 
 
1.9.1 Dilated Cardiomyopathy 
DCM is characterised by unexplained left ventricular dilation, impaired 
systolic function and non-specific histological abnormalities (usually myocardial 
fibrosis) (Richardson et al., 1996, Mestroni et al., 1999a, Towbin and Bowles, 
2002). DCM is the most common cause of heart failure and cardiac 
transplantation in the young, and has a prevalence of 36.5 per 100 000 in the 
U.S population and 38 per 100 000 in Europe (Codd et al., 1989, Cohn et al., 
1997). Patients usually present with symptoms of cardiac failure (fatigue, 
breathlessness, decreased exercise tolerance), and may experience severe 
disease complications including arrhythmia, thrombo-embolic events and 
sudden death (McKenna, 2003, Ebashi and Ohtsuki, 2007).  
Recent family studies have suggested that genetic factors may account 
for as much as 30-35% of cases (Mestroni et al., 1999b, Murphy et al., 2004, 
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Mogensen et al., 2004b). Inheritance is usually autosomal dominant with 
incomplete penetrance, although an X-linked inheritance pattern has also been 
reported (Hershberger, 2005). Numerous disease genes have been identified 
that encode proteins of the sarcomere, nuclear envelope, cytoskeleton, Z-disc, 
and ion channels (Bione et al., 1994, Li et al., 1999, Daehmlow et al., 2002, 
Knoll et al., 2002, Schmitt et al., 2003). For the purpose of this thesis, mutations 
in sarcomeric protein genes as a cause of familial DCM will be described.  
 
1.9.1.1 Disease Genes of DCM 
Genetic investigations of DCM patients have been carried out to evaluate 
the prevalence of sarcomeric gene mutations and associated disease 
expression in affected families (Olson et al., 1998, Kamisago et al., 2000, 
Mogensen et al., 2004b). Considerable locus and allelic heterogeneity have 
been observed (Hershberger, 2005). To date, 25 mutations associated with 
DCM have been identified. Many of these mutations occur in sarcomeric 
proteins (Table 1.1); α-cardiac actin (Olson et al., 1998), α-tropomyosin (Olson 
et al., 2001), cardiac troponin T (Kamisago et al., 2000), cardiac troponin C 
(Mogensen et al., 2004b), b-myosin heavy chain (Kamisago et al., 2000), titin 
(Gerull et al., 2002), and muscle LIM protein (Knoll et al., 2002, Mohapatra et 
al., 2003). It is notable that mutations in the proteins of the thick and thin 
filaments are associated with ‘pure’ DCM and are not accompanied by 
additional phenotypes (Kamisago et al., 2000, Mogensen et al., 2004b). 
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Table 1.1 Sarcomeric Gene Mutations in HCM and DCM 
 
From “Sarcomere Protein Gene Mutations Database”, 
http://genetics.med.harvard.edu/~seidman/cg3 
PROTEIN HCM DCM 
Cardiac α-Actin Glu99Lys, Pro164Ala, 
Tyr166Cys, Ala230Val, 
Ala295Ser, Met305Leu, 
Ala331Pro 
Glu361Gly,  
Arg312His 
 
α-Tropomyosin Glu62Gln, Ala63Val,  
Lys70Thr, Val95A, Ile172Thr, 
Asp175Asn, Glu180Gly, 
Glu180Val, Leu185Arg, 
Glu192Lys, Met281Thr 
Glu40Lys, 
Glu54Lys 
Troponin I Arg21Cys, Arg141Gln,  
Leu144Pro, Arg145Gly, 
Arg145Gln, Ala157Val, 
Arg162Trp, Arg162Gln,  
Arg162Pro, Ser166Phe,  
Lys178del, Lys183Glu, 
Lys183del, Arg186Gln, 
Ile195Met, Asp196Asn, 
Leu198Pro, Leu198Val 
Ser199Gly, Ser199Asn, 
Glu202Gly, Gly203Arg, 
Gly203Ser, Gly203fs, 
Arg204Cys, Arg204His, 
Lys206Gln 
Ala2Val 
Troponin T Phe70Leu, Phe77Leu, 
Ile79Asn, Glu83Lys, 
Val85Leu, Asp86Ala, 
Arg92Gln Arg 92Trp, 
Arg92Leu, Arg94Leu, 
Arg94Cys, Lys97Asn, 
Ala104Val, Phe110Ile, 
Phe110Leu, Phe110Val, 
Lys124Asn, Arg130Cys, 
Glu163Lys, Glu163del, 
Ser179Phe, Glu244Asp, 
Lys247Arg, Asn271Ile, 
Lys273Glu,IVS15+1G>A, 
Arg278Cys, Arg278Pro, 
Arg286His, Arg286Cys, 
Trp287ter,  
Arg113Trp, 
Arg141Trp, 
Ala172Ser, 
Arg205Leu, 
∆Lys210 
Asp270Asn 
 
Troponin C Leu29Gln Glu159Asp 
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1.9.1.1.1 α-Cardiac Actin Mutations 
The cardiac actin gene (ACTC) is located on chromosome 15q14. Two 
missense mutations in ACTC that cosegregate with DCM were identified in a 
candidate gene study of two small unrelated families (Olson et al., 1998). DNA 
sequence analysis demonstrated a G-A transversion leading to Arg312His 
(exon 5) inherited by three individuals with DCM, and an A-G transversion 
leading to Glu361Gly (exon 6) inherited by two individuals with DCM. No other 
group has yet found any other cardiac actin mutation in DCM patients. Cardiac 
actin mutations are therefore a relatively rare cause of autosomal dominant 
DCM. Tesson et al. reported that the proportion of European DCM affected 
individuals bearing a mutation in ACTC must be less than 1.2% (Tesson et al., 
2000). In addition, no ACTC mutations were found in 44 probands in the USA 
(Li et al., 1999), in 30 Japanese DCM patients, in 106 sporadic cases of DCM 
(Takai et al., 1999) or in 11 patients belonging to 8 families and 46 sporadic 
cases of mostly black African origin (56%) (Mayosi et al., 1999). Because of 
their rarity, Tesson et al. suggested that the two reported ACTC mutations could 
be incidental rare polymorphisms and not truly disease causing. However, 
these ACTC mutations have only been found in patients affected with DCM and 
not in healthy individuals. 
Predictions into the pathophysiological mechanism of DCM from 
functional studies of these two ACTC mutations, have put forward the “defective 
force transmission” hypothesis (Hennessey et al., 1993, Wong et al., 2002). As 
previously described, actin filaments transmit force between adjacent 
sarcomeres and neighbouring myocytes to effect the coordination of 
contraction. The E361G  mutation is located in subdomain 1 and is within a 
common binding domain for α-actinin. α-actinin is found at the Z-band and 
intercalated disc and acts to cross-link actin filaments into regular parallel 
arrays. Functional studies of this actin mutation in yeast have shown it to have a 
reduced α-actinin binding affinity which could impair force-transduction in 
muscle fibres, leading to the DCM phenotype  (Wong et al., 2002). However, 
actin is a multifunctional protein and it is also possible that the contractile 
interaction with myosin or the regulatory interaction with tropomyosin and 
troponin could also be altered by the mutation. In this thesis, I have studied 
transgenic mice expressing E361G in their hearts. This mutation is an excellent 
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candidate for transgenic mouse construction since it has the same sequence in 
man and mouse and the mutation can also be detected by 2-D electrophoresis. 
 The DCM mutations in α-tropomyosin, troponin T, troponin C, and 
myosin heavy chain have all been previously studied, mainly by in vitro motility 
assay (Mirza et al., 2005), but also in cardiac myofibrils (Chang and Potter, 
2005, Debold et al., 2007). Mirza et al. and Robinson et al. showed a common 
effect of DCM mutations; decreased Ca2+ sensitivity in every case, and 
commonly decreased cooperativity, cross-bridge turnover rate and Ca2+ binding 
affinity (Mirza et al., 2005, Robinson et al., 2007). 
 
1.9.1.1.2 Cardiac Troponin C Mutation 
In the study reported by Mogensen et al., one family was reported with 
the TNNC1 mutation Gly159Asp (Mogensen et al., 2004b). Penetrance was 
100% and the outcome was poor, with three deaths out of eight (38%), 
including two from heart failure and one from sudden death. Three patients 
underwent transplantation (38%), and two remained stable while receiving long-
term therapy. The amino acid substitution identified in TNNC1 (Glu159Asp) is 
localised at the C-terminal and is close to cardiac troponin I. In the in vitro 
motility assay, recombinant G159D causes a decreased Ca2+ sensitivity, 
decreased cross-bridge turnover and deceased Ca2+ affinity. This mutation has 
been intensely investigated. It has been reported that the decrease in the Ca2+ 
binding affinity of troponin C when troponin I is phosphorylated, essential in the 
inotropic response, is lost due to the G159D mutation (Biesiadecki et al., 2007, 
Dong et al., 2007).  When the troponin is not phosphorylated, the G159D 
mutation did not alter the Ca2+ binding affinity (Biesiadecki et al., 2007, Dong et 
al., 2007). These results correlate with ATPase and tension measurements 
showing that the Ca2+ sensitivity of myofilaments containing the G159D troponin 
C mutation were insensitive to troponin I phosphorylation levels (Biesiadecki et 
al., 2007, Preston et al., 2007b). Alterations in the response to cardiac troponin 
I phosphorylation levels are therefore suggested to be important in the 
development of DCM. Biesiadecki et al. also reported that the effect of G159D 
to inhibit troponin I phosphorylation-induced myofilament Ca2+ desensitisation 
also increased the Ca2+ sensitivity. This is in contrast to in vitro motility and 
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ATPase measurements of G159D which show a decreased Ca2+ sensitivity 
(Robinson et al., 2002, Mirza et al., 2005). 
 In this thesis I have investigated troponin isolated from the heart muscle 
of a patient belonging to the original family with the DCM troponin C G159D 
mutation (Mogensen et al., 2004b). This has allowed comparisons of the real 
disease phenotype with in vitro data. 
 
1.9.2 Hypertrophic Cardiomyopathy  
HCM is the most extensively studied of the four cardiomyopathies and is 
considered to be the commonest hereditary cardiac disease in young adults, 
with a prevalence of 1 in 500 (Maron et al., 1995). It is an idiopathic heart 
muscle disorder, characterised by thickening of the left ventricle (³12-mm) in 
the absence of a cardiac or systemic cause (Richardson et al., 1996, Seidman 
and Seidman, 2001). Hypertrophy in the left ventricle is usually asymmetric, 
involving the anterior and posterior septum and the free wall to a greater extent 
than the posterior wall (Seidman and Seidman, 2001). As a consequence of 
hypertrophy, the left ventricular chamber volumes are diminished and there is 
obstruction of the outflow tract, causing heart failure in some cases (Figure 1.15 
A). Histopathology shows myocyte disarray is prevalent with an increase in 
interstitial fibrosis. Patients show a slow progression of symptoms, which 
include breathlessness on exercise, chest pain, sustained palpitation, syncope, 
gradual deterioration of left ventricular function, and a significant incidence of 
sudden death (McKenna, 2003). Risk factors include a previous cardiac arrest, 
family history of sudden death, left ventricular thickness of ³30mm, abnormal 
blood pressure upon exercise, and unexplained sycope (Maron et al., 1996, 
Elliott et al., 1999, Elliott et al., 2000). 
 HCM is inherited by autosomal dominant transmission in at least 60% of 
cases. The disease starts to manifest itself in adolescence, although clinical 
presentation may occur at any age and varies between related individuals 
(Maron et al., 1986, Niimura et al., 1998, Mogensen et al., 2004a). Molecular 
genetic studies of familial HCM hav e helped explain the clinical diversity, with 
linkage analysis identifying disease-causing mutations in eight different 
sarcomeric protein genes (Geisterfer-Lowrance et al., 1990, Thierfelder et al., 
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1994, Bonne et al., 1995, Watkins et al., 1995, Poetter et al., 1996, Kimura et 
al., 1997, Satoh et al., 1999, Hoffmann et al., 2001). To date, 434 mutations 
associated with HCM have been identified. Myosin and myosin binding protein 
C are the predominantly mutated proteins. HCM seems to be a disease of the 
sarcomere, however 40% of patients do not have mutations in these genes. 
Table 1.1 shows the HCM associated sarcomeric gene mutations in cardiac α-
actin, α-tropomyosin, troponin I, troponin T, and troponin C.  
 
1.9.2.1 α-Cardiac Actin Mutations 
ACTC was first identified as a disease gene implicated in HCM by 
Mogensen et al. (Mogensen et al., 1999). Mutation analysis revealed an 
Ala295Ser mutation in exon 5. Mogensen et al. subsequently identified two 
further novel mutations (Tyr166Cys and Met305Cys) in 3 out of 206 
consecutive families (1.5%) with HCM (Mogensen et al., 2004c). Three other 
mutations have also reported: a heterozygous G-to-C substitution in codon 331 
(Ala331Pro), a heterozygous C-to-G substitution in codon 164 (Pro164Ala), and 
a G-to-A substitution in codon99 (Glu99Lys) (Olson et al., 2000). The E99K 
mutation seems particularly interesting and has been investigated in detail in 
this thesis.  
Olson et al. reported that in one small family, the E99K mutation was 
inherited by six individuals with HCM and one with isolated trabeculation of the 
left ventricular apex. They reported that mutations in ACTC appeared to be a 
rare cause of HCM (³1%), but ACTC mutat ions were disproportionally high in 
apical HCM patients (50%) (Olson et al., 2000). Subsequent genetic analyses 
of DNA from a cohort of 15 probands with apical HCM reported the presence of 
the E99K mutation in 16 individuals from two families with apical HCM (Arad et 
al., 2005b). A shared haplotype was identified in the two families, providing 
odds of >100 to 1 that the E99K mutation caused apical HCM in both families. 
However, the E99K mutation identified in the small family reported by Olson et 
al. was shown to have arisen independently and be genetically unrelated to the 
two families reported by Arad et al. This is strong evidence that the E99K 
mutation is associated with apical hypertrophy. A later large clinical study 
screened for the E99K mutation in 247 families with HCM, DCM, or LVNC (left 
ventricular non-compaction) (Monserrat et al., 2007). This mutation was found 
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in 23 patients with LVNC, in addition to 43 with HCM and 22 with apical HCM. 
Atrial and ventricular septal defects were found in nine E99K mutation carriers 
from the four families.  
Bookwalter and Trybus have reported functional studies on the E99K 
mutation after expression of high yields of E99K and wild type actin in the 
baculovirus/insect cell expression system (Bookwalter and Trybus, 2006). In 
vitro motility studies showed that E99K actin had a reduced velocity and 
supported a 30% lower force than wild type actin when α-actinin was used as a 
load. Bookwalter and Trybus proposed that the slower motility, reduced average 
force, and a weakened interaction with myosin in the presence of ATP might be 
sufficient to trigger the HCM phenotype by the E99K mutation. However, this 
phenotype is unlike any other HCM mutation that has been studied. In this 
thesis, the functional analysis of actin from transgenic mice expressing the 
E99K mutation in their hearts is reported. 
The HCM mutations in α-tropomyosin, troponin T, and troponin I have 
previously been functionally studied, mainly using the in vitro motility assay and 
ATPase measurements (Mirza et al., 2005, Robinson et al., 2002). A common 
pattern is reported of an increased Ca2+ sensitivity and an increased maximum 
cross-bridge cycling rate. Either together or alone, these various alterations in 
myofilament function caused by HCM associated mutations are predicted to 
impair relaxation, reduce diastolic compliance, reduce contractile reserve and 
preserve systolic function under baseline conditions (Knollmann and Potter, 
2001), leading to the HCM phenotype. According to current published data, 
heart failure, DCM and HCM have clearly distinct phenotypes (Marston and 
Hodgkinson, 2001, Knollmann and Potter, 2001, Robinson et al., 2002, 
Marston, 2003, Chang et al., 2005, Mirza et al., 2005) (Figure 1.16). 
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Figure 1.16 Molecular Pathology of HCM and DCM 
Acquired and genetic DCM show opposite trends in Ca2+ sensitivity upon function analysis. 
HCM mutations are hypercontractile, whilst DCM mutations are hypocontractile. 
 
1.9.3 Animal Models of DCM 
Several transgenic mouse models that carry contractile protein mutations 
associated with DCM have been generated to explore the molecular 
mechanism of this disease. The most recent of these models has been the 
troponin T mutation DLys210 (Morimoto et al., 2006). The mutant mice 
developed enlarged hearts and showed a high incidence of sudden death. 
Histological examination showed a significant dilation of both ventricles and 
fibrosis. Echocardiography showed systolic dysfunction of the left ventricle, 
although the cardiac output was unchanged. This suggests systolic dysfunction 
in the mutant mice was fully compensated through the enlarged heart, possibly 
through a compensatory increase in the Ca2+ transient. Skinned cardiac muscle 
fibres from DLys210 mice show a decreased Ca2+ sensitivity of force 
generation, an increase in the intracellular Ca2+ transient, but no difference in 
the maximum isometric force. This suggests that the Ca2+ transient was 
increased to compensate for the decrease in Ca2+ sensitivity (Du et al., 2007). 
These findings correlate with previous results from directly exchanging 
recombinant human DLys210 into skinned rabbit cardiac muscle fibres 
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(Morimoto et al., 2002), and in vitro motility assay and ATPase results (Mirza et 
al., 2005, Robinson et al., 2002).  
The establishment of two transgenic mouse lines carrying the α-
tropomyosin Glu54Lys (E54K) mutation has allowed the molecular mechanism 
of DCM to be further studied (Rajan et al., 2007). Histological analysis showed 
that the mice expressing high levels of the transgene die by one month, due to 
severe dilation of both right and left ventricles. Low copy number mice survive 
for more than six months, although they show altered systolic and diastolic 
function. The time to peak pressure and half time to relaxation were both 
increased. The E54K mutation has shown a number of anomalies in vitro and 
may not conform to the general principles of DCM mutations (Mirza et al., 
2007). 
 
1.9.4 Animal Models of HCM 
Many models have been generated that contain sarcomeric gene 
mutations known to cause HCM, including b-myosin heavy chain, myosin 
binding protein C, α-tropomyosin, cardiac troponin T and cardiac troponin I. The 
first HCM mouse model generated used a gene targeting strategy and 
contained the b-myosin heavy chain mutation Arg403Gln (Fatkin et al., 1999). 
This mutation has a high penetrance in humans, presenting at 90% in HCM 
patients by 20 years old (Doolan et al., 2004). Homozygous animals died 
shortly after birth. Secondary heterozygotes survived but showed considerable 
myocyte disarray, hypertrophy, and fibrosis which increased with age (Fatkin et 
al., 1999). Functional studies showed an increase in actin-activated cycling and 
an increased rate of pressure rise and force development (Fatkin et al., 1999, 
Dalloz et al., 2001).  
The role for cardiac troponin T, troponin I and myosin binding protein C 
mutations in HCM has been investigated through transgenesis (Oberst et al., 
1998, Yang et al., 1998, Tardiff et al., 1999, James et al., 2000). The troponin I 
mutation R145E showed an increase in the Ca2+ sensitivity of skinned muscle 
fibres and at the whole organ level there was hypercontractility with diastolic 
dysfunction (James et al., 2000). Oberst et al. studied the Arg92Gln troponin T 
mutation, which lead to myocyte disarray, substantial fibrosis and diastolic 
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dysfunction, all common features of human HCM. Yang et al. generated 
transgenic mice with varying amounts of a mutated myosin binding protein C 
(lacking the myosin and titin binding domains), and showed an increased Ca2+ 
sensitivity and a decreased power output, resulting in myocyte disarray. 
Similarly, Miller et al. and Chandra et al. reported that transgenic mice 
expressing the Ile79Asn and Arg92Gln troponin T mutations exhibited an 
increase in the Ca2+ sensitivity of force production in skinned muscle fibres 
(Miller et al., 2001, Chandra et al., 2001). Knollman et al. subsequently 
examined the effect of the Ile79Asn mutation on cardiac performance and 
electrophysiology of the whole heart, in vitro, and in vivo (Knollmann et al., 
2001). The higher Ca2+ sensitivity enhanced the base-line contractility but lead 
to cardiac dysfunction during inotropic stimulation with isoproterenol. This lead 
the authors to hypothesise that the effect of a mutation can be dependent upon 
the inotropic state of the heart.  
In many cases, transgenic animals have provided the opportunity to 
examine the functional consequences of sarcomeric gene mutations in an in 
vivo system, thereby removing many of the limitations of the in vitro assays. 
Transgenic models seemed to have validated the hypothesis that HCM and 
DCM are “diseases of the sarcomere” (Doolan et al., 2004). 
 
1.10 Context and Objectives of this Study 
Investigations into how HCM and DCM-associated sarcomeric gene 
mutations affect the in vitro contractile protein function and cause the 
development of the disease state are widely reported, but there is a certain 
amount of variability in the genotype-phenotype correlations that have been 
made. Previous work in our laboratory has used the in vitro motility assay to 
study the functional effects of HCM and DCM mutations in troponin I, troponin 
C, troponin T and α-tropomyosin (Marston, 2003, Mirza et al., 2005, Mirza et al., 
2007). However, these functional investigations used recombinant proteins 
where the troponin was not phosphorylated, hence created an unphysiological 
thin filament. The main objective of this thesis has been to establish whether 
there are alternative or additional mechanisms by which HCM and DCM 
mutations might cause cardiac muscle dysfunction, using an experimental 
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system that is as close as possible to native human cardiac thin filaments. In 
particular it was desirable to test whether the mutations interfere with the 
inotropic response since attenuation of this response is a characteristic of failing 
hearts in general (Messer et al., 2006).   
This thesis represents the first investigation to test the effect of actin HCM 
and DCM linked mutations generated in transgenic mice. The highly conserved 
and abundant nature of actin in the heart has allowed this protein to be a prime 
candidate to functionally investigate. Human and mouse actins have identical 
amino acid sequences and also identical adult isoforms distribution in their 
hearts (20% skeletal, 80% cardiac). Actin cannot be expressed in vitro in 
Eschericia.coli due to its complex folding mechanism and posttranslational 
modifications (Sheterline et al., 1998). The expression of mutant actin has 
however been possible in yeast, drosophila, and Baculovirus/Sf9 cell systems 
but with limited success. It was hypothesised that the generation of transgenic 
models with disease causing ACTC mutations expressed at ratios characteristic 
of the human phenotype will provide a reliable preparation for investigating 
actins interaction with its many partner proteins and its altered functioning in 
disease. It was intended that the reconstitution of mouse actin (containing the 
human ACTC sequence with E361G and E99K sequence substitutions) along 
with human cardiac troponin and tropomyosin will allow the physiological 
conditions of the human thin filament to be closely reproduced. The E361G and 
E99K ACTC mutations are well-defined mutations in DCM and HCM patients 
respectively (Olson et al., 1998, Arad et al., 2005b, Monserrat et al., 2007), 
although few clearly defined functional studies have been reported (Wong et al., 
2002, Bookwalter and Trybus, 2006). This thesis investigates the transgenic 
mice at the molecular level, but the mouse models ought to be suitable for 
investigations of the physiological consequences of these mutations in both the 
intact heart and whole animal. The fortuitous availability of a human muscle 
sample from a patient with the troponin C mutation G159D (Mogensen et al., 
2004b) allowed the study of another DCM linked mutation with the physiological 
post translational modifications and mutant to wild type ratios characteristic of 
the human disease phenotype. 
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2. MATERIALS AND METHODS 
 
2.1 Production of Mutant ACTC Transgenic Mice 
The two mutant cardiac actin cDNA constructs (Glu361Gly and Glu99Lys) 
were provided by Dr. Kristen Nowak (University of Western Australia) in a pBSII 
KS vector. Mutations were inserted into the human cardiac actin sequence by 
Dr. Charles Redwood (University of Oxford). The transgene expression vector 
was first cut with Hind III then partially filled in with two nucleotides (AG) using 
Klenow fragment. After purification the vector was then digested with Sal1. The 
mutant cardiac actin cDNA was removed from the pBSII KS vector by first 
digesting with Spe I, then filling the 3’ end with two nucleotides (C,T) using 
Klenow fragment. After purification the vector was digested with Sal1. This 
allowed directional cloning of the mutant actin construct into the transgene 
expression vector using a Sal1 site at the 5’ end and a Spe1/Hind III hybrid at 
the 3’ end. 
Transgene expression was restricted to the heart using an alpha-myosin 
heavy chain promoter construct kindly provided by Dr. Mike Gollob and 
originally produced in the laboratory of Dr. Jeffrey Robbins (Subramaniam et al., 
1991). In this construct, the promoter region of alpha-myosin heavy chain 
started with the 3’ untranslated region of the beta-myosin heavy chain and the 
first three exons of alpha-myosin heavy chain that were non-coding.  
Transgenic mice were generated by pronuclear microinjection of gel 
purified transgenic constructs (after removal of the plasmid backbone with Not I) 
into the pronucleus of fertilised mouse eggs on a C57BL10xCBA/Ca hybrid 
background (Wells et al., 1995, Akbar et al., 2003, Antoniv et al., 2005, Davies 
et al., 2006, Mollica et al., 2006). Treated embryos were returned to a 
pseudopregnant CD-1 foster mother, generated by mating with a vasectomised 
male mouse, and the resultant pups were identified and genotyped by PCR 
from ear notch samples. 
 
2.2 Using Ear Tissue to Genotype Transgenic Mice by PCR 
PCR was performed in the laboratory of Prof. Dominic Wells (Gene 
Targeting Unit, Charing Cross Hospital). One average sized ear notch (1.5-3 
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mm2 of tissue) provided approximately 5µg of DNA, which was ample for PCR. 
A 10x stock of PCR homogenisation buffer was made up (500mM KCl, 100mM 
Tris-HCl pH 8.3, 0.1mg/ml Gelatin, 0.45% v/v Tween 20, 0.45% v/v Nonidet 
P40). After autoclaving this solution, 5mg/ml Proteinase K was added and 
mixed well. Aliquots of 5ml were made of 1x buffer and kept frozen. Each ear 
notch was placed into individual eppendorf tubes and 50µl of 1x PCR 
homogenisation buffer was added to each one. They were placed in a water 
bath set at 55°C overnight (or until all tissue had fully digested, which took only 
a few hours). Once digested, the samples were heated to 100°C for 10 minutes 
to de-activate the proteinase K in the buffer. Once cooled, the PCR was 
performed directly on this solution.  
 
2.3 PCR Screening Transgenic Mice from Ear Tissue 
Prior to performing PCR, all pipettes were dismantled, washed with warm 
water, and allowed to dry in an oven. They were then irradiated with U.V and 
reassembled. The Qiagen kit, which contained all ingredients for the PCR mix 
was prepared to cover the total number of samples that were being made. To 
achieve good PCR results from ear tissue, the PCR was optimised using ear 
DNA. Usually 1µl of neat ear solution was added to the PCR mix, although it 
was sometimes necessary to dilute the solution 1:10 or 1:25 before adding it to 
the rest of the PCR mix. The Qiagen mix recipe for one reaction consisted of 
2.5µl 10x buffer containing 1.5mM MgCl2, 10µl 5x Q solution, 4µl dNTP, 2µl 
forward primer, 2µl reverse primer, 1µl template (i.e. plasmid or sample DNA). It 
was made up to 25µl with water. The forward primer was located in the 
promoter element of the transgene (MHC-F Sequence (5’-3’) 
TGACAGACAGATCCCTCCTATCTCC and the reverse primer was located in 
the mutant actin (ACTC-R) (5’-3’) GGCATCTTAGAAGCATTTGCGG. Each 
primer was diluted to a 10µM concentration with water before use. The same 
number of reactions worth of enzyme were prepared. The enzyme recipe for 
one reaction consisted of 2.5µl 10x buffer, 0.25µl Taq DNA polymerase, 22.25µl 
water. 25µl of the Qiagen mix was aliquotted into the correct number of labelled 
PCR tubes. Samples were loaded into the PCR and run for the following cycling 
programme: 
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1) 5 minutes at 94°C (Hot start PCR) 
2) Hold at 94°C for addition of enzyme 
Steps 1 and 2 were linked to run one after the other automatically, as were 
steps 3, 4, and 5. When only 1 ½ minutes were left on the first step, the tube of 
enzyme was heated. After the first 5 minute cycling step, 25µl of enzyme was 
pipetted into the bottom of each tube. Steps 3, 4, and 5 were then started.  
3) Cycle (at optimised conditions) 
4) Hold at 72°C for 2.5 minutes 
5) Cool to 4°C for storage 
The PCR cycling step took 2 ½ hours to complete, and samples were stored in 
the freezer if required. 
 
2.4 Screening of Transgenic Mouse by 2-D Electrophoresis 
The charge change of the E361G and E99K mutations (+1 and + 2 
respectively) allowed the identity and quantity of mutant cardiac actin in the 
transgenic mouse cardiac tissue to be separated by 2-D Electrophoresis, using 
the method described by Ilkovski et al. (Ilkovski et al., 2004). This accurate 
screening method of mutant protein in muscle was essential for the efficient 
generation of the transgenic lines.  
 
2.4.1 Sample Preparation and Rehydration of Immobiline 
DryStrips 
15mg tissue (wet weight) was homogenised in 150ml wash buffer (20mM 
KPO4, 2mM MgCl2, 1mM DTT, 1mM NaN3, 50% v/v glycerol, 0.5% v/v Triton X-
100, pH7.0). Tissue homogenate or the pure F-actin was solubilised in lysis 
buffer (8M urea, 2% Triton X-100, 36mM DTT) to a quantity of 15mg/ml tissue or 
4mg/ml actin. Samples were made up to a volume of 340µl with rehydration 
buffer (lysis buffer, 2% IPG buffer from Amersham Biosciences, 1mg/ml 
protease inhibitors E-64, chymostatin, leupeptin and pepstatin which were 
added just prior to use) at 0.15mg/340ml tissue or 0.04mg/340ml actin. The 
protein solutions were loaded slowly into separate slots of the Immobiline 
DryStrip Reswelling Tray. Individual dehydrated 18cm pH4-7 IPG strips 
(Amersham Biosciences) were placed over the protein solutions in the prepared 
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slots (Figure 2.1), and overlayed with 2-3ml DryStrip Cover Fluid to prevent 
evaporation and urea crystalisation. Up to six IPG strips were prepared and 
rehydrated at one time. The Immobiline DryStrip Reswelling Tray was left 
overnight at room temperature. 
 
Figure 2.1. Positioning of IPG Strip on DryStrip Reswelling Tray 
 
 
 
 
 
 
 
Image obtained from Amersham Biosciences 2-D Electrophoresis Principles and Methods 
Handbook (juang.bst.ntu.edu.tw/Protein/proteomics/2D%20Electrophoresis.pdf) 
 
2.4.2  First Dimension Isoelectric Focusing (IEF) 
The first dimension run separated proteins according to their isoelectric 
points. The Immobiline DryStrip tray was placed onto the Multiphor II 
electrophoresis unit cooling plate (20°C) that had been covered with 
approximately 3-4 ml of DryStrip Cover Fluid. This served as conducting fluid to 
ensure good contact between cooling plate and the tray. The anodic electrode 
of the tray was positioned at the top of the plate near the cooling tubes, and 
electrode leads connected to the Multiphor II unit. 
The Drystrip tray was covered with 10ml DryStrip Cover Fluid. This fluid 
protected the strips from evaporation and the samples from oxidation. The 
rehydrated strips were placed into an Immobiline strip aligner, and positioned 
onto the tray (Figure 2.2). Once the electrodes were correctly positioned over 
moistened IEF electrode strips at the cathode and anode, 70-80 ml DryStrip 
Cover Fluid was poured into the tray to completely cover the strips.  
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Figure 2.2 Positioning of IPG Strip Gels in the DryStrip aligner 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image obtained from Amersham Biosciences 2-D Electrophoresis Principles and Methods 
Handbook (juang.bst.ntu.edu.tw/Protein/proteomics/2D%20Electrophoresis.pdf) 
 
Isoelectric focusing was performed in two phases. The first phase ran at 
500V, 1mA, and 5W for 4 hours. The voltage was then increased to 3500V and 
run for 12.5 hours. If more than four strips had been run in the first dimension, 
the unused strips could be wrapped in cling film and stored at –80°C for later 
use. The strips were stored prior to equilibration. 
 
2.4.3 Equilibration of Immobiline DryStrips and Second 
Dimension SDS-PAGE 
Equilibration involved the incubation of each DryStrip with 20ml 
equilibration solution No.1 (375mM Tris-HCl pH8.0, 6M urea, 2% SDS, 20% 
glycerol, 65mM DTT) for 10 minutes. Equilibration solution no.2 (solution no.1, 
243mM iodoacetamide, and a few grains of Bromophenol Blue) replaced the 
first solution for an additional 10 minutes. Each 18 cm DryStrip was cut down to 
6 cm by removing 6 cm from the anodic and cathodic ends, thus enabling two 
strips to be run in second dimension on a 15 cm gel. The remaining 6 cm 
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central part of the DryStrip, which contained the focused actin (Pi 5.7), was 
placed onto a half size (15cm) ExcelGel gradient 8-18% and run in three 
phases. The first phase ran at 600V, 10mA, and 15W for 30 minutes, after 
which the IPG strip gel was removed. The current was then increased to 25mA 
and run for 5 minutes. The cathodic buffer strip was moved forward by 1-2 mm 
and the position of the cathodic electrode adjusted. The final phase ran at 
600V, 25mA, and 15 W for 70 minutes.  
 
Figure 2.3 Positioning Equilibrated IPG Strips on MultiPhor II 
 
 
 
 
 
 
 
 
 
 
Image obtained from Amersham Biosciences 2-D Electrophoresis Principles and Methods 
Handbook (juang.bst.ntu.edu.tw/Protein/proteomics/2D%20Electrophoresis.pdf) 
 
2.4.4 Western Blotting 
2.4.4.1 Protein Transfer 
A nitrocellulose membrane (0.45µm pore size, Amersham Biosciences, 
RPN 303D) and 2 pieces of BIO-RAD extra thick filter paper (Cat No.1703969, 
Protean XL, 18.5x19cm) were cut to the size of the gel (10x13cm) and pre-
soaked in blotting buffer (20% methanol, 48mM Tris, 39mM glycine, 1.3mM 
SDS) for 15 minutes. After SDS-PAGE, the gel was stripped from its plastic 
backing. One sheet of filter paper, the nitrocellulose membrane, the gel and a 
further sheet of filter paper were arranged to form a sandwich on the semi-dry 
transblotter cell (BIO-RAD 221BR). The separated proteins were 
electrophoretically transferred onto the nitrocellulose membrane at 350mA and 
    CHAPTER 2  
  58
25volts for 1 hour at room temperature. The nitrocellulose membrane was 
blocked by immersing the membrane for 1 hour at room temperature 
(alternatively overnight at 4°C) in blocking buffer consisting of 1% dried milk 
powder, 0.1% Tween 20 and 1 x phosphate buffered saline (PBS consisting of 
137 mM NaCl, 27 mM KCl, 4.3 mM Na2HPO4.7H2O, 1.4 mM KH2PO4, pH 7.3). 
 
2.4.4.2 Immunodetection 
The membrane was incubated with primary antibody (Sigma, 5C5 
monoclonal mouse anti-actin, A2172) in blocking buffer at 1/1000 dilution for 1 
hour at 4°C. The membrane underwent 3 x 5 minute washes in PBS with 0.1% 
Tween 20 before incubation with sheep anti-mouse IgG coupled with 
horseradish peroxidase (Amersham Biosciences, NXA931), (1/1000 dilution in 
blocking buffer), for 1 hour at 4°C. Following a further 3 x 5 minute PBS 
washes, the membrane was activated by soaking with enhanced 
chemiluminescence reagents (ECL, Amersham Biosciences, RPN2109) for one 
minute and exposed to ECL Hyperfilm (Hyperfilm, Amersham Biosciences, 
RPN1674K). Films were exposed for approximately 1 minute and then 
developed (Figure 2.4).  
 
Figure 2.4. Immunodetection of E361G (A) and E99K (B) F-actin  
 
  
 
 
 
  
 
 
Non-transgenic (NTg) actin has a pI value of 5.23 (obtained from UniProtKB Swiss-Prot 
database). E361G actin has a pI of 5.30 and E99K of 5.38. The two mutant actins ran at the 
predicted pI. E361G and E99K transgenics express mutant cardiac actin at approximately 50% 
of the total actin. 
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2.4.4.3 Densitometric Analysis of Western Blots 
Protein bands detected by western blotting were measured by scanning 
densitometry. The ECL films were digitised using a HP Scanjet 4800 (HP 
Invent) desktop flatbed scanner with transilluminator, saved as TIFF files, then 
analysed with GeneTools 3.07 software run on an IBM PC (SynGene). 
Upgrades to the system subsequently allowed chemifluorescence directly in 
a G:Box Chemi HR 16 system. TIFF files were analysed with GeneTools 3.07 
software run on GeneSnap 6.08 (SynGene). 
 
2.5 Isolation of Actin from Transgenic Mouse Hearts 
F-actin was isolated simultaneously from 5-7 week-old non-transgenic and 
mutant (E361G and E99K) mouse hearts. E361G F-actin was deficient in the 
mutation when extracted via an acetone powder method (Razzaq et al., 1999). 
This indicated the monomeric form was unstable and aggregated. A method to 
isolate pure actin filaments directly from native thin filaments was developed. 
This preserved the 50% mutant actin content (Tobacman and Sawyer, 1990). 
This actin contained a mixed population of transgenic cardiac actin, non-
transgenic cardiac actin, and α-skeletal actin.  
 
2.5.1 Actin isolation directly from Native Thin Filaments  
One heart (50-100mg) was pulverised in a liquid nitrogen cooled 
percussion mortar and homogenised in 10 x volume of wash buffer containing 
20mM Pi, 0.1M NaCl, 5mM MgCl2, 0.5 mM EGTA, 5mM DTT with 2µg/ml each 
of the protease inhibitors E-64, chymostatin, leupeptin and pepstatin A, pH 7.0. 
Samples were spun at 16,662xg (13,400rpm, eppendorf centrifuge 5417R, F-
45-24-11 rotor) for 3 minutes at 4°C. This extraction step was repeated 4 times 
and the pellet was then extracted twice in 1.5 volume of thin filament extraction 
buffer (5mM ATP/100ml wash buffer) and centrifuged at 16,662xg for 3 minutes 
at 4°C. The two supernatants were combined and centrifuged at 111,700xg 
(50,000rpm, Sorvall RCM120SE, S100-AT6 rotor) for 5 minutes at 4°C. The 
supernatant was further spun at 446,800xg (100,000rpm, Sorvall RCM120SE, 
S100-AT6 rotor) for 20 minutes at 4°C. The pellet containing thin filaments was 
dialysed in 1.5 volume of a buffer containing 20mM Pi, 0.1M NaCl, 5mM MgCl2, 
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and 1mM ATP, pH6.0 for 3 hours at 4°C. A 2-minute spin at 16,662xg 
(13,000rpm, eppendorf centrifuge 5417R, F-45-24-11 rotor) at 4°C removed the 
remaining myosin. 3M KCl stock was added to the supernatant to a final 
concentration of 0.8M to dissociate actin from troponin-tropomyosin. 150nM 
TRITC-phalloidin was also added to the supernatant. The dissociated thin 
filaments were spun at 337,000xg, (100,000rpm Sorvall RCM120SE, S100-AT6 
rotor) for 20 minutes at 4°C, and the pellet containing the F-actin was 
resuspended in 100ml ACEX (actin extraction buffer) (2mM Tris-HCl, 0.2mM 
CaCl2, 0.2mM ATP, 1mM DTT, pH8.0) overnight at 4°C.  
Western blotting analysis determined the F-actin concentration to be 
approximately 0.5 mg/ml and the yield of actin approximately 1mg per 1mg of 
tissue. The F-actin was labelled with TRITC-phalloidin, and remained functional 
for use in the in vitro motility assay for 7-10 days. Various sample fractions were 
taken throughout the isolation process for SDS-PAGE and western blot analysis 
to investigate the mutant actin properties (Figure 2.5).  
 
Figure 2.5 SDS-PAGE of E361G Isolation Fractions 
 
 
 
 
 
 
 
 
 
 
SDS-PAGE stained with Coomassie Blue of E361G actin isolation fractions: (1) whole muscle 
homogenate, (2) first wash supernatant, (3) last wash supernatant, (4) pellet after two 
extractions in thin filament extraction buffer, (5) KCl supernatant* - 150nM TRITC-phalloidin, (6) 
KCl supernatant* + 150nM TRITC-phalloidin, (7) f-actin pellet - TRITC-phalloidin, (8) f-actin 
+TRITC-phalloidin. *Native thin filaments were mixed with 0.8M KCl and f-actin was sedimented 
by centrifugation for 20-min at 100,000rpm. 
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2.6 Preparation of Proteins from Rabbit Skeletal Muscle  
Skeletal muscle actin and myosin were extracted from rabbit back muscle 
for use in in vitro studies. The muscle was excised immediately after sacrifice 
and cooled on ice.  
 
2.6.1 Preparation of F-actin from Rabbit Skeletal Muscle 
The preparation of skeletal muscle F-actin was carried out by O’Neal 
Copeland in the laboratory of Professor Steven Marston, following the method 
of Spudich et al. (Spudich and Watt, 1971). An additional step involving the 
purification of the G-actin through a Sephacryl S300 gel filtration column was 
included (Alahyan and EL-Mezgueldi, 2005, Alahyan et al., 2006). A volume of 
2ml F-actin was routinely obtained, with the concentration ranging between 5-
20 mg/ml. The F-actin was fluorescently labelled with TRITC-phalloidin (section 
2.10.1) or prepared for use in the affinity precipitation of HMM (section 2.10.4). 
It remained functional for up to 3 weeks after preparation. 
 
2.6.2 Preparation of Myosin 
The preparation of skeletal muscle myosin was carried out by O’Neal 
Copeland in the laboratory of Professor Steven Marston, following the method 
of Margossian and Lowry (Margossian and Lowey, 1982). The purified myosin 
was rapidly frozen as a concentrated solution (20-40 mg/ml) in liquid nitrogen. 
The myosin could be stored for up to 1 year in 50 µl aliquots under liquid 
nitrogen. 
 
2.6.3 Preparation of Rabbit Skeletal Muscle HMM 
The method of rabbit skeletal muscle HMM preparation was based on 
that of Okamoto (Okamoto and Sekine, 1985, Fraser and Marston, 1995a), and 
was prepared for use as the immobilised motor in the in vitro motility assay. A 
100µl aliquot of rabbit skeletal myosin of approximately 30 mg/ml was thawed 
from liquid nitrogen on ice and diluted 10-fold with HMM buffer A (0.1mM 
NaHCO3, 0.1mM EGTA pH 7.4, 1mM DTT). The homogenate was incubated on 
ice for 20 minutes.  The myosin was pelleted by centrifugation at 25,000xg 
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(Eppendorf centrifuge 5417R with the F-45-24-11 rotor at 16,400rpm for 10 
minutes at 4°C).  
The myosin was resuspended in 100µl of HMM buffer B (20mM Imidazole-
HCl pH 7.0, 1M KCl, 4mM MgCl2, 2mM DTT) and incubated for 10 minutes on 
ice. The solution was made up to 200µl with HMM Buffer A to a concentration of 
approximately 15mg/ml. It was then incubated for 10 minutes in an eppendorf 
thermomixer at 25°C. 200µl of the myosin solution was digested using TLCK 
treated α-chymotrypsin (Sigma type VII, C-3142) at 15µg/ml concentration 
(7.5µl of a 0.4mg/ml solution) and incubated for exactly 8 minutes at 25°C. The 
digestion was stopped by adding 2700µl of ice cold HMM buffer A containing 
3mM MgCl2 and 0.1mM PMSF. The mixture was incubated on ice for 60 
minutes and then centrifuged at 337,000xg (100,000rpm, Sorvall MC-120SE, 
S100-AT6 rotor) for 15 minutes at 4°C to remove any undigested myosin. The 
supernatant contained pure HMM at 0.3-0.7mg/ml and was suitable for use in 
the motility assay, after affinity precipitation (section 2.10.4) for 3-4 days. 
 
2.7 Collection and Storage of Non-Failing Human Myocardium  
Four non-failing (donor) human heart muscle samples were used as a 
source of human cardiac troponin. Clinical details are shown in Table 2.1.  
Samples were supplied by Professor C. Dos Remedios, University of Sydney, 
Australia.  Ethical approval was obtained from The Brompton, Harefield & NHLI, 
London and St Vincent’s Hospital, Sydney. The investigation conformed to the 
principles outlined in the Declaration of Helsinki (World Medical Association, 
1996). The non-failing adult myocardium was obtained from subjects who were 
assessed as potential heart donors but were subsequently rejected on technical 
grounds or where no suitable transplant recipient was found.  The donors had 
no history of cardiac disease, a normal cardiac examination, a normal 
admission ECG, and normal ventricular function on transthoracic 
echocardiography performed within 24 hours of heart explantation.  These 
criteria were set to exclude any significant myocardial contractile dysfunction. 
Immediately following explantation, the ventricular wall was cut up into 1g 
segments, frozen in liquid nitrogen and stored for later analysis. 
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Table 2.1. Clinical details of Non-Failing Human Heart Samples 
Sample Diagnosis Operation Gender Age 
NF 9 Trauma  Donor M 54 
NF 10 Grade V SAM Donor F 48 
NF 11 Excess 
inotropes; 
grade IV SAH  
Donor M 51 
NF 12 LA/RA/RV Donor F 59 
Donor – heart transplant after brain stem death, SAM - Systolic Anterior Motion, SAH – 
Subarachnoid Haemorrhage 
 
2.8 Preparation of Human Cardiac Troponin 
 Human cardiac troponin was isolated from the non-failing human donor 
hearts by affinity chromatography. 
  
2.8.1 Human Cardiac Troponin Preparation by Affinity 
Chromatography 
An affinity separation method was developed using an anti-cardiac 
Troponin I monoclonal antibody (16A11 HyTest, Finland) conjugated to CNBr 
Sepharose CL-4B.  Professor N. Gusev and G. Filatov from Moscow State 
University provided the immobilised antibodies.  All steps were carried out at 
4°C (Filatov et al., 1998, Katrukha et al., 1995, Messer et al., 2006). 
100-150 mg of frozen non-failing heart muscle was pulverised in a liquid 
nitrogen cooled percussion mortar. Pulverised human heart muscle was 
manually homogenised in 1.5ml of a wash buffer containing 5mM NaH2PO4, 
5mM Na2HPO4 pH 7.0, 0.1M NaCl, 5mM MgCl2, 0.5mM EGTA, 0.1% Triton X-
100 and 5mM DTT with 2µg/ml each of the protease inhibitors E-64, 
chymostatin, leupeptin and pepstatin A. The homogenate was centrifuged at 
13,400rpm (Eppendorf centrifuge 5417R, F-45-24-11 rotor) for 3 minutes and 
the supernatant discarded. This step was repeated 4 times. Cardiac proteins 
were extracted by homogenisation in an extraction buffer (0.7M LiCl, 25mM Tris 
pH 7.5, 5mM EGTA, 0.1mM CaCl2, 5mM DTT, protease inhibitors). The first 
extraction was for 25 minutes on a Dynal sample mixer followed by 
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centrifugation for 3 minutes at 13,400rpm (Eppendorf centrifuge 5417R, F-45-
24-11 rotor). The supernatant was retained and the pellet extracted three more 
times for 20,15 and 10 minutes. The combined supernatants were pooled and 
centrifuged at 337,000xg for 20 minutes (100,000rpm Sorvall MC-120SE, S100-
AT6 rotor). A maximum volume of 2ml of the centrifuged extract was placed on 
the affinity column with 0.6ml of the affinity matrix and mixed for 15 minutes at 
4°C on the Dynal sample mixer to ensure complete binding to the antibody.   
The column was placed on the ‘flow through’ (FT) tube (Figure 2.6) and 
unbound proteins such as actin, myosin and tropomyosin run off. 0.8ml of the 
extraction buffer was passed through the column twice to make sure all 
unbound proteins had been eluted. Troponin was eluted from the column by the 
addition of 0.1M glycine (pH 2) in five 0.4ml aliquots. This was immediately 
neutralised by 1M MOPS (pH 8), avoiding any damage to the troponin structure. 
 
Figure 2.6. Affinity chromatography using the anti-TnI 
monoclonal antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
W - wash, E - Elute fraction.  Troponin routinely eluted in the E2 fraction. 
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The fractions were analysed by SDS gel electrophoresis to locate the 
troponin elution fraction (Figure 2.7). Fractions containing pure troponin were 
dialysed overnight against a buffer consisting of 1M KCl, 10mM MES pH 6.0, 
0.1mM CaCl2, 5mM DTT and 2µg/ml protease inhibitors. The dialysate was 
centrifuged at 16,000rpm, Eppendorf centrifuge 5417R, F-45-24-11 rotor for 3 
minutes to remove any insoluble material. This solution contained pure 
troponin, which was used in functional analysis for a maximum of five days. The 
yield was normally 600µl of 7µM troponin from 100mg of tissue.  
 
Figure 2.7 SDS-PAGE of Extracted Human Cardiac Troponin 
 
 
 
 
 
 
 
 
 
 
XT – Extract, FT – Flow through, W – Wash, E – Elute fraction, MHC – Myosin heavy chain, 
MLC – Myosin light chain, Tm – Tropomyosin, Tn – Troponin. 
 
2.8.1.1 Dephosphorylation of Human Cardiac Troponin 
Before the overnight dialysis step, troponin could be dephosphorylated 
by incubating with 1.4 U/ml acid phosphatase (Sigma, P-0157) (Messer et al., 
2006). The extracted troponin was mixed with the phosphatase and then 
dialysed overnight at 4˚C against the troponin dialysis buffer. The dialysate was 
centrifuged at 16,000rpm, Eppendorf centrifuge 5417R, F-45-24-11 rotor for 3 
minutes to remove any insoluble material. The supernatant contained 
dephosphorylated troponin. 
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2.8.2 Preparation of Human Cardiac Tropomyosin 
Human cardiac tropomyosin was prepared from an ethanol-ether 
powder, based on the method of Potter et al. (Potter, 1982) from 300g of human 
cardiac muscle. The preparation was carried out by O’Neal Copeland in the 
laboratory of Professor Steven Marston. All steps were carried out at 4°C. 
 
2.8.3 Preparation of α-Actinin 
α-actinin was prepared by Professor Steven Marston from chicken 
gizzard based on the method of Craig et al. (Craig et al., 1982). 
 
2.8.4 Use of Protease Inhibitors 
All buffers used during protein extraction contained a mixture of protease 
inhibitors at a concentration of 2µg/ml from 20mg/ml (Marston and Smith, 
1984), to prevent proteolytic degradation. The protease inhibitors used were 
chymostatin, leupeptin, pepstatin A and E-64. 
 
2.9 Protein Analysis 
2.9.1 Determination of Protein Concentration 
Protein concentrations were determined by the method of Lowry et al. 
(Lowry et al., 1951).  Aliquots of protein, typically 10-100µg were taken and 
made up to 500µl with 1M NaOH. 5ml of freshly prepared LOWRY solution A (1 
part 0.5% CuSO4 +1 part 1% NaK Tartrate + 48 parts 2% Na2CO3) was added, 
tubes vortexed and then incubated for 10 minutes at room temperature. After 
addition of 500µl of solution B (1 part Folin and Ciocalteu’s reagent + 1 part 
dH2O) the solution was mixed thoroughly and incubated for 30 minutes at room 
temperature. The absorbance of the solution was measured at 700nm and the 
concentration of protein determined using a calibration chart constructed by 
measuring the total nitrogen content of the actin and myosin. 
The Bradford Assay was used for the rapid measurement of HMM 
concentrations. 100µl of HMM or myosin was added to 1ml of Bradford 
Reagent, mixed thoroughly and incubated at room temperature for 5 minutes.  
The absorbance of the solution was measured at 595nm and the protein 
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concentrations derived from a calibration curve of known HMM concentrations, 
see Figure 2.8. 
 
Figure 2.8 Bradford Assay Calibration graph for 100µl Sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.9.2 Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
2.9.2.1 Sample Preparation 
Protein solutions were mixed 1:1 (vol:vol) with SDS sample buffer (20mM 
Tris-HCl pH 8.0, 2.5% SDS, 5% 2-mercaptoethanol, PAGE Blue) and heated for 
5 minutes at 95-100°C.  Dilute proteins were mixed 5:1 (vol:vol) with 3xSDS 
sample buffer (20mM Tris-HCl pH 8.0, 7.5% SDS, 15% 2-mercaptoethanol, 
PAGE blue) so as to maximise the concentration of the sample loaded. 
 
2.9.2.2 Electrophoresis Using The Pharmacia System 
Precast gels on plastic backings (Excelgel-SDS 8-18% gradient, 
Pharmacia LKB) were orientated on the precooled horizontal plate of a 
Multiphor II electrophoresis system. Polyacrylamide anodic and cathodic buffer 
strips were placed at each end. Loading strips consisting of 5mm x 10mm size 
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pieces of filter paper were spaced approximately 5mm apart adjacent to the 
cathodic buffer strip.  Prepared samples of up to 20µl total volume, 1-10µg pure 
protein, were pipetted onto the filter papers. Full size 24cm gels were run at 
50mA/600V/30W maximum (25mA current for 12cm sized gels) for 80 minutes 
at 10°C. 
Upon completion of electrophoresis, the gels were immersed in a fixing 
solution (50% methanol, 10% acetic acid) for 20 minutes with gentle agitation.  
The protein bands were visualised by soaking the gel for approximately 20 
minutes in Coomassie Blue staining solution (PhastGel tablets, 17-0518-01), 
then destaining in 25% methanol, 8% acetic acid, both steps with gentle 
agitation. The gel was preserved under cellophane by incubating in destain 
containing 10% glycerol for 30 minutes.  The gel was removed and allowed to 
dry overnight at room temperature. 
 
2.9.2.3 Densitometric Analysis of SDS-PAGE Gels 
Protein bands detected by SDS-PAGE gels were quantified by scanning 
densitometry.  
 
2.9.3 Pro-Q Diamond Phosphoprotein Gel Stain 
The Pro-Q Diamond phosphoprotein stain (Molecular probes, P33300) is 
a fluorescent method for detecting phosphoproteins in gels. This highly 
sensitive phosphoprotein stain specifically detects phosphate moieties on 
threonine, serine and tyrosine residues (Steinberg et al., 2003, Schulenberg et 
al., 2003) and enables the analysis of the phosphorylation of a single protein. 
After running a standard SDS-PAGE, the gel was immersed in 100ml of 
fixing solution (50% methanol, 10% acetic acid) and incubated overnight with 
gentle agitation at room temperature. The gel was washed twice in 100ml of 
dH2O with gentle agitation for 10 minutes and then incubated in the dark in 50ml 
of Pro-Q Diamond phosphoprotein gel stain with gentle agitation for 75 – 120 
minutes. The gel was distained by being incubated twice for 60 minutes each in 
the dark with 80ml of Destain Solution (undisclosed formula).  
The gel was removed from its plastic backing to prevent any background 
fluorescence, and viewed on a U.V transilluminator. Digital images were 
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obtained using the GeneGenius apparatus (Syngene) with GeneSnap 
programme and images were saved as TIFF files. The gel was stained with 
Coomassie Blue (2.9.2.2) without agitation.  
 
2.9.4  Sypro Ruby Protein Gel Stain 
Sypro Ruby protein gel stain (Molecular Probes, S12000) is a ready-to-
use, ultrasensitive, luminescent stain for the detection of proteins separated by 
polyacrylamide gel electrophoresis. After running a standard SDS-PAGE, the 
gel was placed in a clean container with 100ml of fix solution (50% methanol, 
7% acetic acid) and gently agitated for 30 minutes. This step was repeated 
once more with fresh fix solution. 60ml of Sypro Ruby gel stain was added and 
incubated overnight at room temperature. The gel was washed in a clean 
container with 100ml of wash solution (10% methanol, 7% acetic acid) for 30 
minutes. This step helps to minimise the background staining irregularities and 
stain speckles on the gel. Before imaging, the gel was rinsed twice in ultrapure 
water for 5 minutes to prevent possible corrosive damage to the imager.  
 Sypro Ruby protein gel stain has two excitation maxima, one at 
approximately 280nm and one at approximately 450nm, and has an emission 
maximum near 610nm. The gel was removed from its plastic backing and 
viewed on a 300nm U.V transilluiminator. Digital images were obtained using 
the GeneGenius apparatus (Syngene) with GeneSnap programme and images 
were saved as TIFF files.  
 
2.10  In Vitro Motility Assay 
The In Vitro Motility Assay technique, devised by Kron and Spudich (Kron 
and Spudich, 1986), was used to make a detailed quantitative analysis of 
human cardiac troponin-tropomyosin control of actin filament movement under 
immobilised HMM. Several modifications have been applied to the original 
technique (Fraser and Marston, 1995a, Fraser and Marston, 1995b, Bing et al., 
1997, Purcell et al., 1999, Bing et al., 2000).  
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2.10.1 Fluorescent Labelling of F-Actin 
F-actin was labelled with TRITC-phalloidin (f), for visualisation under a 
fluorescence microscope. 
 
2.10.1.1 Fluorescent labelling of Skeletal Muscle F-Actin  
36µl of 33µM TRITC-phalloidin in methanol (Sigma P1951), was added 
to 438µl of motility buffer A and mixed thoroughly by vortexing.  20µl of 1mg/ml 
fresh F-actin was added and mixed gently to give a final concentration of 1µM. 
The eppendorf tube was wrapped in aluminium foil to prevent photo-
degradation of the label and incubated at 4°C for 16-18 hours for full labelling of 
the F-actin by the rhodamine-phalloidin. This labelled actin provided a stock of 
actin-f, which could be used for motility studies for 5-10 days. 
 
2.10.1.2  Fluorescent Labelling of Transgenic Mouse F-Actin  
139µl of buffer A was thoroughly mixed with 18µl of 33µM TRITC-
phalloidin. 90ml F-actin, isolated from transgenic mouse cardiac muscle was 
added and gently mixed. This stock of actin-f was incubated for 16-18 hours at 
4°C in a covered eppendorf and remained functional in the in vitro motility assay 
for 5-10 days. 
 
2.10.2  Pre-mixing and Incubation of Thin Filament Proteins 
F-Actin-f -tropomyosin and F-Actin-f -tropomyosin-troponin complexes 
were formed at 10x assay concentration. 100nM F-Actin-f, 100nM human 
cardiac tropomyosin, and 0-80nM human cardiac troponin were mixed in 
motility buffer A (50mM KCl, 25mM Imidazole, 4mM MgCl2, 1mM EDTA, 5mM 
dithiolthreitol, pH 7.4), and incubated for 10 minutes on ice to ensure complete 
binding. The mixtures were subsequently diluted 10-fold in motility buffer A 
immediately prior to infusion into the motility cell.  
 
2.10.3  Motility Assay Flow Cell Preparation 
All in vitro motility assay experiments were carried out with the 
preparation of a motility flow cell as described by Kron et al. (Kron and Spudich, 
1986), (Figure 2.9). The flow cell was constructed from a microscope slide 
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(Sigma, S8400), and a freshly siliconised coverslip prepared by soaking in 0.2% 
dichloromethylsilane (Fluka 39909) in chloroform. 
 
Figure 2.9. Construction of the Motility Flow Cell 
 
 
 
 
 
 
Dual chambers removed variation and allowed simultaneous 
comparisons of different samples under identical conditions. Any coverslip 
showing adherent liquid after immersion in the solution was discarded, as this 
indicated incomplete silconisation (Sundberg et al., 2003). 
 
2.10.4 Affinity Precipitation of HMM 
Filament movement was inhibited by the presence of “rigor heads”, 
which show ATP insensitive binding to actin filaments. This effect was 
minimised by the affinity precipitation of HMM preparations. HMM, F-Actin, and 
ATP were mixed to final concentrations of 200 µm/ml, 150µg/ml, and 1mM 
respectively in buffer A, and incubated on ice for 10 minutes. The mixture was 
centrifugated at 100,000rpm (Sorvall RCM120SE, S100-AT6 rotor) for 15 
minutes at 4°C to pellet F-actin and associated myosin “rigor heads”. HMM 
remained in the supernatant and was suitable for use in the in vitro motility 
assay for up to three hours. 
 
2.10.5 Infusion of Proteins 
Protein components and buffers were infused into the motility flow cell at 
30-second intervals. A 100µl aliquot of HMM at 100 µg/ml was infused down 
first, providing the base of immobilised HMM on the coverslip. This was followed 
by 100 µl of buffer B (A + 0.5mg/ml bovine serum albumin) and then 100 µl of 
10nM actin-f ± associated tropomyosin-troponin in buffer A. 50 µl of buffer C (B 
2 Flow Chambers coverslip 
grease 
wire 
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± 0.1 mg/ml glucose oxidase, 0.02 mg/ml catalase, 3 mg/ml glucose, 0.5% 
methylcellulose, ± troponin at assay concentration), and 50µl of buffer D (C + 
1mM ATP) were then infused. 
 
Figure 2.10. Infusion of Proteins 
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2.10.6 Ca2+/EGTA buffer Preparation 
Ca2+-EGTA buffers were prepared by adapting the method of McGuigan, 
(McGuigan et al. 1991). Buffers of different [Ca2+] were made by mixing an 
EGTA buffer (50mM KCl, 25mM Imidazole pH 7.4, 50mM EGTA (free acid), 
1mM EDTA, 4mM MgCl2, 95mM KOH, 1.43mM HCl, 8mM NaCl with the pH 
adjusted using concentrated HCl) and a Ca2+-EGTA buffer (50mM KCl, 25mM 
Imidazole pH 7.4, 50mM EGTA, 50mM CaCl2, 1mM EDTA, 4mM MgCl2, 8mM 
NaCl with the pH adjusted using 1M KOH) using appropriate ratios to obtain 
Ca2+-EGTA buffers ranging from pCa9 to pCa5.4, shown in table Table 2.2. The 
pCa values were determined using the Maxchelator computer programme (Bers 
et al. 1994). 
 
Table 2.2 Ca2+ Buffer Solutions 
 
 
Solution  Volume of 
50mM EGTA 
buffer added 
(ml) 
Volume of 
50mM 
Ca/EGTA 
buffer added 
(ml) 
Ratio pCa Free 
[Ca2+] 
A 47 0.5 94/1 9.00 1.00 x 10-9 
C 40 4 10/1 8.14 7.24 x 10-9 
D 40 10 4/1 7.74 1.82 x 10-8 
E 30 15 2/1 7.43 3.72 x 10-8 
F 25 17.5 1/0.7 7.24 5.75 x 10-8 
G 25 25 1/1 7.13 7.41 x 10-8 
H 20 30 1/1.5 6.95 1.12 x 10-7 
I 15 30 1/2 6.84 1.45 x 10-7 
J 10 30 1/3 6.64 2.29 x 10-7 
K 10 40 1/4 6.52 3.02 x 10-7 
L 8 40 1/5 6.42 3.80 x 10-7 
M 7 42 1/6 6.34 4.57 x 10-7 
N 6 42 1/7 6.28 5.25 x 10-7 
P 5 40 1/8 6.23 5.89 x 10-7 
Q 5 45 1/9 6.18 6.61 x 10-7 
R 2 40 1/20 5.88 1.32 x 10-6 
S 1.5 45 1/30 5.75 1.79 x 10-6 
T 0 50 -/1 5.43 3.72 x 10-6 
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2.10.7 Visualisation Apparatus 
Figure 2.11. Visualisation and recording apparatus used for the 
analysis of the in vitro motility assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two different visualisation setups were used during this research. Both 
setups used a Zeiss AxioLab microscope fitted with an epifluorescence 
illuminator (Zeiss 39 26 42-9901). One microscope was connected to a DAGW 
MTI SIT 68 video camera, which was linked to a TV monitor. Image digitisation 
and filament movement was performed on a single hardware unit containing 
integrated software.  Computing hardware was a Macintosh G4 computer with a 
built in PCI Neotech frame grabber. The other setup used a Hamamatsu 
C2400-80 camera head. Analogue signals from the time base corrector 
(DataVideo TCB-1000) were digitised by a Formac Studio DV converter 
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attached to a Macintosh G4 computer. The live images were viewed and 
recorded using iMovie software. A Macintosh G3 computer was used with a 
built in PCI Neotech frame grabber to perform image digitisation and analysis of 
filament movement  
 
2.10.8 Acquisition of image software 
Filament movement was analysed directly from the image viewed via the 
camera by using a Filament Tracker program (Marston et al., 1996, 
Marston.S.B. et al., 1998, Marston, 2003). If successive pairs of frames were 
compared the program searched for and detected the new position of every 
filament and showed its vector on screen. Velocity was calculated and shown 
as a frequency histogram. Normally 10-15 images were acquired to obtain 250-
500 filament vectors, which ensured minimum random errors. In order to give 
the maximum ratio between random filament oscillation, pixel size and distance 
of filament movement between images, the timer interval was set to allow 
filament movement of approximately 1.6-1.8µm between captured images 
(Figure 2.12). These timer intervals were fixed for any single experiment. The 
algorithm could not deal with filaments that met, crossed or divided. Direct 
comparisons show that the data produced by automatic tracking was 
indistinguishable from manual tracking. For any given experiment once the 
conditions were optimum for image acquisition, images were captured from four 
separate areas chosen at random to obtain data that was representative of the 
whole flow cell, without experimental bias.  
 
Figure 2.12. Optimum Timer intervals plotted against velocity 
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2.11 Statistical Analysis 
The in vitro motility experiments consisted of direct comparisons of non-
transgenic and transgenic thin filaments in the same motility cell to give minimal 
errors. The mean sliding speed and percentage motile were calculated and 
mean values and standard errors were recorded. Results are expressed as 
mean ± standard error unless otherwise indicated.  Data was compared for 
statistical significance using the Student’s t-test where p<0.05 was classed as 
significant.  Ca2+-activation curves were fitted to the Hill equation. 
      bn [Ca2+]n          a  = min value 
Hill Equation:   X  =  a +           bn  = max - min 
    (k + [Ca2+]n)          k  = EC50 
               n  = hill co-efficient 
 
2.12  Competitive Binding Assay of Fluorescent and Non-
Fluorescent Actin to α -Actinin 
The in vitro motility technique was extended to measure the relative 
affinity of α -actinin binding by competition between TRITC-phalloidin labelled 
actin and non-fluorescent phalloidin labelled actin. The principle was to coat the 
flow cell cover glass with 100µl α -actinin at low concentration (5µg/ml in Buffer 
A), followed by 100 µl of buffer B (A + 0.5mg/ml bovine serum albumin). Actin 
was bound to the surface by infusing a 100ml mixture of TRITC actin-f and non-
fluorescent actin in a range of ratios at fixed 10nM concentrations. 50ml buffer C 
(B ± 0.1 mg/ml glucose oxidase, 0.02 mg/ml catalase, 3 mg/ml glucose) was 
added without methylcellulose to prevent non-specific binding. Up to 10 filament 
fields were recorded per cell and the number of actin filaments was determined 
using the Tracker software. 
Since actin is in great excess over α-actinin, TRITC actin-f competes with 
non-fluorescent actin to bind to the α-actinin. The amount of fluorescent relative 
to non-fluorescent actin filaments bound depends upon the ratio of the two 
species to their relative affinity, defined by the equation: 
 
y = F.K / (FK+ (1-F)) 
 
F= fraction of fluorescently labelled filaments 
K= ratio of binding constant 
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Figure 2.13 illustrates how the number of labelled actin filaments varies 
with the fraction of labelled actin for various binding constant values.  
 
Figure 2.13 Theoretical Curve of Filament Competition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The images in Figure 2.14 show the displacement of fluorescent skeletal 
rabbit actin filaments by increasing concentrations of non-fluorescent rabbit 
actin. There is an equal affinity of fluorescent and non-fluorescent rabbit actin 
for the α-actinin. The number of rabbit actin filaments can be plotted against the 
fraction that are labelled, producing a K value of approximately 1 (Figure 2.15). 
 
Figure 2.14. Displacement of Rabbit TRITC-Actin Filaments 
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Figure 2.15 Skeletal Rabbit Actin Competitive Binding Assay 
(A) and Fit (B) 
 
 
 
 
 
 
 
 
 
 
The K value for rabbit actin is 0.843 ± 0.042. 
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3. FUNCTIONAL INVESTIGATION OF DCM ACTIN MUTANT 
GLU361GLY 
3.1 Introduction 
Mutations that cause DCM have been found in genes that code for most of 
the proteins in the cardiac muscle contractile apparatus, including the cardiac 
actin gene (ACTC). This chapter will describe the functional investigation of the 
cardiac actin DCM mutation Glu361Gly (E361G) (Olson et al., 1998) by the 
well-established in vitro motility assay. 
The transgenic mice that over expressed the E361G actin in their hearts 
were supplied by Professor Dominic Wells, Gene Targeting Unit, Charing Cross 
Hospital. This has been the first functional study on cardiac actin extracted from 
transgenic mouse hearts that carried the E361G mutation. It has allowed the 
E361G mutation to be studied in an experimental system that reproduced the 
conditions in the muscle of patients with familial DCM more accurately than 
previous experiments.  
 
3.2 Location of E361G in the Actin Polymer 
The location of the E361G mutation is shown in Figure 3.1 A and B. It 
occupies subdomain 1 of the actin monomer, and is located at an important α-
actinin binding site. The E361G substitution may therefore affect the anchoring 
of thin filaments to the Z-bands and intercalated discs in the sarcomere (Olson 
et al., 1998). It was reported by Wong et al. (Wong et al., 2002) that E361G 
yeast mutant actin had a threefold reduction in α-actinin binding.  
E361G is a charge change mutation. The substitution of glycine for 
glutamic acid leads to a loss in the surface charge and a hole in the 
hydrophobic core. Only a small proportion of the glutamic acid side chain is 
actually located on the surface of the actin molecule (Figure 3.1 B), with the 
majority of the mutation embedded in the core. The position of the mutation is 
unlikely to be involved directly with actin polymerisation.  
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Figure 3.1. Ribbon Representation (A) and Space Filling Model 
(B) of the E361G Location in the Actin Polymer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The position of the E361G mutation on the actin surface is shown as black spheres in figure A. 
Figure B shows the position of E361G in yellow. The space filling molecular model illustrates the 
proportion of the mutation that is exposed on the surface of the actin molecule. Much is hidden 
in the core of the actin subunit. These molecular graphics images were produced using the 
USSF Chimera package (Pettersen et al., 2004). 
A B 
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3.3 Generation of E361G Transgenic Lines 
Early stages of the study established two transgenic E361G lines, line 13 
and line 20 (Table 3.1, Table 3.2). PCR analysis determined the presence or 
absence of the mutant transgene in individuals of each line. The PCR was 
performed at the Gene Targeting Unit, Charing Cross Hospital by Dr. Ke Liu.  
 
Table 3.1. E361G Transgenic Mouse Line 13 
Line 13 Sample PCR Gender Age 
(days) 
Body 
weight 
(g) 
Heart 
weight 
(g) 
1st 
generation 
361.13.14 + N/A N/A 18.20 0.08 
 361.13.15 + N/A N/A 16.06 0.05 
 361.13.16 + N/A N/A 15.91 0.06 
 361.13.17 - N/A N/A 14.82 0.05 
 361.13.18 + N/A N/A 13.86 0.05 
 361.13.19 + N/A N/A 17.10 0.07 
 361.13.20 - N/A N/A 16.43 0.08 
2nd 
generation 
361.13.2.7 - M 46 34.65 0.14 
 361.13.2.8 + M 46 34.55 0.14 
 361.13.2.10 + F 46 26.91 0.13 
 361.13.2.11 + F 46 23.84 0.11 
 361.13.2.12  F 46 25.85 0.13 
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Table 3.2. E361G Transgenic Mouse Line 20 
Line 20 Sample PCR Gender Age 
(Days) 
Body 
Weight 
(g) 
Heart 
Weight 
(g) 
1st 
generation 
361.20.3 + N/A N/A N/A N/A 
 361.20.4 - N/A N/A N/A N/A 
 361.20.6 - N/A N/A 20.28 0.08 
 361.20.7 - N/A N/A 19.47 0.09 
 361.20.8 + N/A N/A 17.79 0.07 
 361.20.9 + N/A N/A 18.06 0.07 
 361.20.12 + N/A N/A 16.76 0.08 
2nd 
generation 
361.20.1.6 + F 48 27.00 0.15 
 361.20.1.7 + F 48 24.30 0.10 
 361.20.1.8 - F 48 35.30 0.11 
 361.20.1.9 + M 35 29.85 0.12 
 361.20.1.10 + M 35 29.67 0.13 
 361.20.1.11 - M 35 26.42 0.11 
 361.20.1.12 + M 35 27.29 0.12 
 361.20.1.13 - M 35 28.12 0.10 
 361.20.1.15 + F 35 N/A N/A 
 361.20.1.16 + F 35 23.60 0.09 
 361.20.1.17 - F 35 22.59 0.11 
 361.20.1.20 + F N/A N/A N/A 
 361.20.1.22 + F N/A N/A N/A 
 361.20.55.26 + F N/A N/A N/A 
3rd 
generation 
361.20.1.20.1 + F N/A N/A N/A 
 
Two generations of transgenic mouse line 361.13 were successfully bred. 
Line 361.20 was bred into the third generation. The hearts were excised from 4-
7 week old mice. The heart-weight to body-weight ratios did not indicate cardiac 
dilation in transgenic-E361G mice. 
 
3.4 Screening of E361G Transgenic Lines 
The 2-D Electrophoresis technique (Ilkovski et al., 2004) was developed to 
test for the presence of the E361G mutant actin protein. Some of the first 
generation of PCR positive mice in lines 361.13 and 361.20 showed expression 
of mutant actin in their hearts that amounted to 50% of the total actin (Table 3.3, 
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Table 3.4). There were at least 50% false positives in the first generation (Table 
3.3 and Table 3.4, starred individuals*). These were detected as PCR positive 
but no expression was detected upon 2-D Electrophoresis. The PCR cycling 
program was modified at this stage to be more specific (performed in the 
laboratory of Prof Dominic Wells). The modifications involved an improved hot 
start - putting the enzyme into the master mix, warming up the heat block to 
94°C and then quickly adding the tubes. Additionally, the ramp speed of the 
temperature change was slowed. The original set of primers remained in use. 
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Table 3.3. Screening First Generation Transgenic Line 361.13 
 Sample PCR Result 2-DE % E361G actin 
361.13 
1st 
generation 
13.14 * +  
 
0 
 13.15 +  
 
41 
 13.16 * +  
 
0 
 13.17 -  
 
0 
 13.19 * +  
 
0 
 
Table 3.4. Screening First Generation Transgenic Line 361.20 
 Sample PCR Result 2-DE % E361G actin 
361.20 
1st 
generation 
20.3 + 
 
 48 
 20.8 * +  
 
7.5 
 20.9 * +  
 
0 
 20.12 + 
 
 22 
 
After improvements to the PCR technique, the transmission of the 
transgene into the second generation of line 13 was still only successful in 50% 
of the PCR positive hearts (Table 3.5). Transgenic line 361.13 was abandoned 
after the second generation due to the low and inconsistent transgene 
transmission rates. 
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Table 3.5 Screening Second Generation Transgenic Line 361.13 
 Sample PCR Result 2-DE % E361G 
actin 
361.13 
2nd 
generation 
13.2.8 +  
 
48 
 13.2.10 +  
 
0 
 13.2.11 +  
 
0 
 13.2.14 +  
 
49 
 
All second-generation PCR positive mice in line 361.20 were stably 
expressing E361G cardiac actin at 50% (Table 3.6). 
Table 3.6 Screening Second Generation Transgenic Line 361.20 
 Sample PCR Result 2-DE % E361G 
actin 
361.20 
2nd 
generation 
20.1.6 +  52 
 20.1.7 + 
 
 48 
 20.1.9 + 
 
 57 
 20.1.10 + 
 
 44 
 20.1.12 + 
 
 49 
 
A third generation of mice were bred from line 361.20 (Table 3.7). 
Expression levels remained consistent, amounting to approximately 50% of the 
total actin. Having shown that PCR correctly predicted transgenic mice, most of 
the third generation mice were not tested by 2-D electrophoresis. 
CHAPTER 3  
 86
Table 3.7 Screening Third Generation Transgenic Line 361.20 
 Sample PCR Result 2-DE % E361G 
actin 
361.20 
3rd 
generation 
361.20.1.20.1 +  52  
 
 
3.5 Transgenic-E361G Mouse Phenotype 
E361G-transgenic mice exhibited no overt phenotype at rest. Their heart 
weights and cardiac morphology appeared normal when measured by Magnetic 
Resonance Imaging (MRI), and the mice had a normal lifespan. However, the 
effects of increasing their cardiac output through exercise or through drugs such 
as the beta-1 adrenergic agonist dobutamine were not studied. 
 
3.6 Isolation of F-actin from E361G Transgenic Mouse Hearts 
Initially actin was isolated from mouse hearts by a modification of the 
methods of Bing et al. and Razzaq et al., developed for the preparation of actin 
from a small quantity of starting material (Bing et al., 1998, Razzaq et al., 1999). 
This involved acetone dehydration followed by extraction of actin in the 
monomeric form. The mutation was not incorporated into the F-actin by this 
method unless 150nM TRITC- phalloidin was added during the polymerisation 
step. This lead to approximately 25-40% of E361G actin being retained in the F-
actin. In order to obtain F-actin containing E361G G-actin at higher levels, 
native thin filaments were extracted. This successfully preserved the 50% 
mutation expression in the F-actin. The results of these three modifications to 
the F-actin isolation procedure and the in vitro motility assay results are outlined 
below.  
 
3.6.1 The Acetone Powder Method: Loss of E361G 
F-actin was originally isolated via an acetone powder method, based on 
the method of Razzaq et al. (Razzaq et al., 1999). 2-D Electrophoresis of the 
E361G transgenic mouse heart myofibrils showed mutant actin was expressed 
in the heart at 50%. In vitro motility analysis was carried on the F-actin isolated 
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from these mouse hearts (3.6.2) but no significant differences from non-
transgenic were ever observed. The 2-D Electrophoresis technique was 
subsequently used at this stage to assess the expression of E361G mutant 
cardiac actin in the F-actin. It showed the pure F-actin to be entirely deficient in 
the E361G mutation (Figure 3.2).  
 
Figure 3.2. 2-DE of E361G Transgenic Mouse Heart Myofibrils 
(A) and F-actin (B), Isolated via an Acetone Powder Method 
 
 
 
 
A single spot of non-transgenic F-actin (probed with 5C5 anti actin antibody) indicated the loss 
of mutant cardiac actin when extracted via the acetone powder method. 
 
3.6.2 In Vitro Motility Analysis of Mouse F-actin  
The in vitro motility assay is a versatile method of studying thin filament 
regulation. Several parameters can be measured at one time, including the 
percentage motility, sliding speed, and the number of filaments attached onto 
the myosin-covered surface. Comparative experiments are run in split motility 
cells where the actin is the only variable.  
A large amount of in vitro motility analysis was carried out on actin from 
transgenic mice before discovering the final F-actin had lost the mutant E361G 
actin. However, the results of these experiments are still useful. These 
experiments have demonstrated the contractile and regulatory properties of 
mouse actin, and have allowed comparisons to be made with rabbit actin. The 
reproducibility of the actin preparation and its measurement has also been 
demonstrated. The finding that two actin preparations can give identical results 
was an important control. It has meant that any differences that were seen were 
due to the mutation and likely to be real. The actin isolated from PCR positive 
transgenic mice which contained no transgene will be referred to as ‘TG-NTG’ 
in the following sections. 
A B 
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The basic experiments included measuring the sliding speed of 
transgenic and non-transgenic actin over skeletal muscle HMM, the titration of 
troponin at 3.9µM and 1nM Ca2+, and measuring the Ca2+-dependence of 
motility at saturating troponin concentrations. 
 
3.6.2.1  Length Distribution of Non-Transgenic and TG-NTG Actin 
Filaments 
Non-transgenic and TG-NTG actin filaments had similar appearances 
when labelled with TRITC-phalloidin (Figure 3.3). Measurements using the 
DIAS 3.2 programme showed TG-NTG actin and non-transgenic actin had 
similar filament length distributions (Figure 3.4). The mean length of non-
transgenic actin was 9.362µm ± 0.502 and TG-NTG actin was 9.042µm ± 
0.545.  
 
Figure 3.3 Non-Transgenic and TG-NTG Actin Filaments 
labelled with TRITC-phalloidin 
 
 
 
 
 
 
 
 
TG-NTG Actin 
(sample 13.15) 
 
Non-Transgenic 
Actin 
(sample 13.16) 
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Figure 3.4 Length Distribution of Non-Transgenic (13.16) and 
TG-NTG (13.15) Actin 
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Non-transgenic (13.16) and TG-NTG (13.15) are the individual mice identification numbers. 
 
3.6.2.2 Non-Transgenic and TG-NTG Actin Filament Motility 
The sliding speed and percentage motility of non-transgenic and TG-
NTG actin over HMM was compared (Table 3.8). Actin sliding speeds and the 
percentage motile of filaments were of a high standard and comparable to 
values that can be obtained with rabbit actin. Good consistencies of actin sliding 
speeds were established. There was no significant difference between the 
sliding speeds of the two actins (paired t-test, p = 0.78, n = 18). The percentage 
motile of filaments was also not significantly different for non-transgenic and 
transgenic actin (paired t-test, p = 1.0). 
 
 
NTG 
TG-NT  
CHAPTER 3  
 90
Table 3.8. Comparison of Non-Transgenic and TG-NTG Actin 
Sliding Speeds and Percentage Motile of Filaments 
Mouse Line Filament Sliding Speed            
(mm/sec) 
Filament Percentage Motile 
NTG TG-
NTG 
NTG TG-NTG NTG TG-NTG 
13.17 20.3 3.3 ± 0.05 
3.2 ± 0.05 
3.6 ± 0.07 
3.2 ± 0.03 
3.6 ± 0.06 
3.7 ± 0.05 
95 ± 1.49 
97 ± 0.73 
94 ± 1.26 
96 ± 2.01 
96 ± 1.24 
97 ± 0.73 
13.16 13.15 3.5 ± 0.16 
3.2 ± 0.10 
4.1 ± 0.04 
2.3 ± 0.19 
2.8 ± 0.12 
3.2 ± 0.30 
3.0 ± 0.04 
3.7 ± 0.12 
2.8 ± 0.07 
3.1 ± 0.16 
3.3 ± 0.20 
3.8 ± 0.27 
3.7 ± 0.28 
4.0 ± 0.12 
4.2 ± 0.34 
3.7 ± 0.01 
4.0 ± 0.09 
4.0 ± 0.28 
2.1 ± 0.12 
2.6 ± 0.12 
2.8 ± 0.17 
3.2 ± 0.05 
3.0 ± 0.07 
3.5 ± 0.04 
3.0 ± 0.02 
3.4 ± 0.11 
4.2 ± 0.11 
4.0 ± 0.29 
3.6 ± 0.14 
3.7 ± 0.02 
98 ± 1.10 
95 ± 1.25 
96 ± 0.87 
99 ± 0.29 
99 ± 0.29 
98 ± 0.75 
98 ± 2.63 
99 ± 0.58 
98 ± 0.91 
91 ± 6.37 
99 ± 0.58 
88 ± 12.1 
91 ± 1.15 
94 ± 2.08 
83 ± 3.70 
95 ± 2.45 
94 ± 4.37 
98 ± 0.85 
91 ± 2.80 
99 ± 0.63 
91 ± 2.35 
92 ± 3.50 
96 ± 1.29 
99 ± 0.75 
91 ± 1.37 
99 ± 0.95 
95 ± 5.40 
91 ± 2.67 
93 ± 1.93 
99 ± 0.25 
Mean ± SE 
(n = 18) 
3.38 ± 0.12 
 
3.41 ± 0.13 95.11 ± 1.04 95.11 ± 0.72 
T Test 
P Value 
Paired     = 0.78 
Unpaired = 0.87 
Paired     = 1.0 
Unpaired = 1.0 
 
3.6.2.3 Effects of Human Cardiac Tropomyosin on Actin Filament Motility 
The functional effect of human cardiac tropomyosin was measured by 
titrating tropomyosin against 10nM non-transgenic and transgenic actin 
filaments. An optimal increase was seen at 40 nM tropomyosin provided that 
actin and tropomyosin were mixed at a 10 times concentration and then diluted 
to the working concentration. 6 measurements were taken from one set of 
paired non-transgenic and TG-NTG mouse hearts and the averages are shown 
in Table 3.9 and Table 3.10. 
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Figure 3.5 Effect of Human Cardiac Tropomyosin on Non-
Transgenic and TG-NTG Actin Motility: (A) Sliding Speed, and 
(B) % motility  
 
 
Non-transgenic and TG-NTG actin sliding speeds increased when 
tropomyosin was added. Non-transgenic actin increased by 23%. This was a 
significant increase in the paired t-test (P = 0.01). TG-NTG actin increased by 
15%, which was also a significant increase in the paired t-test, (p = 0.002). 
Overall, TG-NTG actin.tropomyosin had a 7% slower sliding speed compared to 
non-transgenic actin, and this was significant in the paired t-test (p = 0.001).  
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The addition of tropomyosin caused a decrease in the percentage motile 
of filaments (Table 3.10). Non-transgenic actin-tm decreased by 12% and TG-
NTG actin-tm decreased by 7%. However, there was no significant difference 
between the TG-NTG and non-transgenic actin.tropomyosin in the paired t-test 
(p=0.61). This can be compared with the percentage motility of rabbit actin 
filaments, which increased by 13% (Messer, 2007 PhD Thesis).  
 
Table 3.9 Comparison of Non-Transgenic Actin-Tm and TG-NTG 
Actin-Tm Sliding Speeds 
Filament Sliding Speed (mm/sec) 
Mouse Line Actin Actin.Tm 
NTG TG-NTG NTG TG-NTG NTG TG-NTG 
13.16 13.15 4.1 ± 0.04 
2.3 ± 0.19 
2.8 ± 0.12 
3.2 ± 0.30 
3.0 ± 0.04 
2.8 ± 0.07 
 
4.0 ± 0.28 
2.1 ± 0.12 
2.6 ± 0.12 
2.8 ± 0.17 
3.2 ± 0.05 
3.5 ± 0.04 
 
5.0 ± 0.67 
2.8 ± 0.12 
3.1 ± 0.09 
3.4 ± 0.13 
4.0 ± 0.12 
4.1 ± 0.13 
4.7 ± 0.09 
2.6 ± 0.12 
2.8 ± 0.12 
3.3 ± 0.12 
3.6 ± 0.14 
3.8 ± 0.15 
Mean ±SE 
(n = 6) 
3.03 ± 0.25 
 
3.03 ± 0.27 3.73 ± 0.33 3.47 ± 0.31 
T Test 
P Value 
Paired     =1.0 
Unpaired =1.0 
Paired     =0.001 
Unpaired =0.57 
T-test of Actin: Actin.Tm Paired=0.01 
Unpaired=0.12 
 
Paired=0.002 
Unpaired=0.32 
 
Table 3.10 Comparison of Non-Transgenic Actin-Tm and TG-
NTG Actin-Tm Percentage Motile of Filaments 
Percentage Motile of Filaments 
Mouse Line Actin Actin.Tm 
NTG TG-NTG NTG TG-NTG NTG TG-NTG 
13.16 13.15 96 ± 0.87 
98 ± 0.75 
99 ± 0.29 
99 ± 0.29 
98 ± 2.63 
98 ± 0.91 
98 ± 0.85 
91 ± 2.35 
91 ± 2.80 
99 ± 0.63 
92 ± 3.50 
98 ± 0.75 
85 ± 0.82 
88 ± 12.1 
69 ± 0.57 
91 ± 6.80 
99 ± 1.41 
83 ± 1.30 
86 ± 2.64 
95 ± 5.40 
53 ± 2.52 
97 ± 1.30 
99 ± 1.50 
99 ± 6.80 
Mean ± SE 
(n = 6) 
98.00 ± 
0.45 
94.83 ± 1.58 85.83 ± 4.07 88.17 ± 7.30 
T Test 
P Value 
Paired     = 0.13 
Unpaired = 0.08 
Paired     = 0.61 
Unpaired = 0.79 
T-test of Actin: Actin.Tm Paired =0.03 
Unpaired=0.01 
Paired=0.37 
Unpaired=0.39 
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3.6.2.4 Effects of Non-failing Human Cardiac Troponin on Non-transgenic 
and TG-NTG Thin Filament Motility at High and Low Ca2+ 
Thin filaments were assembled using TG-NTG or non-transgenic actin, 
human cardiac tropomyosin and non-failing human cardiac troponin. Troponin 
at increasing concentrations (20-40nM) was titrated with 10nM actin and 60nM 
human cardiac tropomyosin.  
 
Figure 3.6 Effect of Non-Failing Human Cardiac Troponin on 
Non-Transgenic and TG-NTG Actin Motility at High and Low 
Ca2+ 
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An initial titration was carried out at 1nM Ca2+ to obtain a concentration 
where troponin produced a maximum switch-off. Filament motility for both non-
transgenic and TG-NTG actin was switched off by 40nM troponin with the 
percentage motility at 3-4% and the sliding speed reduced by 46% for TG-NTG 
actin and 52% for non-transgenic actin. Troponin I is responsible for this 
‘switch-off’ effect (Bing et al., 1997). There were no significant differences 
between non-transgenic and TG-NTG actin sliding speeds at low Ca2+ (paired t-
test, p = 0.56). The percentage motile of non-transgenic and TG-NTG actin 
filaments was also not significantly different in the paired t-test (p = 0.33). The 
motility of both non-transgenic and TG-NTG actin were inhibited to a similar 
degree at low Ca2+. 
At high Ca2+, actin filament sliding speeds and the percentage motile of 
filaments reach a maximum value with increasing troponin concentrations and 
then level off or fall below the maximum value. This ‘switch-on’ effect is 
mediated by troponin T and troponin C. At high Ca2+, 40nM troponin produced a 
maximum increase in the actin sliding speed and the percentage motile of actin 
filaments. Non-transgenic actin sliding speed increased 3% over 
actin.tropomyosin. In comparison, TG-NTG actin produced a much larger 
increase in sliding speed of 13% over actin.tropomyosin. This larger increase in 
sliding speed of the TG-NTG actin caused the significant difference between 
non-transgenic and TG-NTG actin.tropomyosin to be lost. At high Ca2+, there 
was no significant difference between non-transgenic and TG-NTG actin sliding 
speeds (paired t-test, p = 0.67). The percentage motile of non-transgenic and 
TG-NTG actin filaments was also not significantly different in the paired t-test (p 
= 0.72). The collective data from 6 experiments are shown in Table 3.11 to 
Table 3.15. 
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Table 3.11 Comparison of Non-transgenic and TG-NTG Actin 
Sliding Speeds at 1nM Ca2+ (40nM NF Tn) 
 
Table 3.12 Comparison of Non-transgenic and TG-NTG Actin 
Percentage Motility at 1nM Ca2+ (40nM NF Tn) 
Mouse Line % Motile Actin.Tm % Motile  
Actin.Tm.Tn 
(1nM Ca2+) 
Relative % motility 
of Actin.Tm.Tn: 
Actin.Tm 
NTG TG-
NTG 
NTG TG-NTG NTG TG-NTG NTG TG-
NTG 
13.16 13.15 85 ± 0.82 
88 ± 12.1 
69 ± 0.57 
91 ± 6.80 
99 ± 1.41 
83 ± 1.30 
86 ± 2.64 
95 ± 5.40 
53 ± 2.52 
97 ± 1.30 
99 ± 1.50 
99 ± 6.80 
1 ± 0.20 
9 ± 0.63 
4 ± 1.45 
3 ± 4.52 
1 ± 6.23 
2 ± 7.21 
3 ± 1.42 
9 ± 0.98 
9 ± 5.42 
2 ± 1.46 
2 ± 5.23 
1 ± 2.31 
0.01 
0.10 
0.06 
0.03 
0.01 
0.02 
0.03 
0.10 
0.17 
0.02 
0.02 
0.01 
Mean ± SE 
 (n = 6) 
85.83 ± 
4.07 
88.17 ± 
7.3 
3.33 
±1.23 
4.33 
±1.50 
0.04 
±0.01 
0.06 
±0.03 
T-test 
P Value 
Paired = 0.61 
Unpaired = 0.79 
Paired = 0.33 
Unpaired = 0.62 
Paired = 0.33 
Unpaired = 0.52 
T-test of Actin.Tm: Actin.Tm.Tn Paired=<.0001 
Unpaired=<.0001 
Paired=0.0002 
Unpaired=<.00
01 
 
 
 
 
 
 
 
Mouse Line Sliding Speed 
Actin.Tm 
Sliding Speed 
Actin.Tm.Tn 
 (1nM Ca2+) 
Relative Sliding 
Speed of 
Actin.Tm.Tn: 
Actin.Tm 
NTG TG-
NTG 
NTG TG-NTG NTG TG-NTG NTG TG-
NTG 
13.16 13.15 5.0±0.67 
2.8±0.12 
3.1±0.09 
3.4±0.13 
4.0±0.12 
4.1±0.13 
4.7±0.09 
2.6±0.12 
2.8±0.12 
3.3±0.12 
3.6±0.14 
3.8±0.15 
3.8±0.03 
1.3±0.13 
1.7±0.13 
1.4±0.15 
1.1±0.09 
1.5±0.25 
4.1±0.03 
1.5±0.46 
1.6±0.52 
1.6±0.67 
1.5±0.16 
1.0±0.10 
0.8 
0.5 
0.6 
0.4 
0.3 
0.4 
0.9 
0.6 
0.6 
0.5 
0.4 
0.3 
Mean ± SE 
(n = 6) 
3.73 
± 0.33 
3.47 
±0.31 
1.80 
±0.41 
1.88 
±0.45 
0.50 ± 
0.07 
0.55 
±0.08 
T-test 
P Value 
Paired = 0.001 
Unpaired = 0.57 
Paired = 0.56 
Unpaired = 0.89 
Paired = 0.20 
Unpaired = 0.66 
T-test of Actin.Tm: Actin.Tm.Tn Paired=0.001 
Unpaired=0.004 
Paired=0.004 
Unpaired=0.016 
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Table 3.13 Comparison of Non-transgenic and TG-NTG Actin 
Sliding Speeds at 3.9µM Ca2+ (40nM NF Tn) 
 
Table 3.14 Comparison of Non-transgenic and TG-NTG Actin 
Percentage Motility at 3.9µM Ca2+ (40nM NF Tn) 
 
 
 
 
Mouse Line Sliding Speed 
Actin.Tm 
Sliding Speed Actin.Tm.Tn 
(3.9µM Ca2+) 
Relative Sliding 
Speed of 
Actin.Tm.Tn: 
Actin.Tm 
NTG TG-
NTG 
NTG TG-NTG NTG TG-NTG NTG TG-
NTG 
13.16 13.15 5.0±0.67 
2.8±0.12 
3.1±0.09 
3.4±0.13 
4.0±0.12 
4.1±0.13 
4.7±0.09 
2.6±0.12 
2.8±0.12 
3.3±0.12 
3.6±0.14 
3.8±0.15 
4.1±0.28 
2.7±0.14 
3.2±0.21 
3.9±0.18 
4.5±0.04 
4.7±0.76 
4.8±0.14 
2.8±0.07 
2.6±0.19 
3.9±0.10 
4.9±0.14 
4.6±0.09 
0.8 
0.9 
1.1 
1.2 
1.1 
1.2 
1.0 
1.1 
0.9 
1.2 
1.4 
1.2 
Mean ± SE 
(n = 6) 
3.73 
± 0.33 
3.47 
±0.31 
3.85 
±0.31 
3.93 
± 0.42 
1.05 
± 0.07 
1.13 
± 0.07 
T-test 
P Value 
Paired = 0.001 
Unpaired = 0.57 
Paired = 0.67 
Unpaired = 0.88 
Paired = 0.32 
Unpaired = 0.42 
T-test of Actin.Tm: Actin.Tm.Tn Paired=0.64 
Unpaired=0.
80 
Paired=0.09 
Unpaired=0.
39 
 
Mouse Line % Motile Actin.Tm % Motile  
Actin.Tm.Tn 
(3.9µM Ca2+) 
Relative % 
motility of 
Actin.Tm.Tn: 
Actin.Tm 
NTG TG-
NTG 
NTG TG-NTG NTG TG-NTG NTG TG-
NTG 
13.16 13.15 85 ± 0.82 
88 ± 12.1 
69 ± 0.57 
91 ± 6.80 
99 ± 1.41 
83 ± 1.30 
86 ± 2.64 
95 ± 5.40 
53 ± 2.52 
97 ± 1.30 
99 ± 1.50 
99 ± 6.80 
90±2.62 
99±6.23 
63±1.65 
87±1.59 
92±2.36 
97±4.26 
83±1.50 
98±5.60 
66±4.20 
90±1.36 
97±1.87 
98±4.63 
1.1 
1.1 
0.9 
0.9 
0.9 
1.2 
1.0 
1.0 
1.2 
0.9 
1.0 
1.0 
Mean ± SE 
(n = 6) 
85.83 ± 
4.07 
88.17 ± 7.3 88.00 ± 5.32 88.67 ± 5.14 1.02 ± 
0.05 
1.02 ± 
0.04 
T-test 
P Value 
Paired = 0.61 
Unpaired = 0.79 
Paired = 0.72 
Unpaired = 0.93 
Paired = 1.0 
Unpaired = 1.0 
T-test of Actin.Tm: Actin.Tm.Tn Paired=0.59 
Unpaired=0.75 
Paired=0.87 
Unpaired=0.96 
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3.6.2.5 Comparing Ca2+ Concentration Curves of Non-transgenic and TG-
NTG Actin  
The minimum concentration of troponin that gave a good switch off at 
low Ca2+ and a good switch on at high Ca2+ was used for the Ca2+ concentration 
curves. 10nM non-transgenic or transgenic actin was titrated against 40-60nM 
human cardiac troponin and 60nM tropomyosin to determine the optimum 
troponin concentration. Thin filaments were then compared simultaneously over 
a range of Ca2+ concentrations from 1nM to 3.9µM Ca2+. All experiments were 
carried out at 28˚C. The percentage motile of filaments and sliding speed 
parameters were fitted to a 4-parameter Hill Equation using KaleidaGraph. 
 
      bn [Ca2+]n          a  = min value 
Hill Equation:   X  =  a +           bn  = max - min 
    (k + [Ca2+]n)          k  = EC50 
               n  = hill co-efficient 
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Figure 3.7 Ca2+ Regulation of Thin Filaments Containing Non-
Transgenic and TG-NTG Actin, (A) Sliding Speed and (B) 
Percentage Motile (40nM Troponin)  
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A single paired experiment was completed and is shown above. Thin 
filaments containing TG-NTG and non-transgenic actin were not significantly 
different. The EC50 ratio of non-transgenic to TG-NTG actin sliding speeds was 
1.4, and 0.95 for the percentage motility. The sliding speed of non-transgenic 
actin increased by 3.2µm/sec from low to high Ca2+, and TG-NTG actin 
A 
B 
TG-NTG 
NTG 
TG-NTG 
NTG 
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increased by 3.8µm/sec. The percentage motile of non-transgenic filaments 
increased 98% from low to high Ca2+, and TG-NTG actin increased 99%.  
 
3.6.2.6 Competitive Binding Assay of Fluorescent and Non-Fluorescent 
Actin to α-Actinin 
The E361G substitution in actin is located within the α-actinin binding site 
and may affect the anchoring of thin filaments to the Z-bands and intercalated 
discs in the sarcomere (Olson et al., 1998). Because of the possibility that the 
E361G mutation may disrupt important contacts between actin and α-actinin, 
the actin-α-actinin binding affinity in a competitive binding assay was 
investigated. TRITC- phalloidin labelled TG-NTG and non-transgenic actin 
filaments were mixed in a range of ratios with non-fluorescent TG-NTG or non-
transgenic actin.  
 
Figure 3.8 α-actinin Competitive Binding Assay  
 
 
 
 
 
 
 
 
 
 
 
 
 
Both graphs show how the number of fluorescent filaments varies with the fraction of unlabelled 
TG-NTG and non-transgenic actin. Graphs A and B were produced from the same assay. The 
actual numbers of fluorescent actin filaments are plotted in graph A. In graph B, the numbers of 
both TG-NTG and non-transgenic fluorescent actin filaments have been normalised to start at 
100 filaments. The remaining numbers have then been plotted as a ratio to this original number. 
 
When normalised, there was no difference in the binding of TG-NTG and 
non-transgenic actin for α-actinin. Since actin was in great excess over α-
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actinin, TRITC actin-f competed with non-fluorescent actin to bind to the α-
actinin. The amount of fluorescent relative to non-fluorescent actin filaments 
that bound depended upon the ratio of the two species to their relative affinity, 
defined by the equation: 
    y = Filament number 
y = F.K / (FK+ (1-F)) F= Fraction of fluorescently labelled filaments 
K= Ratio of binding constant 
 
Figure 3.9 shows the fraction of labelled actin plotted against the number 
of filaments normalised to 1 for 100% labelled actin. It has been fitted to the α-
actinin binding equation and shows there is no difference in the affinity of TG-
NTG actin for α-actinin compared to non-transgenic actin for α-actinin. TG-NTG 
actin had K value of 0.381 ± 0.002, and non-transgenic actin had a K value of 
0.423 ± 0.006. Both TG-NTG and non-transgenic actin had an affinity for α-
actinin of less than rabbit actin (K<1). 
 
Figure 3.9 α-actinin Competitive Binding Fit 
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3.6.3 The Acetone Powder Method: Partial Extraction of E361G 
in the F-actin 
Since the E361G mutation was not incorporated into the F-actin when 
actin was isolated from an acetone powder (Bing et al., 1998, Razzaq et al., 
1999), the extraction process was modified. The extraction involved acetone 
dehydration, the extraction of actin in its monomeric form, and polymerisation 
by MgCl2 and KCl. The addition of 150nM TRITC-rhodamine phalloidin during 
the polymerisation step allowed E361G transgenic actin to be partially extracted 
from the acetone powder. The actin extracted via this method and described in 
this section will be referred to as actin-f. 
2D-electrophoresis showed that E361G transgenic actin-f was extracted 
less than the non-transgenic actin-f, with only 25-40% of E361G actin being 
expressed in the F-actin (Figure 3.10). The E361G actin could not co-
polymerise with the non-transgenic actin if phalloidin was not present. 2D-
electrophoresis results showed a considerable amount of the mutant cardiac 
actin was lost during its extraction from the acetone powder using ACEX. This 
highlights the unstable nature of the mutant G-actin. Mutant actin expression in 
the ACEX extraction supernatant after the high-speed spin was reduced to 
approximately 20%, since the instability of the mutant G-actin caused it to 
aggregate. 
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Figure 3.10 2-DE of E361G Expression During Extraction via an 
Acetone Powder  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
3.6.4 In Vitro Motility Analysis of Mouse F-actin-f 
3.6.4.1 Actin-f Filament Motility 
27 separate measurements were taken using 5 pairs of hearts and the 
averages are shown in Table 3.15. E361G actin-f sliding speeds were slower 
than non-transgenic actin-f. The difference was significant in the paired t-test (p 
= <0.001). The sliding speed of the E361G actin-f was 0.95 x the sliding speed 
of the non-transgenic actin-f, which was a 5% drop. E361G also had a 
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significantly lower percentage motile of filaments than non-transgenic actin-f 
(paired t-test, p = 0.006). The percentage motile of E361G actin-f filaments was 
3% lower. 
 
Table 3.15 Comparison of Non-Transgenic and Transgenic 
Actin-f Sliding Speeds and Percentage Motile of Filaments 
Mouse Line Filament Sliding Speed 
(mm/sec) 
Filament Percentage Motile 
NTg E361G NTg E361G NTg E361G 
20.1.17 20.1.10 2.3 ± 0.06 
2.1 ± 0.03 
2.2 ± 0.07 
2.3 ± 0.03 
2.5 ± 0.11 
2.5 ± 0.06 
2.8 ± 0.03 
2.9 ± 0.03 
3.1 ± 0.03 
3.5 ± 0.05 
3.1 ± 0.15 
3.3 ± 0.04 
3.4 ± 0.08 
3.3 ± 0.04 
2.3 ± 0.45 
2.0 ± 0.03 
2.1 ± 0.03 
2.2 ± 0.05 
2.3 ± 0.06 
2.4 ± 0.07 
2.7 ± 0.08 
2.8 ± 0.05 
3.0 ± 0.12 
3.3 ± 0.05 
3.2 ± 0.07 
3.2 ± 0.08 
3.2 ± 0.06 
3.2 ± 0.09 
99 ± 0.67 
91 ± 3.49 
85 ± 4.6 
99 ± 0.75 
95 ± 1.25 
96 ± 0.87 
97 ± 1.69 
97 ± 1.26 
98 ± 0.97 
98 ± 0.68 
97 ± 2.76 
99 ± 0.40 
99 ± 0.51 
97 ± 1.22 
96 ± 2.33 
94 ± 0.50 
79 ± 6.09 
87 ± 7.64 
94 ± 4.37 
98 ± 0.85 
88 ± 3.20 
92 ± 3.37 
96 ± 2.91 
97 ± 2.27 
99 ± 0.55 
98 ± 0.60 
98 ± 1.11 
93 ± 2.63 
20.1.13 20.1.9 2.7 ± 0.08 
3.0 ± 0.02 
3.1 ± 0.05 
2.9 ± 0.06 
2.5 ± 0.13 
2.8 ± 0.04 
2.9 ± 0.08 
2.9 ± 0.05 
95 ± 1.49 
97 ± 0.73 
96 ± 1.21 
97 ± 1.6 
96 ± 2.01 
96 ± 1.24 
94 ± 1.26 
99 ± 0.50 
20.1.8 20.1.7 2.2 ± 0.04 
2.2 ± 0.04 
2.1 ± 0.01 
2.2 ± 0.01 
88 ± 1.20 
85 ± 4.19 
84 ± 1.96 
86 ± 4.76 
13.2.13 20.1.12 2.7 ± 0.04 
2.4 ± 0.02 
2.6 ± 0.002 
2.5 ± 0.07 
97 ± 0.29 
84 ± 7.88 
96 ± 1.19 
93 ± 2.01 
13.2.12 20.1.16 3.0 ± 0.04 
2.9 ± 0.04 
3.0 ± 0.02 
3.0 ± 0.09 
2.6 ± 0.04 
2.8 ± 0.11 
2.6 ± 0.13 
2.6 ± 0.02 
2.7 ± 0.04 
2.5 ± 0.03 
86 ± 4.10 
78 ± 4.16 
86 ± 4.50 
89 ± 3.00 
75 ± 2.56 
76 ± 6.40 
68 ± 11.4 
72 ± 2.32 
81 ± 1.15 
67 ± 4.91 
Mean ± SE 
(n = 27) 
2.78 ± 0.08 2.65 ± 0.07 92.59 ± 1.32 89.56 ± 1.87 
T Test 
P Value 
Paired     = <0.001 
Unpaired = 0.24 
Paired     = 0.006 
Unpaired = 0.19 
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3.6.4.2 Effects of Human Cardiac Tropomyosin on Actin-f Filament 
Motility 
Cardiac tropomyosin was titrated against 10nM non-transgenic and 
E361G actin-f. The data for a single paired non-transgenic and E361G 
comparison is shown in Figure 3.11. An optimal increase was seen at 60nM 
tropomyosin. Data was collected from 12 separate plots (5 paired mouse 
hearts) and the averages are shown in Table 3.16 and Table 3.17. 
 
Figure 3.11 Effect of Human Cardiac Tropomyosin on Non-
Transgenic and Transgenic Actin-f Motility: (A) Sliding Speed, 
and (B) % motility  
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After 12 separate measurements, the sliding speed of pure E361G actin-
f was 0.94 x slower than non-transgenic actin-f. This was a 6% drop and the 
difference was significant (p = 0.002), as previously found. At optimum 
tropomyosin concentrations, the sliding speeds of E361G increased by 7% and 
non-transgenic actin-f increased by 2%. The addition of tropomyosin therefore 
removed the difference seen between the sliding speeds of pure non-transgenic 
and E361G actin-f (p = 0.57).  
The percentage motile of E361G actin-f filaments was 0.94 x lower than 
the percentage of non-transgenic actin-f filaments. This is a 6% drop, which is 
significant (p = 0.02). The addition of tropomyosin removed the difference in the 
percentage of non-transgenic and E361G motile actin-f filaments (p = 0.75). 
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Table 3.16 Comparison of Non-Transgenic-Tm and E361G-Tm 
Sliding Speeds  
Filament Sliding Speed (mm/sec) 
Mouse Line Actin-f Actin.Tm 
NTg Tg Non-
Transgenic 
Transgenic Non-
Transgenic 
Transgenic 
20.1.17 20.1.10 2.3 ± 0.06 
2.1 ± 0.03 
2.2 ± 0.07 
2.3 ± 0.45 
2.0 ± 0.03 
2.1 ± 0.03 
2.4 ± 0.04 
2.5 ± 0.03 
2.6 ± 0.06 
2.5 ± 0.02 
2.5 ± 0.08 
2.7 ± 0.05 
20.1.13 20.1.9 3.0 ± 0.02 
2.7 ± 0.08 
2.8 ± 0.04 
2.5 ± 0.13 
3.2 ± 0.03 
2.9 ± 0.04 
2.9 ± 0.23 
2.8 ± 0.09 
20.1.8 20.1.7 2.2 ± 0.04 2.1 ± 0.01 2.4 ± 0.03 2.3 ± 0.02 
13.2.13 20.1.12 2.7 ± 0.04 
2.4 ± 0.02 
2.6 ± 0.002 
2.5 ± 0.07 
2.6 ± 0.07 
2.5 ± 0.05 
3.0 ± 0.11 
2.6 ± 0.02 
13.2.12 20.1.16 3.0 ± 0.04 
2.9 ± 0.04 
3.0 ± 0.02 
3.0 ± 0.09 
2.8 ± 0.11 
2.6 ± 0.13 
2.6 ± 0.02 
2.7 ± 0.04 
2.7 ± 0.03 
2.9 ± 0.09 
2.8 ± 0.009 
2.6 ± 0.02 
2.5 ± 0.07 
2.6 ± 0.08 
2.7 ± 0.08 
2.6 ± 0.02 
Mean ± SE  
(n = 12) 
2.63 ± 0.10 2.47 ± 0.08 2.68 ± 0.07 2.64 ± 0.06 
T Test 
P Value 
Paired     = 0.002 
Unpaired = 0.24 
Paired     = 0.57 
Unpaired = 0.71 
T-test of Actin-f: Actin.Tm Paired=0.52 
Unpaired=0.69 
Paired= 0.04 
Unpaired=0.09 
 
Table 3.17 Comparison of Non-Transgenic-Tm and E361G-Tm 
Percentage Motile of Filaments 
Percentage Motile of Filaments 
Mouse Line Actin-f Actin.Tm 
NTg Tg Non-
Transgenic 
Transgenic Non-
Transgenic 
Transgenic 
20.1.17 20.1.10 85 ± 4.60 
99 ± 0.75 
97 ± 1.69 
79 ± 6.09 
87 ± 7.64 
88 ± 3.20 
86 ± 2.12 
87 ± 2.16 
99 ± 0.29 
93 ± 1.70 
96 ± 3.57 
91 ± 2.80 
20.1.13 20.1.9 95 ± 1.49 
97 ± 0.73 
96 ± 2.01 
96 ± 1.24 
91 ± 3.14 
100 ± 0.29 
96 ± 1.88 
94 ± 1.44 
20.1.8 20.1.7 88 ± 1.20 84 ± 1.96 83 ± 3.81 83 ± 3.43 
13.2.13 20.1.12 97 ± 0.29 
84 ± 7.88 
96 ± 1.19 
93 ± 2.01 
93 ± 2.25 
81 ± 1.73 
92 ± 1.11 
74 ± 5.70 
13.2.12 20.1.16 86 ± 4.10 
78 ± 4.16 
86 ± 4.50 
75 ± 2.56 
76 ± 6.4 
68 ± 11.4 
72 ± 2.32 
67 ± 4.91 
72 ± 9.33 
74 ± 6.59 
86 ± 1.85 
76 ± 9.61 
63 ± 6.35 
72 ± 5.34 
86 ± 4.49 
81 ± 2.53 
Average ± SE 
(n = 12) 
88.92 ± 2.31 83.50 ± 3.15 85.67 ± 2.63 85.08 ± 3.10 
T Test 
P Value 
Paired     = 0.02 
Unpaired = 0.18 
Paired     = 0.75 
Unpaired = 0.89 
T-test of Actin-f: Actin.Tm Paired =0.06 
Unpaired=0.36 
Paired=0.61 
Unpaired=0.72 
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3.6.4.3 Effects of Non-failing Human Cardiac Troponin on Non-transgenic 
and E361G Filament Motility at High and Low Ca2+ 
Troponin at increasing concentrations (20-40nM) was titrated with 10nM 
actin-f and 60nM human cardiac tropomyosin.  Sliding speeds and the 
percentage motile of actin-f filaments were measured at high Ca2+ 
concentration (3.9µM Ca2+) and low Ca2+ concentration (1nM Ca2+).  
 
Figure 3.12 Effects of Non-failing Human Cardiac Troponin on 
Non-transgenic and E361G filament Motility at 3.9µM Ca2+ and 
1nM Ca2+ 
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Actin-f filament motility for both non-transgenic and E361G actin-f was 
switched off by 40nM troponin with the percentage motility at less than 3% and 
the sliding speed reduced by 50%. There were no significant differences 
between non-transgenic and transgenic actin-f sliding speeds at low Ca2+ 
(paired t-test, p = 0.36). The percentage motile of non-transgenic and 
transgenic actin-f filaments was also not significantly different in the paired t-
test (p = 0.45) (Table 3.18 and Table 3.19).  
At high Ca2+, 40nM troponin produced a maximum increase in the actin-f 
sliding speed and the percentage motile of actin-f filaments. Non-transgenic 
actin sliding speed increased 11% over actin.tropomyosin, and transgenic actin-
f increased 9% over actin.tropomyosin. Troponin increased the percentage 
motile of actin-f filaments an average of 1% for non-transgenic actin-f and 4% 
for E361G actin-f. Over 9 assays, the percentage motile of E361G actin-f 
filaments was not significantly different from non-transgenic actin-f (paired t-
test, p = 0.61) (Table 3.20 and Table 3.21).  
At high Ca2+, the increase in the sliding speed and the percentage motile 
of non-transgenic and E361G actin-f filaments was small. This is a 
characteristic of mouse actin-f. Larger increases are produced with rabbit actin-
f. At high Ca2+, 40nM non-failing troponin increased rabbit actin-f sliding speed 
by 26% over actin-tropomyosin thin filaments and the percentage motility was 
increased by approximately 5% (Messer, PhD Thesis, 2007).  
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Table 3.18 Comparison of Non-Transgenic and E361G Actin-f 
Sliding Speeds at 1nM Ca2+ 
Mouse Line Sliding Speed 
Actin.Tm 
Sliding Speed Actin.Tm.Tn 
(1nM Ca2+) 
Relative Sliding 
Speed of 
Actin.Tm.Tn: 
Actin.Tm 
Tg NTg NTg E361G NTg E361G NTg E361G  
20.1.17 20.1.1
0 
2.4 ± 0.04 
2.5 ± 0.03 
2.6 ± 0.06 
2.5 ± 0.02 
2.5 ± 0.08 
2.7 ± 0.05 
1.7 ± 0.21 
1.7 ± 0.34 
1.4 ± 0.20 
1.0 ± 0.01 
1.6 ± 0.12 
1.5 ± 0.20 
0.7 
0.7 
0.5 
0.4 
0.6 
0.6 
20.1.13 20.1.9 3.2 ± 0.03 
2.9 ± 0.04 
2.9 ± 0.23 
2.8 ± 0.09 
1.1 ± 0.69 
0.6 ± 0.11 
1.3 ± 0.33 
1.0 ± 0.13 
0.3 
0.2 
0.4 
0.4 
20.1.8 20.1.7 2.4 ± 0.03 2.3 ± 0.02 1.0 ± 0.14 0.5 ± 0.25 0.4 0.2 
13.2.13 20.1.1
2 
2.6 ± 0.07 
2.5 ± 0.05 
3.0 ± 0.11 
2.6 ± 0.02 
1.5 ± 0.19 
1.6 ± 0.24 
0.8 ± 0.49 
1.8 ± 0.11 
0.6 
0.6 
0.3 
0.7 
13.2.12 20.1.1
6 
2.6 ± 0.02 2.6 ± 0.02 1.2 ± 0.05 1.1 ± 0.37 0.5 0.4 
Mean ± SE 
n = 9  
2.63 ± 
0.09 
2.66 ± 0.07 1.31 ± 0.12 1.18 ± 0.14 0.50 ± 
0.06 
0.44 ± 
0.05 
T-test 
P Value 
 Paired     = 0.74 
Unpaired = 0.85 
Paired     = 0.36 
Unpaired = 0.48 
Paired = 0.40 
Unpaired = 0.49 
T-test of Actin.Tm: Actin.Tm.Tn Paired=<.0001 
Unpaired=<.00
01 
Paired=<.0001 
Unpaired=<.000
1 
 
 
Table 3.19 Comparison of Non-Transgenic and E361G Actin-f 
Percentage Motility at 1nM Ca2+ 
Mouse Line % Motile Actin.Tm % Motile Actin.Tm.Tn 
(1nM Ca2+) 
Relative % 
Motility of 
Actin.Tm.Tn: 
Actin.Tm 
Tg NTg NTg E361G NTg E361G NTg E361G  
20.1.1
7 
20.1.1
0 
86 ± 2.12 
87 ± 2.16 
99 ± 0.29 
93 ± 1.7 
96 ± 3.57 
91 ± 2.8 
1 ± 0.75 
6 ± 1.65 
3 ± 0.30 
1 ± 0. 
7 ± 1.48 
3 ± 1.08 
0.01 
0.10 
0.02 
0.01 
0.07 
0.03 
20.1.1
3 
20.1.9 91 ± 3.14 
100 ± 0.29 
96 ± 1.88 
94 ± 1.44 
1 ± 0.58 
1 ± 0.28 
1 ± 0.20 
1 ± 0.48 
0.01 
0.01 
0.01 
0.01 
20.1.8 20.1.7 83 ± 3.81 83 ± 3.43 4 ± 1.25 4 ± 1.85 0.05 0.04 
13.2.1
3 
20.1.1
2 
93 ± 2.25 
81 ± 1.73 
92 ± 1.11 
74 ± 5.70 
8 ± 2.39 
2 ± 0.25 
6 ± 1.49 
1 ± 0.41 
0.08 
0.03 
0.06 
0.01 
13.2.1
2 
20.1.1
6 
72 ± 9.33 63 ± 6.35 1 ±0.10 1 ± 0.47 0.01 0.02 
Mean ± SE 
n = 9 
88.00 ± 
2.97 
86.89 ± 3.85 3.00 ± 0.85 2.78 ± 0.80 0.04 ± 
0.01 
0.03 ± 
0.008 
T-test 
P Value 
Paired     = 0.64 
Unpaired = 0.82 
Paired = 0.45 
Unpaired = 0.85 
Paired = 0.20 
Unpaired = 0.63 
T-test of Actin.Tm: Actin.Tm.Tn Paired=<.0001 
Unpaired=<.0001 
Paired=<.0001 
Unpaired=<.0001 
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Table 3.20 Comparison of Non-Transgenic and E361G Actin-f 
Sliding Speeds at 3.9µM Ca2+ 
 
Table 3.21 Comparison of Non-Transgenic and E361G Actin-f 
Percentage Motility at 3.9µM Ca2+ 
 
 
Mouse Line Sliding Speed Actin.Tm Sliding Speed Actin.Tm.Tn 
(3.9µM Ca2+) 
Relative Sliding 
Speed of 
Actin.Tm.Tn: 
Actin.Tm 
Tg NTg NTg E361G NTg E361G NTg E361G  
20.1.1
7 
20.1.1
0 
2.4 ± 0.04 
2.5 ± 0.03 
2.6 ± 0.06 
2.5 ± 0.02 
2.5 ± 0.08 
2.7 ± 0.05 
3.2 ± 0.08 
2.8 ± 0.03 
2.3 ± 0.05 
3.5 ± 0.09 
2.4 ± 0.05 
2.2 ± 0.04 
1.3 
1.1 
0.9 
1.4 
1.0 
0.8 
20.1.1
3 
20.1.9 3.2 ± 0.03 
2.9 ± 0.04 
2.9 ± 0.23 
2.8 ± 0.09 
3.6 ± 0.03 
2.8 ± 0.03 
3.6 ± 0.04 
2.7 ± 0.04 
1.2 
0.9 
1.3 
0.9 
20.1.8 20.1.7 2.4 ± 0.03 2.3 ± 0.02 3.5 ± 0.15 3.8 ± 0.06 1.5 1.6 
13.2.1
3 
20.1.1
2 
2.6 ± 0.07 
2.5 ± 0.05 
3.0 ± 0.11 
2.6 ± 0.02 
2.6 ± 0.18 
2.8 ± 0.02 
2.9 ± 0.04 
2.4 ± 0.03 
1.0 
1.1 
0.9 
0.9 
13.2.1
2 
20.1.1
6 
2.6 ± 0.02 2.6 ± 0.02 2.7 ± 0.08 2.7 ± 0.04 1.0 1.1 
Mean ± SE  
n = 9 
2.63 ± 
0.09 
2.66 ± 0.07 2.92 ± 0.14 2.91 ± 0.19 1.11 ± 
0.06 
1.10 ± 
0.09 
T-test 
P Value 
 Paired     = 0.74 
Unpaired = 0.85 
Paired = 0.91 
Unpaired = 0.96 
Paired = 0.78 
Unpaired = 0.92 
T-test of Actin.Tm: Actin.Tm.Tn Paired=0.08 
Unpaired=0.10 
Paired=0.27 
Unpaired=0.24 
 
Mouse Line % Motile Actin.Tm % Motile  
Actin.Tm.Tn 
(3.9µM Ca2+) 
Relative % 
motility of 
Actin.Tm.Tn: 
Actin.Tm 
Tg NTg NTg Tg NTg Tg NTg Tg 
20.1.1
7 
20.1.1
0 
86 ± 2.12 
87 ± 2.16 
99 ± 0.29 
93 ± 1.7 
96 ± 3.57 
91 ± 2.8 
99 ± 0.95 
82 ± 4.29 
87 ± 2.81 
97 ± 0.48 
81 ± 3.49 
81 ± 3.71 
1.2 
0.9 
0.9 
1.1 
0.8 
0.9 
20.1.1
3 
20.1.9 91 ± 3.14 
100 ± 0.29 
96 ± 1.88 
94 ± 1.5 
97 ± 1.07 
98 ± 0.6 
98 ± 0.37 
91 ± 3.08 
1.1 
1.0 
1.0 
1.0 
20.1.8 20.1.7 83 ± 3.81 83 ± 3.43 82 ± 1.65 95 ± 1.08 1.0 1.1 
13.2.1
3 
20.1.1
2 
93 ± 2.25 
81 ± 1.73 
92 ± 1.11 
74 ± 5.70 
89 ± 0.33 
97 ± 0.35 
92 ± 1.25 
96 ± 0.45 
1.0 
1.2 
1.0 
1.3 
13.2.1
2 
20.1.1
6 
72 ± 9.33 63 ± 6.35 72 ± 2.89 83 ± 2.47 1.0 1.3 
Mean ± SE 
n = 9 
88.00 ± 
2.97 
86.89 ± 3.85 89.20 ± 3.11 90.40 ± 2.32 1.03 ± 
0.04 
1.07 ± 
0.06 
T-test 
P Value 
Paired     = 0.64 
Unpaired = 0.82 
Paired = 0.61 
Unpaired = 0.76 
Paired = 0.50 
Unpaired = 0.63 
T-test of Actin.Tm: Actin.Tm.Tn Paired=0.69 
Unpaired=0.78 
Paired=0.42 
Unpaired=0.44 
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3.6.4.4 Comparing Ca2+ Concentration Curves of Non-Transgenic and 
E361G Actin-f  
The Ca2+ dependence of motility was measured across a range of Ca2+ 
concentrations from 1nM to 3.9µM Ca2+. 10nM actin-f, 60nM tropomyosin and 
40nM non-failing troponin were incubated. This troponin concentration 
produced an optimal switch on and switch off of sliding speed and percentage 
motility. 
 
Figure 3.13 Ca2+ Regulation of Thin Filaments containing Non-
Transgenic and E361G actin-f, (A) Sliding Speed and (B) 
Percentage Motile (40nM Troponin) 
 
In graph A, the minimum sliding speed values of both non-transgenic and E361G actin-f have 
been set at 1.6µm/sec. This produces an accurate fit of both curves. Graph B shows the 
percentage motile of filaments fitted to the 4-parameter Hill equation. 
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Measurement of the Ca2+ dependence of motility showed that thin 
filaments containing E361G and non-transgenic actin-f were not significantly 
different. The EC50 ratio of non-transgenic to transgenic actin-f sliding speeds 
was 0.93, and 1.01 for the percentage motility. The sliding speed of non-
transgenic actin-f increased by 1.6 µm/sec from low to high Ca2+, and 
transgenic actin-f increased 1.4 µm/sec. The percentage motile of non-
transgenic filaments increased 92% from low to high Ca2+, and transgenic actin-
f increased 94%.  
Numerous Ca2+ concentration curves were carried out but only one 
suitable curve was produced. This is specific to actin-f and may have been due 
to the method used to extract the mouse actin-f, which involved acetone 
dehydration followed by the extraction of actin-f in the monomeric form. 
Subsequent experiments on actin extracted from native thin filaments produced 
suitable Ca2+ concentration curves from the start.  
 
3.6.4.5 Competitive Binding Assay of Fluorescent and Non-Fluorescent 
Actin-f to α -Actinin 
E361G actin-f was displaced from α -actinin by lower concentrations of 
non-fluorescent actin-f compared to the non-transgenic actin-f. This indicates 
the E361G actin-f filaments have a weaker binding affinity for α -actinin and 
may have a weaker attachment at the Z-line. Graph A shows the actual number 
of filaments and graph B shows these numbers fitted to the α-actinin binding 
equation. There was 2.88-fold less affinity of E361G actin-f for α -actinin 
compared to non-transgenic actin-f. Transgenic actin-f had a K value of 0.59 ± 
0.14, and non-transgenic actin-f had a K value of 1.70 ± 0.64. The affinity of 
E361G actin-f for α -actinin was less than rabbit actin, whilst the affinity of the 
non-transgenic actin-f is greater than rabbit actin. 
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Figure 3.14 α-actinin Competitive Binding Assay of E361G and 
Non-transgenic Actin-f Filaments 
 
 
3.6.5 Isolation of F-actin from Whole Thin Filaments 
Since monomeric E361G actin extracted by the acetone powder route 
was unstable, a method was tried that did not involve the polymerisation of 
actin. Actin was isolated directly from whole thin filaments. This preserved the 
50% expression of E361G in the F-actin. The E361G content was therefore the 
same as in the whole tissue. The properties of E361G cardiac actin were 
assessed by SDS-PAGE (stained with Sypro Ruby stain) (Figure 3.15) and 
western blotting (Figure 3.16). 
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A 
B 
 
Figure 3.15 NTg (A) and E361G (B) Actin Isolation Fractions 
 
 (1) Whole muscle homogenate, (2) first wash s/n, (3) last wash s/n, (4) S/n after 2 extractions in 
thin filament extraction buffer, (5) S/n after 50K spin, (6) Pellet after 50K spin, (7) S/n after 100K 
spin, (8) Resuspended pel let of 100K spin before dialysis, (9) S/n after dialysis, (10) KCl s/n + 
150nM phalloidin, (11) KCl s/n – 150nM phalloidin, (12) F-actin (+ phalloidin), (13) F-actin (- 
phalloidin).  
 
 
 
 
 
The whole thin filaments were pelleted after the 100K spin of the thin 
filament extract supernatants (fraction 8). The pellet was resuspended in an 
ATP buffer and dialysed for 3 hours. After dialysis (fraction 9), the thin filaments 
were mixed with 0.8M KCl, with and without phalloidin (fraction 10 and 11), and 
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the F-actin was pelleted (fraction 12 and 13). No differences were detected 
during the isolation of non-transgenic and E361G actin. The final F-actin pellet 
was pure for both non-transgenic and E361G actin.  
 
Figure 3.16 Western Blot of E361G and Non-Transgenic Actin 
Isolation Fractions 
 
 
 
 
(1) whole homogenate, (2) first wash, (3) KCl supernatant - 150nM TRITC-phalloidin, (4) KCl 
supernatant + 150nM TRITC-phalloidin, (5) f-actin pellet - TRITC-phalloidin, (6) f-actin + TRITC-
phalloidin, (7) 0.02µg actin marker, (8) 0.05µg marker. 
 
The E361G F-actin yield was optimal when TRITC-phalloidin was added 
(fraction 6). Western blotting analysis determined the F-actin concentration to 
be approximately 0.5 mg/ml and the yield of actin approximately 1mg per 1mg of 
tissue (Figure 3.17). 
 
Figure 3.17 Determination of the E361G and Non-Transgenic   
F-Actin Concentration 
 
 
 
The actins in lane A had 150nM TRITC-phalloidin added to the KCl supernatant. Lane B  had no 
TRITC-phalloidin added.  
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Figure 3.18 2-DE of E361G Expression during F-Actin 
Extraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2-D Electrophoresis was carried out on the whole muscle homogenate, 
whole thin filaments, and F-actin from three separate actin preparations. 
Extracting actin from whole thin filaments preserved the E361G actin 
expression at approximately 50% in the final F-actin. The expression was the 
same as in the whole tissue. E361G actin could only be extracted when TRITC-
phalloidin was added to the supernatant containing the thin filaments along with 
0.8M KCl.  
 
F-
ac
tin
 - 
TR
IT
C
-p
ha
llo
id
in
 
F-
ac
tin
 +
 T
R
IT
C
-p
ha
llo
id
in
 
M
ou
se
 L
in
e 
W
ho
le
 H
om
og
en
at
e
 
W
ho
le
 T
hi
n 
Fi
la
m
en
ts
 
20.1.22 
20.55.19 
20.55.26 
52 % 0 % 53 % 
0 % 50 % 
65 % 
45 % 
43 % 
48 % 
48 % 
32 % 0 % 
CHAPTER 3  
 117
3.6.6 In Vitro Motility Analysis of Mouse Thin Filament F-actin  
3.6.6.1 E361G Thin Filament Actin Stability 
E361G thin filament actin remained stable for use in the in vitro motility 
assay for up to 10 days from its isolation. The brightness and contrast of the 
filaments were retained and the properties of the thin filament actin in the in 
vitro motility assay remained consistent.  
 
3.6.6.2 Thin Filament Actin Motility 
E361G actin filaments moved 7% slower than non-transgenic filaments. 
This was statistically significant over 34 measurements made from 7 separate 
paired non-transgenic and E361G mouse hearts (p=0.003). There was no 
difference in the percentage of E361G and non-transgenic filaments that were 
motile (p= 0.58) (Table 3.22). 
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Table 3.22 Comparison of Motility of Non-Transgenic and 
E361G Thin Filament Actin 
Mouse Line Filament Sliding Speed 
(mm/sec) 
Filaments Percentage Motile 
NTg E361G NTg E361G NTg E361G 
13.29- 20.1.18 3.2 ± 0.09 
2.9 ± 0.13 
2.7 ± 0.22 
3.4 ± 0.14 
3.9 ± 0.07 
2.8 ± 0.11 
55 ± 3.60 
49 ± 2.60 
50 ± 4.05 
64 ± 3.66 
54 ± 2.03 
61 ± 4.33 
4.1 ± 0.26 
3.3 ± 0.24 
2.6 ± 0.39 
3.1 ± 0.24 
2.7 ± 0.39 
2.8 ± 0.14 
69 ± 5.78 
66 ± 11.5 
62 ± 8.00 
64 ± 2.65 
67 ± 5.84 
68 ± 7.23 
13.30 20.1.17 3.0 ± 0.27 
3.5 ± 0.40 
2.4 ± 0.20 
3.5 ± 0.16 
79 ± 5.03 
72 ± 1.00 
68 ± 3.61 
78 ± 3.76 
2.4 ± 0.11 
2.7 ± 0.22 
2.1 ± 0.15 
2.6 ± 0.18 
72 ± 7.02 
62 ± 3.71 
71 ± 5.51 
72 ± 3.21 
2.7 ± 0.02 2.8 ± 0.12 67 ± 4.55 57 ± 10.3 
20.1.19 20.1.15 2.3 ± 0.06 
2.5 ± 0.11 
2.0 ± 0.04 
1.9 ± 0.05 
88 ± 1.37 
89 ± 1.45 
72 ± 4.24 
55 ± 3.19 
2.9 ± 0.18 
2.1 ± 0.04 
1.9 ± 0.07 
2.0 ± 0.18 
2.7 ± 0.09 
2.0 ± 0.10 
1.9 ± 0.03 
2.2 ± 0.12 
87 ± 4.98 
59 ± 4.10 
58 ± 2.35 
65 ± 12.06 
84 ± 8.29 
53 ± 5.61 
58 ± 6.99 
73 ± 11.08 
20.1.14 20.1.22 2.3 ± 0.09 
2.7 ± 0.34 
3.6 ± 0.11 
2.4 ± 0.07 
2.6 ± 0.13 
3.1 ± 0.03 
64 ± 3.94 
74 ± 9.28 
83 ± 2.72 
77 ± 2.42 
89 ± 3.28 
81 ± 0.29 
20.1.20 20.1.20.1 
 
3.0 ± 0.06 2.7 ± 0.08 91 ± 0.91 88 ± 0.96 
3.6 ± 0.32 2.9 ± 0.02 74 ± 6.49 66 ± 2.90 
1.9 ± 0.09 1.6 ± 0.02 67 ± 6.92 77 ± 1.80 
20.1.16                                                                                                                      20.55.19 3.3 ± 0.04 
3.6 ± 0.34 
2.8 ± 0.03 
2.9 ± 0.05 
76 ± 3.42 
76 ± 13.9 
71 ± 2.12 
61 ± 2.91 
2.5 ± 0.06 2.4 ± 0.09 70 ± 0.58 64 ± 9.3 
3.2 ± 0.07 3.2 ± 0.05 88 ± 3.68 93 ± 2.01 
3.4 ± 0.12 3.3 ± 0.08 94 ± 1.29 92 ± 1.63 
20.55.1
6 
20.55.26 2.1 ± 0.03 
2.5 ± 0.06 
1.9 ± 0.05 
2.5 ± 0.05 
79 ± 4.53 
80 ± 2.17 
77 ± 2.04 
84 ± 2.92 
3.5 ± 0.07 3.1 ± 0.24 95 ± 1.31 99 ± 0.25 
2.3 ± 0.03 2.3 ± 0.09 85 ± 2.17 78 ± 1.80 
2.9 ± 0.06 2.2 ± 0.07 80 ± 2.99 83 ± 2.72 
3.9 ± 0.09 3.3 ± 0.24 94 ± 2.50 88 ± 7.97 
Mean ± SE 
n = 34 
2.86 
±0.10 
 
2.65 
±0.09 
74.09 
±2.51 
73.1 
±2.09 
T Test 
P Value 
Paired     =0.003 
Unpaired =0.13 
Paired     =0.58 
Unpaired =0.76 
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3.6.6.3 Effects of Cardiac Tropomyosin on Thin Filament Actin Motility 
20-60nM human cardiac tropomyosin was titrated against 10nM non-
transgenic and E361G thin filament actin. 30 measurements were taken from 7 
separate paired non-transgenic and E361G mouse hearts (Table 3.23). 
 
Figure 3.19 Effect of Human Cardiac Tropomyosin on Non-
Transgenic and E361G Thin Filament Actin Motility: (A) Sliding 
Speed, and (B) % motility 
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An optimal increase in non-transgenic and E361G thin filament actin 
sliding speeds was seen at 60nM tropomyosin. The sliding speed of non-
transgenic thin filament actin increased by 8% and E361G thin filament actin 
increased by 7%. The increase in non-transgenic thin filament actin sliding 
speeds with tropomyosin was significant in the paired t-test (p = 0.03). The 
increase with E361G thin filament actin was not significant (p = 0.07). The 
significant difference in the sliding speeds of pure non-transgenic and E361G 
thin filament actin was maintained at optimum tropomyosin concentrations. 
E361G thin filament actin moved 7% slower than non-transgenic thin filament 
actin (p = 0.001).  
The percentage motility of plain non-transgenic and E361G thin filament 
thin filament actin was not significantly different over 30 measurements (p = 
0.65). An optimal increase occurred at 60nM tropomyosin. The percentage 
motile of non-transgenic actin.tropomyosin increased 5% and E361G 
actin.tropomyosin increased 3%. The increase in the percent motility of non-
transgenic thin filament actin with 60nM tropomyosin was significantly different 
(p = 0.03). The percent motility of E361G thin filament actin was not significantly 
different (p = 0.40). Over 30 measurements, the percent motility of E361G thin 
filament actin was 0.97 x that of non-transgenic actin (3% drop). This was 
significant (p = 0.05). 
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Table 3.23 Comparison of Non-Transgenic.Tm and E361G.Tm 
Filament Sliding Speeds 
 Filament Sliding Speed 
(mm/sec) 
Mouse Line Actin Actin.Tm 
NTg E361G NTg E361G NTg E361G 
13.29 20.1.18 3.2 ± 0.09 
2.9 ± 0.13 
2.7 ± 0.22 
3.4 ± 0.14 
3.9 ± 0.07 
2.8 ± 0.11 
3.8 ± 0.06 
3.5 ± 0.14 
3.5 ± 0.40 
3.2 ± 0.03 
3.3 ± 0.06 
2.9 ± 0.13 
4.1 ± 0.26 
2.6 ± 0.39 
3.1 ± 0.24 
2.8 ± 0.14 
3.5 ± 0.14 
2.8 ± 0.29 
3.9 ± 0.22 
2.2 ± 0.12 
13.30 20.1.17 3.0 ± 0.27 2.4 ± 0.20 3.4 ± 0.40 2.3 ± 0.09 
2.4 ± 0.11 
2.7 ± 0.22 
2.1 ± 0.15 
2.6 ± 0.18 
3.0 ± 0.22 
2.9 ± 0.33 
2.8 ± 0.08 
2.8 ± 0.03 
2.7 ± 0.02 2.8 ± 0.12 3.2 ± 0.13 3.0 ± 0.23 
20.1.19 20.1.15 2.3 ± 0.06 
2.5 ± 0.11 
2.0 ± 0.04 
1.9 ± 0.05 
2.6 ± 0.06 
2.9 ± 0.33 
2.5 ± 0.04 
2.3 ± 0.27 
2.9 ± 0.18 
2.1 ± 0.04 
1.9 ± 0.07 
2.0 ± 0.18 
2.7 ± 0.09 
2.0 ± 0.10 
1.9 ± 0.03 
2.2 ± 0.12 
2.1 ± 0.02 
3.0 ± 0.07 
2.6 ± 0.08 
2.4 ± 0.08 
2.1 ± 0.11 
2.8 ± 0.07 
2.1 ± 0.19 
2.4 ± 0.28 
20.1.14 20.1.22 2.3 ± 0.09 
2.7 ± 0.34 
2.4 ± 0.07 
2.6 ± 0.13 
2.9 ± 0.10 
2.9 ± 0.17 
2.6 ± 0.21 
3.0 ± 0.04 
20.1.20 20.1.20.1 
 
3.0 ± 0.06 2.7 ± 0.08 3.4 ± 0.07 3.6 ± 0.02 
3.6 ± 0.32 2.9 ± 0.02 2.5 ± 0.01 2.3 ± 0.04 
1.9 ± 0.09 1.6 ± 0.02 1.9 ± 0.06 2.3 ± 0.06 
20.1.16                                                                                                                      20.55.19 3.3 ± 0.04 2.8 ± 0.03 3.2 ± 0.08 2.9 ± 0.15 
2.5 ± 0.06 2.4 ± 0.09 2.8 ± 0.19 2.4 ± 0.09 
3.2 ± 0.07 3.2 ± 0.05 2.0 ± 0.15 2.3 ± 0.02 
3.4 ± 0.12 3.3 ± 0.08 3.8 ± 0.04 3.3 ± 0.07 
20.55.16 20.55.26 2.1 ± 0.03 
2.5 ± 0.06 
1.9 ± 0.05 
2.5 ± 0.05 
2.2 ± 0.30 
3.1 ± 0.07 
1.6 ± 0.10 
2.9 ± 0.11 
3.5 ± 0.07 3.1 ± 0.24 3.7 ± 0.16 3.7 ± 0.08 
2.3 ± 0.03 2.3 ± 0.09 2.6 ± 0.05 2.5 ± 0.10 
2.9 ± 0.06 2.2 ± 0.07 3.6 ± 0.09 3.3 ± 0.03 
3.9 ± 0.09 3.3 ± 0.24 4.0 ± 0.04 3.7 ± 0.06 
Mean ± SE 
n = 30 
2.77 
±0.10 
2.59 
±0.10 
2.99 
±0.10 
2.77 
±0.10 
T Test  
P Value  
Paired     =0.02 
Unpaired =0.22 
Paired     =0.001 
Unpaired =0.12 
T-test of Actin: Actin.Tm 
 
Paired= 0.03 
Unpaired= 0.13 
Paired=0.07 
Unpaired=0.23 
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Table 3.24 Comparison of Non-Transgenic.Tm and E361G.Tm 
Percentage Motile of Filaments 
 Filaments Percentage Motile 
Mouse Line Actin Actin.Tm 
NTg E361G NTg E361G NTg E361G 
13.29 20.1.18 55 ± 3.60 
49 ± 2.60 
50 ± 4.05 
69 ± 5.78 
66 ± 11.5 
64 ± 3.66 
54 ± 2.03 
61 ± 4.33 
64 ± 2.65 
67 ± 5.84 
71 ± 4.73 
56 ± 6.08 
72 ± 1.41 
81 ± 1.41 
53 ± 7.50 
71 ± 4.00 
69 ± 6.11 
66 ± 1.45 
80 ± 4.91 
32 ± 7.78 
13.30 20.1.17 79 ± 5.03 
62 ± 3.71 
72 ± 7.02 
67 ± 4.55 
68 ± 3.61 
72 ± 3.21 
71 ± 5.51 
57 ± 10.3 
82 ± 15.40 
76 ± 5.17 
79 ± 2.00 
75 ± 5.64 
73 ± 6.89 
79 ± 14.5 
77 ± 8.54 
83 ± 0.48 
20.1.19 20.1.15 87 ± 1.37 
89 ± 1.45 
87 ± 4.98 
59 ± 4.10 
58 ± 2.35 
64 ± 12.06 
72 ± 4.24 
55 ± 3.19 
84 ± 8.29 
53 ± 5.61 
58 ± 6.99 
73±11.08 
85 ± 2.53 
87 ± 5.60 
64 ± 2.29 
68 ± 0.75 
58 ± 0.65 
70 ± 0.88 
82 ± 1.03 
84 ± 4.19 
67 ± 4.07 
65 ± 5.05 
49 ± 2.0 
58 ± 5.69 
20.1.14 20.1.22 64 ± 3.94 
74 ± 9.28 
77 ± 2.42 
89 ± 3.28 
68 ± 2.87 
78 ± 2.17 
63 ± 3.09 
78 ± 2.33 
20.1.20 20.1.20.1 91 ± 0.91 
74 ± 6.49 
67 ± 6.92 
88 ± 0.96 
66 ± 2.90 
77 ± 1.80 
94 ± 0.48 
75 ± 4.26 
75 ± 4.26 
91 ± 0.96 
69 ± 4.19 
59 ± 2.93 
20.1.16  20.55.19 76 ± 3.42 
70 ± 0.58 
88 ± 3.68 
94 ± 1.29 
71 ± 2.12 
64 ± 9.3 
93 ± 2.01 
92 ± 1.63 
94 ± 4.36 
79 ± 2.0 
82 ± 3.33 
95 ± 0.84 
93 ± 3.12 
77 ± 3.54 
87 ± 4.33 
92 ± 1.83 
20.55.16 20.55.26 79 ± 4.53 
80 ± 2.17 
95 ± 1.31 
85 ± 2.17 
80 ± 2.99 
94 ± 2.50 
77 ± 2.04 
84 ± 2.92 
99 ± 0.25 
78 ± 1.80 
83 ± 2.72 
88 ± 7.97 
74 ± 6.51 
86 ± 2.45 
94 ± 4.36 
96 ± 2.63 
85 ± 1.75 
89 ± 4.10 
78 ± 5.23 
89 ± 1.83 
93 ± 3.12 
93 ± 1.04 
85 ± 1.11 
83 ± 1.20 
Mean ± SE 
n = 30 
74.13 
± 2.43 
73.30 
± 2.31 
78.03 
± 2.11 
75.50 
± 2.59 
T Test  
P Value  
Paired     =0.65 
Unpaired =0.80 
Paired     =0.05 
Unpaired =0.45 
T-test of Actin: Actin.Tm 
 
Paired=0.03 
Unpaired=0.23 
Paired=0.40 
Unpaired=0.53 
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3.6.6.4 Effects of Non-failing Human Cardiac Troponin on Non-transgenic 
and E361G Thin Filament Actin Motility at High and Low Ca2+ 
20-60nM human cardiac troponin was titrated with 10nM actin and 60nM 
tropomyosin at high Ca2+ (3.9µM) and low Ca2+ (1nM). 30 measurements were 
taken from 7 separate paired non-transgenic and E361G mouse hearts (Table 
3.25 - Table 3.28).  
 
Figure 3.20 Effects of Non-failing Human Cardiac Troponin on 
Non-transgenic and E361G filament Motility at 3.9µM Ca2+ and 
1nM Ca2+ 
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In these titration experiments, between 40-60nM troponin produced an 
optimum switch-off and switch-on in the percentage motility and the sliding 
speeds of thin filament actin. At low Ca2+ the sliding speed was reduced by 32% 
for non-transgenic actin and 34% for E361G actin, compared to 
actin.tropomyosin. The decrease in the sliding speed for both actins was 
significant (<0.0001). At optimum troponin concentrations, the sliding speed of 
E361G actin was 10% slower than non-transgenic actin, although this is not a 
significant difference in the paired t-test (p = 0.06). The reduced sliding speeds 
of mouse actin at low Ca2+ were not as large as those seen with rabbit actin, 
which had a 58% reduction. However, these differences could be due to 
technical reasons as the mouse and rabbit contractile systems incorporated 
different human cardiac troponin and tropomyosin preparations.   
The percentage motility was reduced by 89% for both non-transgenic 
and E361G thin filament actin to an average of 9% motility at low Ca2+. These 
reductions are slightly less than were seen with rabbit actin, which reduced by 
96% motility at low Ca2+. At optimum troponin concentrations, there was no 
significant difference in the percentage motility of non-transgenic and E361G 
thin filament actin (p = 0.85). 
At high Ca2+, non-transgenic thin filament actin sliding speed increased 
2% over actin.tropomyosin and E361G thin filament actin increased 14% over 
actin.tropomyosin. The increase of E361G was significant (p = 0.005). The 
change in sliding speed at high Ca2+ was very small. This appears to be a 
characteristic of mouse thin filament actin and is different from the changes 
seen with rabbit actin, which increased sliding speed at high Ca2+ by 26%. A 
significant observation has been the “crossing over” of non-transgenic and 
E361G thin filament actin when comparing their sliding speeds at high Ca2+. 
E361G thin filament actin had a 7% slower sliding speed when incorporated 
with tropomyosin compared to non-transgenic thin filament actin with 
tropomyosin (p = 0.001). At high Ca2+, the sliding speed of E361G thin filament 
actin increases to have a slightly faster sliding speed than non-transgenic actin, 
although this is not a significant difference (p = 0.14). The percent motility of 
thin filament actin did not significantly change at high Ca2+ and there was no 
difference between non-transgenic and E361G thin filament actin (p = 0.42). 
Thus, non-transgenic and E361G thin filament actin were indistinguishable  
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when incorporated into thin filaments.  
 
Table 3.25 Effect of Human Cardiac Troponin on Filament 
Sliding Speed at Low Ca2+ (1nM Ca2+) 
 
 
Mouse Line Sliding Speed Actin.Tm Sliding Speed 
Actin.Tm.Tn 
(1nM Ca2+) 
Relative 
Sliding Speed 
of Actin.Tm.Tn: 
Actin.Tm 
NTg E361G NTg E361G NTg E361G NTg E361G  
13.29 20.1.18 3.8 ± 0.06 
3.5 ± 0.14 
3.5 ± 0.40 
3.5 ± 0.14 
2.8 ± 0.29 
3.2 ± 0.03 
3.3 ± 0.06 
2.9 ± 0.13 
3.9 ± 0.22 
2.2 ± 0.12 
2.6 ± 0.46 
2.8 ± 0.05 
2.9 ± 0.31 
3.1 ± 0.57 
1.1 ± 0.33 
2.6 ± 0.36 
1.9 ± 0.44 
2.1 ± 0.15 
2.1 ± 0.47 
1.4 ± 0.18 
0.7 
0.8 
0.8 
0.9 
0.3 
0.8 
0.6 
0.7 
0.5 
0.6 
13.30 20.1.17 3.4 ± 0.4 
3.0 ± 0.22 
2.9 ± 0.33 
3.2 ± 0.13 
2.3 ± 0.09 
2.8 ± 0.08 
2.8 ± 0.03 
3.0 ± 0.23 
2.3 ± 0.13 
1.7 ± 0.18 
0.8 ± 0.47 
2.4 ± 0.15 
2.2 ± 0.42 
1.8 ± 0.33 
1.9 ± 0.10 
1.6 ± 0.22 
0.7 
0.6 
0.3 
0.7 
1.0 
0.6 
0.7 
0.5 
20.1.19 20.1.15 2.6 ± 0.06 
2.9 ± 0.33 
2.1 ± 0.02 
3.0 ± 0.07 
2.6 ± 0.08 
2.4 ± 0.08 
2.5 ± 0.04 
2.3 ± 0.27 
2.1 ± 0.11 
2.8 ± 0.07 
2.1 ± 0.19 
2.4 ± 0.28 
2.5 ± 0.13 
1.4 ± 0.75 
1.9 ± 0.06 
1.6 ± 0.09 
2.1 ± 0.35 
1.5 ± 0.10 
2.4 ± 0.06 
2.1 ± 0.19 
1.7 ± 0.13 
1.8 ± 0.21 
1.3 ± 0.45 
1.4 ± 0.18 
0.9 
0.5 
0.9 
0.5 
0.8 
0.7 
0.9 
0.9 
0.8 
0.6 
0.6 
0.6 
20.1.14 20.1.22 2.9 ± 0.10 
2.9 ± 0.17 
2.6 ± 0.21 
3.0 ± 0.04 
2.5 ± 0.24 
1.8 ± 0.20 
2.5 ± 0.20 
2.1 ± 0.21 
0.9 
0.6 
1.0 
0.7 
20.1.20 20.1.20
.1 
 
3.4 ± 0.07 
2.5 ± 0.01 
1.9 ± 0.06 
3.6 ± 0.02 
2.3 ± 0.04 
2.3 ± 0.06 
2.4 ± 0.21 
2.5 ± 0.36 
2.1 ± 0.35 
1.7 ± 0.20 
2.1 ± 0.22 
1.3 ± 0.45 
0.7 
1.0 
1.1 
0.5 
0.9 
0.6 
20.1.16                                                                                                                      20.55.1
9 
3.2 ± 0.08 
2.8 ± 0.19 
2.0 ± 0.15 
3.8 ± 0.04 
2.9 ± 0.15 
2.4 ± 0.09 
2.3 ± 0.02 
3.3 ± 0.07 
2.6 ± 0.46 
1.8 ± 0.08 
1.3 ± 0.11 
1.5 ± 0.08 
2.6 ± 0.36 
0.3 ± 0.14 
1.4 ± 0.79 
1.9 ± 0.43 
0.8 
0.6 
0.7 
0.4 
0.9 
0.1 
0.6 
0.6 
20.55.16 20.55.2
6 
2.2 ± 0.30 
3.1 ± 0.07 
3.7 ± 0.16 
2.6 ± 0.05 
3.6 ± 0.09 
4.0 ± 0.04 
1.6 ± 0.10 
2.9 ± 0.11 
3.7 ± 0.08 
2.5 ± 0.10 
3.3 ± 0.03 
3.7 ± 0.06 
2.1 ± 0.47 
1.9 ± 0.19 
2.0 ± 0.06 
2.5 ± 0.24 
2.1 ± 0.09 
1.5 ± 0.20 
2.5 ± 0.27 
1.5 ± 0.17 
2.0 ± 0.21 
2.5 ± 0.20 
1.2 ± 0.42 
1.3 ± 0.13 
1.0 
0.6 
0.5 
1.0 
0.6 
0.4 
1.6 
0.5 
0.6 
1.0 
0.4 
0.3 
Mean ± SE 
n = 30 
2.99 
±0.10 
2.77 
±0.10 
2.04±0.10 1.84±0.09 0.70±0
.04 
0.69±0
.05 
T-test 
P Value 
Paired     =0.001 
Unpaired =0.12 
Paired = 0.06 
Unpaired = 0.15 
Paired = 0.83 
Unpaired =0.87 
T-test of Actin.Tm: Actin.Tm.Tn Paired=≤.0001 
Unpaired=≤.0001 
Paired=≤.0001 
Unpaired=≤.0001 
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Table 3.26 Effect of Human Cardiac Troponin on Filament 
Percentage Motility at Low Ca2+ (1nM Ca2+) 
Mouse Line % Motility Actin.Tm % Motility Actin.Tm.Tn 
(1nM Ca2+) 
Relative % 
Motility of 
Actin.Tm.Tn: 
Actin.Tm 
NTg E361G NTg E361G NTg E361G NTg E361G 
13.29 20.1.18 71 ± 4.73 
56 ± 6.08 
72 ± 1.41 
81 ± 1.41 
53 ± 7.5 
71 ± 4.00 
69 ± 6.11 
66 ± 1.45 
80 ± 4.91 
32 ± 7.78 
5 ± 1.73 
4 ± 5.66 
10 ± 1.15 
10 ± 2.40 
6 ± 0.14 
7 ± 2.96 
14 ± 14.1 
13 ± 2.03 
8 ±2.96 
3 ± 0.08 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.2 
0.2 
0.1 
0.1 
13.30 20.1.17 82 ± 15.4 
76 ± 5.17 
79 ± 2.0 
75 ± 5.64 
73 ± 6.89 
79 ± 14.50 
77 ± 8.54 
83 ± 0.48 
19 ± 2.60 
10 ± 3.86 
6 ± 3.40 
10 ± 1.67 
19 ± 2.03 
7 ± 3.28 
6 ± 0.95 
3 ± 1.76 
0.2 
0.1 
0.1 
0.1 
0.3 
0.1 
0.1 
0.03 
20.1.19 20.1.15 85 ± 2.53 
87 ± 5.6 
64 ± 2.29 
68 ± 0.75 
58 ± 0.65 
70 ± 0.88 
82 ± 1.03 
84 ± 4.19 
67 ± 4.07 
65 ± 5.05 
49 ± 2.0 
58 ± 5.69 
19 ± 1.78 
9 ± 6.17 
6 ± 2.65 
4 ± 0.96 
6 ± 1.93 
5 ± 3.5 
14 ± 0.41 
5 ± 1.35 
5 ± 2.50 
5 ± 1.93 
5 ± 2.35 
4 ± 2.38 
0.2 
0.1 
0.01 
0.1 
0.1 
0.1 
0.2 
0.1 
0.1 
0.1 
0.1 
0.1 
20.1.14 20.1.22 68 ± 2.87 
78 ± 2.17 
63 ± 3.09 
78 ± 2.33 
7 ± 1.00 
6 ± 1.76 
14 ± 1.67 
3 ± 0.88 
0.1 
0.1 
0.2 
0.04 
20.1.20 20.1.20.1 
 
94 ± 0.48 
75 ± 4.26 
75 ± 4.26 
91 ± 0.96 
69 ± 4.19 
59 ± 2.93 
10 ± 2.10 
13 ± 1.85 
6 ± 1.93 
3 ± 1.11 
7 ± 1.65 
5 ± 2.35 
0.1 
0.2 
0.1 
0.04 
0.1 
0.1 
20.1.16                                                                                                                      20.55.19 94 ± 4.36 
79 ± 2.0 
82 ± 3.33 
95 ± 0.84 
93 ± 3.12 
77 ± 3.54 
87 ± 4.33 
92 ± 1.83 
5 ± 1.73 
7 ± 3.28 
8 ± 1.04 
6 ± 2.33 
7 ± 2.96 
6 ± 0.39 
7 ± 1.25 
12 ± 4.57 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
20.55.1
6 
20.55.26 74 ± 6.51 
86 ± 2.45 
94 ± 4.36 
96 ± 2.63 
85 ± 1.75 
89 ± 4.10 
78 ± 5.23 
89 ± 1.83 
93 ± 3.12 
93 ± 1.04 
85 ± 1.11 
83 ± 1.20 
16 ± 9.70 
5 ± 2.14 
21 ± 0.87 
7 ± 1.00 
14 ± 1.70 
5 ± 1.80 
17 ± 7.05 
6 ± 0.65 
32 ± 1.53 
14 ± 1.67 
5 ± 2.56 
4 ± 1.04 
0.2 
0.1 
0.2 
0.1 
0.2 
0.1 
0.2 
0.1 
0.4 
0.2 
0.1 
0.04 
Mean ± SE 
n = 30 
78.03 
± 2.11 
75.50 
± 2.59 
8.83 
±0.86 
8.67 
±1.15 
0.12 
±0.01 
0.13 
±0.01 
T-test 
P Value 
Paired     =0.05 
Unpaired =0.45 
Paired     =0.85 
Unpaired =0.91 
Paired =0.36 
Unpaired =0.50 
T-test of 
Actin.Tm: 
Actin.Tm.Tn 
 Paired=≤.0001 
Unpaired=≤.0001 
Paired=≤.0001 
Unpaired=≤.0001 
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Table 3.27 Effect of Human Cardiac Troponin on Filament 
Sliding Speed at High Ca2+ (3.9µM Ca2+) 
Mouse Line Sliding Speed 
Actin.Tm 
Sliding Speed 
Actin.Tm.Tn 
(3.9µM Ca2+) 
Relative Sliding 
Speed of 
Actin.Tm.Tn: 
Actin.Tm 
NTg E361G NTg E361G NTg E361G NTg E361G  
13.29 20.1.18 3.8 ± 0.06 
3.5 ± 0.14 
3.5 ± 0.40 
3.5 ± 0.14 
2.8 ± 0.29 
3.2 ± 0.03 
3.3 ± 0.06 
2.9 ± 0.13 
3.9 ± 0.22 
2.2 ± 0.12 
3.4 ± 0.05 
3.7 ± 0.47 
3.6 ± 0.13 
4.6 ± 0.10 
2.5 ± 0.18 
3.4 ± 0.02 
3.5 ± 0.20 
3.8 ± 0.04 
4.8 ± 0.07 
3.2 ± 0.01 
0.9 
1.1 
1.0 
1.3 
0.9 
1.2 
1.1 
1.3 
1.2 
1.5 
13.30 20.1.17 3.4 ± 0.4 
3.0 ± 0.22 
2.9 ± 0.33 
3.2 ± 0.13 
2.3 ± 0.09 
2.8 ± 0.08 
2.8 ± 0.03 
3.0 ± 0.23 
3.4 ± 0.11 
4.6 ± 0.02 
3.0 ± 0.12 
3.1 ± 0.38 
3.2 ± 0.09 
4.9 ± 0.22 
3.0 ± 0.04 
2.9 ± 0.25 
1.0 
1.6 
1.0 
1.0 
1.4 
1.8 
1.1 
1.0 
20.1.1
9 
20.1.15 2.6 ± 0.06 
2.9 ± 0.33 
2.1 ± 0.02 
3.0 ± 0.07 
2.6 ± 0.08 
2.4 ± 0.08 
2.5 ± 0.04 
2.3 ± 0.27 
2.1 ± 0.11 
2.8 ± 0.07 
2.1 ± 0.19 
2.4 ± 0.28 
2.9 ± 0.14 
3.0 ± 0.11 
3.2 ± 0.03 
2.8 ± 0.05 
2.3 ± 0.06 
2.1 ± 0.12 
3.4 ± 0.27 
3.0 ± 0.04 
3.2 ± 0.26 
3.0 ± 0.035 
2.2 ± 0.06 
2.2 ± 0.04 
1.1 
1.0 
1.5 
0.9 
0.9 
0.9 
1.4 
1.3 
1.5 
1.1 
1.1 
0.9 
20.1.1
4 
20.1.22 2.9 ± 0.10 
2.9 ± 0.17 
2.6 ± 0.21 
3.0 ± 0.04 
3.1 ± 0.15 
2.9 ± 0.02 
3.3 ± 0.07 
2.9 ± 0.07 
1.1 
1.0 
1.3 
1.0 
20.1.2
0 
20.1.20.
1 
 
3.4 ± 0.07 
2.5 ± 0.01 
1.9 ± 0.06 
3.6 ± 0.02 
2.3 ± 0.04 
2.3 ± 0.06 
3.3 ± 0.08 
2.7 ± 0.10 
2.6 ± 0.31 
3.4 ± 0.05 
2.5 ± 0.04 
2.8 ± 0.04 
1.0 
1.1 
1.4 
1.0 
1.1 
1.2 
20.1.1
6                                
20.55.1
9
3.2 ± 0.08 
2.8 ± 0.19 
2.0 ± 0.15 
3.8 ± 0.04 
2.9 ± 0.15 
2.4 ± 0.09 
2.3 ± 0.02 
3.3 ± 0.07 
3.1 ± 0.03 
2.8 ± 0.06 
2.4 ± 0.04 
2.9 ± 0.07 
2.8 ± 0.11 
2.8 ± 0.06 
2.7 ± 0.38 
3.3 ± 0.12 
1.0 
1.0 
1.2 
0.8 
1.0 
1.2 
1.2 
1.0 
20.55.
16 
20.55.2
6 
2.2 ± 0.30 
3.1 ± 0.07 
3.7 ± 0.16 
2.6 ± 0.05 
3.6 ± 0.09 
4.0 ± 0.04 
1.6 ± 0.10 
2.9 ± 0.11 
3.7 ± 0.08 
2.5 ± 0.10 
3.3 ± 0.03 
3.7 ± 0.06 
2.5 ± 0.08 
2.9 ± 0.11 
4.1 ± 0.24 
3.0 ± 0.05 
3.2 ± 0.05 
2.1 ± 0.12 
3.3 ± 0.04 
3.1 ± 0.08 
3.3 ± 0.14 
3.3 ± 0.09 
3.0 ± 0.04 
2.2 ± 0.04 
1.2 
0.9 
1.1 
1.2 
0.9 
0.5 
2.1 
1.0 
0.9 
1.4 
0.9 
0.6 
Mean ± SE 
n = 30 
2.99 
±0.10 
2.77 
±0.10 
3.06 ± 0.11 3.15 ± 0.11 1.05 ± 
0.04 
1.19 ± 
0.05 
T-test 
P Value 
Paired     =0.001 
Unpaired =0.12 
Paired = 0.14 
Unpaired = 0.58 
Paired = 0.002 
Unpaired = 0.03 
T-test of Actin.Tm: Actin.Tm.Tn Paired=0.56 
Unpaired=0.66 
Paired=0.005 
Unpaired=0.01 
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Table 3.28 Effect of Human Cardiac Troponin on Filament 
Percentage Motility at High Ca2+ (3.9µM Ca2+) 
Mouse Line % Motility Actin.Tm % Motility Actin.Tm.Tn 
(3.9µM Ca2+) 
Relative % 
Motility of 
Actin.Tm.Tn: 
Actin.Tm 
NTg E361G NTg E361G NTg E361G NTg E361G 
13.29 20.1.18 71 ± 4.73 
56 ± 6.08 
72 ± 1.41 
81 ± 1.41 
53 ± 7.5 
71 ± 4.00 
69 ± 6.11 
66 ± 1.45 
80 ± 4.91 
32 ± 7.78 
90 ± 1.33 
80 ± 7.42 
82 ± 1.86 
86 ± 1.53 
56 ± 2.19 
95 ± 0.65 
60 ± 3.48 
63 ± 5.03 
90 ± 4.33 
79 ± 4.41 
1.3 
1.4 
1.1 
1.1 
1.1 
1.3 
0.9 
1.0 
1.1 
2.5 
 
13.30 20.1.17 82 ± 15.4 
76 ± 5.17 
79 ± 2.0 
75 ± 5.64 
73 ± 6.89 
79 ± 14.50 
77 ± 8.54 
83 ± 0.48 
83 ± 1.20 
73 ± 4.30 
83 ± 2.70 
79 ± 3.28 
89 ± 4.10 
73 ± 5.36 
81 ± 0.29 
73 ± 4.16 
1.0 
1.0 
1.2 
1.1 
1.2 
0.9 
1.4 
0.9 
 
20.1.19 20.1.15 85 ± 2.53 
87 ± 5.6 
64 ± 2.29 
68 ± 0.75 
58 ± 0.65 
70 ± 0.88 
82 ± 1.03 
84 ± 4.19 
67 ± 4.07 
65 ± 5.05 
49 ± 2.0 
58 ± 5.69 
77 ± 8.33 
72 ± 2.85 
67 ± 5.68 
70 ± 2.31 
46 ± 2.67 
63 ± 1.50 
87 ± 11.5 
75 ± 1.25 
71 ± 3.83 
76 ± 1.00 
58 ± 6.50 
71 ± 3.09 
0.9 
0.8 
1.0 
1.0 
0.8 
0.8 
1.1 
0.9 
1.1 
1.2 
1.2 
0.9 
 
20.1.14 20.1.22 68 ± 2.87 
78 ± 2.17 
63 ± 3.09 
78 ± 2.33 
52 ± 5.33 
85 ± 3.57 
51 ± 1.86 
82 ± 2.48 
0.8 
1.1 
0.8 
1.1 
 
20.1.20 20.1.20.1 
 
94 ± 0.48 
75 ± 4.26 
75 ± 4.26 
91 ± 0.96 
69 ± 4.19 
59 ± 2.93 
79 ± 6.57 
78 ± 3.67 
58 ± 4.00 
83 ± 4.50 
79 ± 1.85 
80 ± 3.81 
0.9 
1.0 
0.8 
 
0.9 
0.8 
1.1 
 
20.1.16                                                                                                                      20.55.19 94 ± 4.36 
79 ± 2.00 
82 ± 3.33 
95 ± 0.84 
93 ± 3.12 
77 ± 3.54 
87 ± 4.33 
92 ± 1.83 
84 ± 4.19 
76 ± 2.20 
77 ± 1.90 
70 ± 1.30 
87 ± 5.60 
65 ± 2.00 
81 ± 1.65 
79 ± 3.93 
0.9 
1.0 
0.9 
0.7 
0.9 
1.2 
1.4 
0.9 
 
20.55.1
6 
20.55.26 74 ± 6.51 
86 ± 2.45 
94 ± 4.36 
96 ± 2.63 
85 ± 1.75 
89 ± 4.10 
78 ± 5.23 
89 ± 1.83 
93 ± 3.12 
93 ± 1.04 
85 ± 1.11 
83 ± 1.20 
79 ± 6.10 
68 ± 1.00 
87 ± 3.18 
64 ± 2.89 
81 ± 3.10 
71 ± 3.10 
89 ± 7.8 
57 ± 8.00 
79 ± 2.72 
59 ± 3.38 
85 ± 3.32 
63 ± 1.50 
1.0 
0.8 
0.9 
0.7 
0.9 
0.8 
0.9 
0.9 
0.9 
1.1 
0.6 
0.8 
Mean ± SE 
n = 30 
78.03 
± 2.11 
75.50 
± 2.59 
73.87±1.9
8 
75.33±2.08 0.96 ± 
0.03 
1.06 ± 
0.06 
T-test 
P Value 
Paired     =0.05 
Unpaired =0.45 
Paired     =0.42 
Unpaired =0.61 
Paired = 0.09 
Unpaired =0.13 
T-test of Actin.Tm: Actin.Tm.Tn Paired=0.08 
Unpaired=0.16 
Paired=0.96 
Unpaired=0.96 
 
 
CHAPTER 3  
 129
 
3.6.6.5 Comparing Ca2+ Concentration Curves of Non-Transgenic and 
E361G Thin Filament Actin using Human Cardiac Troponin 
Initial experiments tested the effect of E361G thin filament actin in a non-
failing thin filament. Thin filaments were reconstituted with E361G or non-
transgenic thin filament actin, human cardiac tropomyosin, and cardiac troponin 
that was purified from non-failing human heart muscle (troponin I 
phosphorylation 2.1 mols/mol). The Ca2+ sensitivity of sliding and the 
percentage motile of thin filament actin were measured with actin from 6 paired 
non-transgenic and E361G mouse hearts (Figure 3.21 A-F, Table 3.29). The 
individual mouse heart sample numbers for non-transgenic and mutant actin 
are highlighted in blue and red respectively.  
Tracking of E361G and non-transgenic actin sliding speeds produced 
large variability in the Ca2+ sensitivity plots. No accurate fit has been possible of 
the sliding speeds, and the points have simply been plotted.  
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Figure 3.21 Ca2+ Regulation of Thin Filaments containing Non-
Transgenic and E361G Thin Filament Actin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The percentage motility curves have had the following parameters fixed to obtain an accurate 
sigmoidal curve: Graph A ( Max value fixed at 65%), Graph C ( Min and Max values fixed at 6% 
and 79%).  
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Graph D (Max value fixed at 79%), Graph F (Min and Max values fixed at 3% and 89%) . 
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Table 3.29 Ca2+ Sensitivity data for all E361G v Non-Transgenic 
Actin in a Non-Failing Thin Filament. 
The table shows the actual EC50 values and the difference in EC50 values expressed as a ratio 
of NTg to E361G for the percentage motility. 
 
 The Ca2+ sensitivity of E361G thin filament actin was the same as non-
transgenic actin in both the sliding speed and percentage motile parameters. 
The thin filament actin sliding speeds were variable across a range of Ca2+ 
concentrations. Only the percentage motility could be accurately fitted to the Hill 
Equation. There was no significant difference between the percentage motility 
EC50 values of non-transgenic and E361G actin (p = 0.34), and the ratio of EC50 
values was not significantly different from 1 (p = 0.59).  
The change in sliding speed from low to high Ca2+ was minimal. The 
sliding speed of non-transgenic thin filament actin increased by 1.2 µm/sec from 
low to high Ca2+, and transgenic thin filament actin increased by 1.5 µm/sec. 
This is in contrast to the large change obtained when the mouse actin was 
extracted from an acetone powder (Figure 3.7), which produced an increase of 
3.8 µm/sec. The percentage motile of non-transgenic and E361G thin filament 
actin both increased between 90-95% from low to high Ca2+. 
Mouse Line EC50 Percentage Motility, µM EC50 NTg 
EC50 E361G 
 
Non-
Transgenic 
E361G Non-
Transgenic 
E361G  
13.3 20.1.17 1.437 ± 0.450 1.073 ± 0.283 1.34 
20.1.19 20.1.15 0.261 ± 0.039 0.242 ± 0.001 1.08 
20.1.16 20.55.19 0.039 ± 0.025 0.031 ± 0.016 1.27 
20.1.16 20.55.19 0.070 ± 0.022 0.090 ± 0.098 0.77 
20.55.16 20.55.26 0.143 ± 0.193 0.114 ± 6.606 1.25 
20.55.16 20.55.26 0.035 ± 0.014 0.052 ± 0.018 0.68 
Mean: ± SE 
(n = 6) 
0.330 ± 0.224 0.267 ± 0.164 1.065 ± 0.114 
Student’s t-test (paired)  p = 0.34 single group, p = 
0.592 (compared 
with 1) 
(Unpaired) p = 0.82 
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Considerable variation between experiments was observed in both the 
non-transgenic and E361G EC50 values. This variability between experiments 
was thought to be a characteristic of the mouse actin, and was different from 
the reproducible EC50 values that can be obtained between experiments using 
rabbit actin.  
 
3.6.6.6 Competitive Binding Assay of Fluorescent and Non-Fluorescent 
Actin to α-Actinin 
Altering the method of actin isolation did not change the α -actinin 
competitive binding assay result. E361G thin filament actin was displaced from 
α -actinin by lower concentrations of non-fluorescent actin compared to the non-
transgenic actin. The assay has been repeated 3 times to produce reduced 
binding affinity of E361G actin by an average of 5.3-fold. The results are shown 
in Figure 3.22 A, B, and C. F itting the number of filaments to the α -actinin 
binding equation produces the graph on the right.  
 
Figure 3.22 α -actinin Competitive Binding Assay of E361G and 
Non-transgenic Actin Filaments 
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There is 5.2-fold less affinity of E361G actin for α -actinin compared to non-transgenic actin. 
Transgenic actin has a K value of 0.19 ± 0.03, and non-transgenic actin has a K value of 0.98 ± 
0.15. 
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There is 4.6-fold less affinity of E361G actin for α-actinin compared to non-transgenic actin. 
Transgenic actin has a binding constant of 0.46 ± 0.12, and non-transgenic actin has a binding 
constant of 2.13 ± 0.39 
0
50
100
150
200
0 0.2 0.4 0.6 0.8 1
E361G
NTg
Fi
la
m
en
t N
um
be
r
Fraction of Unlabelled Actin  
There is 6.2-fold less affinity of E361G actin for α-actinin compared to non-transgenic actin. 
Transgenic actin has a binding constant of 0.20 ± 0.08, and non-transgenic actin has a binding 
constant of 1.24 ± 0.23. 
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3.7 Discussion 
Transgenic mice were generated to over express E361G mutant cardiac 
actin in their hearts. The mutant cardiac actin cDNA construct was provided by 
Dr. Kristen Nowak at the University of Western Australia, and inserted into the 
human cardiac actin sequence by Dr. Charles Redwood at the University of 
Oxford. The transgenic expression was restricted to the heart using an alpha-
myosin heavy chain promoter construct kindly provided by Dr. Mike Gollob and 
originally produced in the laboratory of Dr. Jeffrey Robbins. The transgenic mice 
were generated by Professor Dominic Wells by pronuclear injection of gel 
purified transgenic constructs into the pronucleus of fertilised mouse eggs on a 
C57BL10 x CBA/Ca hybrid background. Successive screening by PCR fo llowed 
by 2-D Electrophoresis showed one stably expressing transgenic line (361.20) 
had been generated, which expressed E361G at 50% of the total actin in the 
hearts of the transgenic mice. Extracting actin directly from native thin filaments 
preserved the 50% mutant actin content in the F-actin. 
 
3.7.1 Native Human Sequence Thin Filaments 
Actin is the most highly conserved contractile protein. An important 
reason for choosing this DCM mutation in actin was that the amino acid 
sequence of cardiac actin in man and mouse is identical, and the distribution of 
cardiac and skeletal actin isoforms in the heart (ratio of 1:4) is reported to be 
the same in most species (Vandekerckhove et al., 1986, Bergen et al., 2003). 
Thin filaments were reconstituted from purified polymeric actin from the mouse 
hearts, along with human cardiac tropomyosin and troponin isolated from non-
failing human heart muscle. The amino acid sequences, post-translational 
modifications and the phosphorylation levels of the non-transgenic thin 
filaments should have been the same as in non-failing human heart muscle, 
and the E361G thin filament should represent the conditions of the muscle of 
familial DCM patients. Line 20 expressed 50% mutation, which is the expected 
ratio in a dominant mutation and has been found with mutations in myosin 
(Fananapazir et al., 1993) and tropomyosin (Bottinelli et al., 1998).  
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3.7.2 Stability of E361G Mutant Actin 
The E361G actin was largely present in an insoluble state when it was 
extracted from a mouse-muscle acetone powder, indicating that monomeric 
E361G actin tended to aggregate. The small proportion of the E361G actin 
monomer present did not polymerise unless phalloidin was present. This 
property has also been observed in other actin mutations, including the 
nemaline myopathy mutations M132V (Marston et al., 2004) and the EGFP-
tagged D286G actin (J-J.Feng, PhD Thesis 2007). This instability in laboratory 
conditions causes problems for experimentation, but does not necessarily affect 
the mutant mouse in vivo, since 50% mutant was clearly incorporated into 
myofibrils of line 20 mice. 
 
3.7.3 Reproducibility of the In Vitro Motility Assay 
The F-actin extracted initially from E361G transgenic mouse hearts 
contained no mutation. These comparative experiments with non-transgenic 
actin have provided a measure of the reproducibility of simultaneous actin 
isolations as well as the functional measurements by the in vitro motility assay 
(Table 3.30). The finding that actin extracted from two hearts can produce 
functionally identical actin is strong evidence that any later differences seen 
between thin filament transgenic E361G-actin and non-transgenic actin are 
genuine and caused by the mutation. 
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Table 3.30 Comparison of Mouse Actin from Acetone Powder 
 
 Non-Transgenic Actin Transgenic Actin 
Actin Sliding Speed 
(µm/sec) 
3.03 ± 0.25 3.03 ± 0.27 
Paired = 1.0, Unpaired = 1.0 (n = 6) 
Actin % Motility 98 ± 0.45 95 ± 1.58 
Paired = 0.13, Unpaired = 0.08 (n = 6) 
Actin.Tm sliding speed 
(µm/sec) 
3.73 ± 0.33 3.47 ± 0.31 
Paired = 0.001, Unpaired = 0.57 (n = 6) 
Actin.Tm % motility 86 ± 4.07 88 ± 7.30 
Paired = 0.61, Unpaired = 0.79 (n = 6) 
Actin.Tm.Tn sliding 
speed + Ca2+ 
3.85 ± 0.31 3.93 ± 0.42 
Paired = 0.67, Unpaired = 0.88 (n = 6) 
Actin.Tm.Tn sliding 
speed - Ca2+ 
1.8 ± 0.41 1.88 ± 0.45 
Paired = 0.56, Unpaired = 0.89 (n = 6) 
Actin.Tm.Tn % motility 
+ Ca2+ 
88 ± 5.32 89 ± 5.14 
Paired = 0.72, Unpaired =0.93 (n = 6) 
Actin.Tm.Tn % motility 
- Ca2+ 
3.33 ± 1.23 4.33 ± 1.50 
Paired = 0.33, Unpaired = 0.62 (n = 6) 
Ca2+ sensitivity of sliding  
EC50 value (n = 1) 
0.190 ± 0.09 
 
0.138 ± 0.06 
Ca2+ sensitivity of % 
motile  
EC50 value (n = 1) 
0.054 ± 0.007 
 
0.057 ± 0.007 
α-actinin binding 
 (K value) (n = 1) 
0.423 ± 0.006 
 
0.381 ± 0.002 
 
3.7.4 Comparisons of Transgenic Mouse and Skeletal Rabbit 
Actin 
Skeletal rabbit actin is regularly used in our laboratory and hence motor 
and regulatory comparisons can be made with the non-transgenic mouse actin 
(Table 3.31). Although it is interesting to draw these comparisons, it is important 
to note that the two actins are not entirely identical. Rabbit F-actin has been 
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depolymerised and the G-actin purified on sephacryl300 before a second 
polymerisation, giving it a higher purity than the mouse actin. The rabbit actin in 
vitro motility data was provided from studies by A. Messer (PhD Thesis, 2007). 
Thin filaments were reconstituted using skeletal rabbit actin, human cardiac 
tropomyosin, and troponin extracted from donor non-failing human heart 
muscle. All other conditions of the in vitro motility assay were identical. 
The motor properties of mouse actin proved comparable with the rabbit 
actin. There was no significant difference between the sliding speeds (p = 0.52), 
although the percentage motility of rabbit actin was significantly less (p = 
<0.0001). The effects of human cardiac tropomyosin on mouse and rabbit actin 
sliding speed were not significantly different (p = 0.40). Both mouse and rabbit 
actin sliding speed increased by 10%. The regulatory properties were compared 
by reconstituting thin filaments with mouse or rabbit actin, along with human 
cardiac tropomyosin and troponin. Measurements of actin sliding speeds and 
percentage motility were made at high and low Ca2+. Mouse and rabbits actins 
were switched on and off optimally within similar ranges of human cardiac 
troponin (40-60nM). At high Ca2+, the rabbit actin exhibited greater increases in 
its sliding speed (26%) compared to mouse actin (3%). However, the 
percentage motility increases over actin.tropomyosin were not different for 
rabbit (5%) or mouse actin (3%). At low Ca2+, the sliding speeds of both actins 
were switched off to a similar degree, and the percentage motility of both actins 
was reduced to approximately 3%. Only one Ca2+ activation curve was assayed 
with non-transgenic mouse actin (Figure 3.7). The pCa50 and the hill co-efficient 
were in the range of those obtained with rabbit actin, as was the range of 
velocity and percentage motility between high and low Ca2+. Finally, the α-
actinin binding experiments indicated that mouse actin affinity was not different 
from rabbit, and both had a K value of 0.8. 
 In conclusion, the function of non-transgenic mouse actin in the in vitro 
motility assay was very similar to the well-studied rabbit actin. This is to be 
expected, as they have the same amino acid sequence and were prepared by 
similar methods.  
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Table 3.31 Comparison of Mouse and Rabbit Actin 
 Non-Transgenic Actin Rabbit Actin 
Actin Sliding Speed 
(µm/sec) 
3.03 ± 0.25 
(n = 6) 
3.23 ± 0.18 
(n = 16) 
Unpaired = 0.52 
Actin % Motility 98 ± 0.45 
(n = 6) 
75 ± 2.24 
(n = 16) 
Unpaired = <0.0001 
Actin.Tm sliding speed 
(µm/sec) 
3.73 ± 0.33 
(n = 6) 
3.47 ± 0.143 
(n = 16) 
Unpaired = 0.40 
Actin.Tm % motility 86 ± 4.07 
(n = 6) 
85 ± 1.91 
(n = 16) 
Unpaired = 0.87 
Actin.Tm.Tn sliding 
speed + Ca2+ 
3.85 ± 0.31 
(n = 6) 
4.36 ± 0.23 
(n = 16) 
Unpaired = 0.25 
Actin.Tm.Tn sliding 
speed - Ca2+ 
1.8 ± 0.41 
(n = 6) 
1.47 ± 0.04 
(n = 16) 
Unpaired = 0.20 
Actin.Tm.Tn % motility 
+ Ca2+ 
88 ± 5.32 
(n = 6) 
89.23 ± 1.90 
(n = 16) 
Unpaired = 0.78 
Actin.Tm.Tn % motility 
- Ca2+ 
3.33 ± 1.23 
(n = 6) 
3.10 ± 0.56 
(n = 16) 
Unpaired = 0.84 
Ca2+ sensitivity of sliding  
EC50 value 
 
0.190 ± 0.09 
 
0.195 ± 0.026 
Hill Co-efficient 1.67 ± 0.98 2.21 ± 0.48 
Ca2+ sensitivity of % 
motile  
EC50 value 
 
 
0.054 ± 0.007 
 
 
0.08 ± 0.07 
Hill Co-efficient 8.30 ± 3.06 2.17 ± 0.41 
α-actinin binding (K 
value) 
0.833 ± 0.433 0.843 ± 0.042 
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3.7.5 Comparison of Actin-f and Thin Filament Actin 
Preparing native thin filaments and then removing troponin and 
tropomyosin successfully isolated pure mouse actin. This avoided the unstable 
monomeric state of the E361G actin. The thin filament actin contained 50% 
mutant actin, which was the same as the whole muscle it was derived from. 
However, the functional properties of thin filament actin were not identical to 
actin-f (Figure 3.23). The sliding speed of non-transgenic thin filament actin 
was 5% faster than non-transgenic actin-f, and this difference was increased to 
10% upon titration with human cardiac tropomyosin. Non-transgenic thin 
filament actin had a sliding speed of 2.99µm/sec with 60nM tropomyosin 
compared to 2.68µm/sec with actin-f.tropomyosin. Comparing the actin 
regulation at high and low Ca2+ has shown that at optimum troponin 
concentrations, the acetone powder extracted non-transgenic actin-f showed a 
greater increase in its sliding speed (9%) than thin filament actin (2%), and a 
greater switch off in its sliding speed (51%) compared to thin filament actin 
(32%). A similar trend was shown for E361G thin filament actin compared to 
E361G-f (Figure 3.24). The sliding speed of E361G thin filament actin was 5% 
faster than E361G-f, and 3% faster than E361G-f actin upon titration with 
human cardiac tropomyosin. At high Ca2+, E361G-f showed a lower increase in 
its sliding speed (9%) compared to thin filament actin (14%), although the 
switch off was greater for E361G-f (56%) compared to thin filament actin 
(34%). 
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Figure 3.23 Sliding Speed Comparisons of Non-transgenic 
Actin 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Figure 3.24 Sliding Speed Comparisons of E361G Actin 
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Overall, a greater range in sliding speeds from high to low Ca2+ was 
shown for actin-f compared to thin filament actin (1.6µm/sec and 0.7µm/sec 
respectively). The inability of thin filament extracted mouse actin to produce 
adequate Ca2+ curves based on the actin sliding speeds may have been due to 
this small net increase. In contrast, the change in percentage motility from high 
to low Ca2+ for the thin filament actin (90%) was comparable to that of actin-f 
(96%), and suitable Ca2+ curves could be plotted for thin filament mouse actin. 
Variability was also observed in the percentage motility EC50 values for 
mouse thin filament extracted actin. This variability was encountered between 
repeated experiments but not within a paired assay. Non-transgenic thin 
filament actin had a 5.5-fold range in EC50 percentage motility values, and 
E361G actin had a 4.4-fold range. Such large variability was not shown for 
actin-f (Figure 3.13) or for rabbit actin, which only had a 2-fold range over 6 
measurements. The variability of the EC50 values may simply be due to the 
nature of the thin filament mouse actin, since mouse actin-f and rabbit actin thin 
filaments were similarly incorporated with non-failing human cardiac 
tropomyosin and troponin. However, the troponin could potentially have been 
the cause of the variability. Mouse actin thin filaments were reconstituted with 
troponin extracted from the more recently received non-failing human heart 
samples N10-N12. Mouse actin-f and rabbit thin filaments were reconstituted 
with troponin extracted from five different heart samples (N5-N9). Although all 
these heart samples were all from non-failing human donors there was the 
potential for a difference. 
 
3.7.6 Comparison of Non-Transgenic Thin Filament Actin with 
E361G Thin Filament Actin 
E361G thin filament actin moved 7% more slowly than non-transgenic 
thin filament actin, and this was a significant difference (p = 0.003). The slower 
sliding speed of E361G thin filament actin was maintained upon titration with 
human cardiac tropomyosin (p = 0.001). The percentage motility of E361G thin 
filament actin was not statistically different to non-transgenic thin filament actin 
(p = 0.58), and the addition of tropomyosin did not alter this trend. The slower 
sliding speed of E361G actin is in contrast to the findings of Wong et al. They 
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reported no impact on actomyosin function on studies of E361G expressed in 
yeast and purified for in vitro motility functional studies (Wong et al., 2002). 
Similarly, Johara et al. found that mutations in this region of actin did not affect 
the sliding speed in the in vitro motility assay (Johara et al., 1993).  
E361G and non-transgenic thin filament actin regulation of sliding speed 
was not statistically different at high Ca2+ (p = 0.14) or low Ca2+ (p = 0.06), nor 
was the percentage motility statistically different at high Ca2+ (p = 0.42) or low 
Ca2+ (p = 0.85). The Ca2+ sensitivity of E361G and non-transgenic thin filament 
actin across a range of Ca2+ concentrations showed no differences in the sliding 
speeds or the EC50 values of percentage motility (p = 0.34). The ratio of 
percentage motility EC50 values was also not significantly different from 1 (p = 
0.59). 
 
3.7.7 Altered α-Actinin Binding  
Two identical subunits of α-actinin (Mr = 100,000) bind to actin within 
residues 112-125 and 360-372 (Lebart et al., 1993). Due to the position of the 
E361G mutation in this universally conserved region of actin that binds to α -
actinin (Figure 3.25), the mutation has been postulated to cause a defective 
force transmission in cardiac myocytes (Olson et al., 1998). Indeed, the studies 
reported in this thesis support this idea, as the E361G thin filament actin had a 
5.3-fold reduction in α -actinin binding compared to non-transgenic actin (Figure 
3.22). Similarly, Wong et al. showed a 3-fold reduction in E361G actin 
expressed in yeast (Wong et al., 2002). Since the E361G mutation showed only 
moderate changes in actomyosin function, the reduction in binding of E361G 
actin for α -actinin and the resulting impairment of cardiac muscle function may 
be enough alone to cause the DCM phenotype.  
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Figure 3.25 Location of E361G  
 
Location of E361G (red) on the actin molecule in relation to the α -actinin binding sites (residues 
112-125 and 360-372, shown in yellow). Molecular graphic image was drawn from atomic 
coordinates published by (Otterbein et al., 2001) (pdb file 1J6Z), using the USSF Chimera 
package (Pettersen et al., 2004). 
 
This hypothesis is further supported by data from two other actin 
mutations (K336E and R372H), which have been shown to have a reduced 
binding affinity for α -actinin. Both are also located close to the α-actinin binding 
site. K336E is a lysine to glutamate substitution and is the first report of HCM 
associated with nemaline myopathy and a mutation in ACTA1 (D'Amico et al., 
2006). Nemaline myopathy is characterised by general muscle weakness and 
the presence of nemaline bodies (Sanoudou and Beggs, 2001). More than 100 
ACTC1 mutations are known to cause the disease (Costa et al., 2004). The α -
actinin competitive binding assay was carried out on a skeletal muscle biopsy 
sample from a 6-month-old patient with this mutation (J-J.Feng, PhD Thesis 
2007), and K336E actin bound to α -actinin with a 7-fold lower affinity than 
control actin (Figure 3.26). This weaker binding of actin to α -actinin could 
impair the force transmission in both skeletal and cardiac muscle, which was 
E361G 
Subdomain 1 
Subdomain 2 Subdomain 4 
Subdomain 3 
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compatible with the patient’s symptoms of muscle weakness and 
cardiomyopathy.  
 
Figure 3.26 α -actinin Competitive Binding Assay of K336E  
 
 
 
 
 
 
 
 
 
 
 
 
 
Data supplied by J-J Feng (PhD Thesis 2007). Three K336E α -actinin plots were carried out. 
One average result, defined by the α -actinin binding equation is shown above. Over three 
separate experiments, the control actin had a k value of 3.5 ± 1.86 and the K336E actin had a K 
value of 0.5 ± 0.18, indicating a 7-fold difference in affinity for α-actinin. 
 
Additionally, drosophila studies on the ACTA1 nemaline myopathy 
mutation R372H have suggested that the primary defect caused by this 
mutation is reduced α -actinin-actin binding (Sevdali and Sparrow, 2007). 
Transgenic flies heterologous for the R372H mutation complete the normal IFM 
myogenesis and hatching flies can fly. However, they become flightless by day 
7 and the Drosophila show the equivalent of human nemaline myopathy. 
Immunofluorescence and electron microscopy showed severe loss of muscle 
structure resulting from the R372H mutation. From the known α-actinin binding 
sites on the actin monomer, the mutation is thought to decrease the strength of 
the F-actin/ α -actinin binding, leading to muscle damage and the breakdown of 
the muscle structure.  
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3.7.8  The DCM Phenotype  
Previous in vitro studies on cardiac muscle thin filament mutations 
associated with DCM, have reported that there are features common to all DCM 
mutations (Robinson et al., 2002, Mirza et al., 2005). These include a slower 
sliding speed, diminished ATPase rates and a decreased Ca2+ sensitivity (1.3-
2.0 fold increase in EC50). DCM has therefore been described as having a 
hypocontractile phenotype (Marston, 2003). Collectively, these findings were 
made from five troponin T mutants (R131W, R141W, R205L, D Lys-210, 
D270N), two α-tropomyosin mutants (E40K and E54K), and one troponin C 
mutation (G159D). Human cardiac troponin was reconstituted using 
recombinant troponin T, I and C subunits. Wild type troponin and tropomyosin 
containing either troponin T or troponin C DCM mutants were compared in thin 
filaments reconstituted with human Ala-Ser α-tropomyosin (for ATPase assays) 
or native human cardiac tropomyosin (for in vitro motility analysis). Tropomyosin 
mutations were studied using thin filaments reconstituted using recombinant 
troponin (ATPase assays) or native human troponin (in vitro motility).  
These common functional properties reported for DCM-causing 
mutations are however in contrast to the E361G actin in vitro motility results 
covered in this chapter. The cross bridge turnover difference was small (E361G 
actin 7% slower) and the Ca2+ sensitivity was indistinguishable from actin of 
non-transgenic littermates (EC50 NTg/E361G = 1.1, p = 0.59). However, one 
important difference to note is that the studies reported in this thesis tested 
E361G actin in combination with non-failing human cardiac troponin that had 
native phosphorylation levels of 3.1 mols Pi/mol TnT and 2.1 mol/Pi/mol TnI 
(Messer et al., 2006). Previous studies used recombinant troponin that was not 
phosphorylated (Robinson et al., 2002, Mirza et al., 2005). The phosphorylation 
state of the troponin incorporated into the thin filament may have uncovered the 
genuine functional effect caused by the E361G mutation. In vitro motility results 
of the E361G actin in combination with altered levels of troponin 
phosphorylation are covered in the next chapter. 
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4. THE EFFECT OF TROPONIN PHOSPHORYLATION ON E361G 
THIN FILAMENT FUNCTION  
Chapter 3 outlined the in vitro motility results of E361G actin when 
incorporated with human cardiac tropomyosin and native human cardiac 
troponin. In contrast to previous DCM mutations investigated by in vitro motility 
assay (Robinson et al., 2002, Mirza et al., 2005), E361G actin did not cause 
any significant difference in Ca2+ regulation. However, it has previously been 
reported that the type of troponin incorporated into the thin filament could reveal 
different effects of mutant proteins  (Bing et al., 2000). The effect of non-
transgenic and E361G actin in combination with rabbit skeletal troponin (in 
which troponin I is not phosphorylated) was therefore investigated. 
 
4.1 Effects of Rabbit Skeletal Muscle Troponin on Non-
Transgenic and E361G Actin Motility at High and Low Ca2+ 
The regulation of thin filaments containing E361G and non-transgenic 
actin with human cardiac tropomyosin and rabbit skeletal muscle troponin was 
investigated. 10-20nM rabbit skeletal troponin was titrated with 10nM actin and 
60nM tropomyosin at high Ca2+ (3.9µM) and low Ca2+ (1nM). 20nM troponin 
produced an optimum switch-off and switch-on of the percentage motility and 
the sliding speeds of actin filaments (Figure 4.1). 8 measurements from 2 
paired non-transgenic and E361G heart hearts are tabulated in Table 4.1 to 
Table 4.4. 
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Figure 4.1 Effects of Rabbit Skeletal Troponin on Non-
Transgenic and E361G filament Motility at 3.9µM Ca2+ and 1nM 
Ca2+ 
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At low Ca2+, the sliding speed was reduced by 26% for non-transgenic 
actin and 27% for E361G actin. The decrease in the sliding speed for both 
actins was significant (<0.0001 and 0.005 respectively). At optimum troponin 
concentrations, the sliding speed of E361G actin was 10% slower than non-
transgenic actin, although this was not a significant difference in the paired t-
test (p = 0.22). The percentage motility at low Ca2+ was reduced by 86% for 
both non-transgenic and E361G actin to 11% and 10% respectively. These 
values were similar to the conditions seen with rabbit actin, which was reduced 
by 96% motility at low Ca2+. At optimum troponin concentrations, there was no 
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significant difference in the percentage motility of non-transgenic and E361G 
actin (p = 0.67). 
At high Ca2+, non-transgenic actin sliding speed increased 13% over 
actin.tropomyosin and E361G actin increased 19% over actin.tropomyosin. 
These increases were larger than when human cardiac troponin was used (2% 
and 14% respectively). At high Ca2+, no “crossing over” of the sliding speeds 
was observed. E361G actin had a 16% slower sliding speed when incorporated 
with tropomyosin compared to non-transgenic actin with tropomyosin (p = 0.03), 
and at high Ca2+ the sliding speed of E361G was still slower by 9%. This 
difference at high Ca2+ was significant (p = 0.03). The percent motility of E361G 
actin filaments was 6% less than non-transgenic actin at high Ca2+. This 
difference is not significant however (p = 0.14). 
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Table 4.1 Effect of Rabbit Skeletal Troponin on Filament Sliding 
Speed at Low Ca2+ (1nM Ca2+) 
Mouse Line Sliding Speed Actin.Tm Sliding Speed 
Actin.Tm.Tn 
(1nM Ca2+) 
Relative Sliding 
Speed of 
Actin.Tm.Tn: 
Actin.Tm 
NTg E361G NTg E361G NTg E361G NTg E361G  
20.1.19 20.1.15 2.6 ± 0.02 
3.3 ± 0.05 
2.7 ± 0.28 
3.1 ± 0.12 
2.4 ± 0.04 
3.0 ± 0.14 
2.3 ± 0.06 
2.8 ± 0.11 
1.9 ± 0.1 
2.5 ± 0.13 
1.9 ± 0.06 
2.1 ± 0.47 
2.0 ± 0.17 
2.4 ± 0.06 
1.7 ± 0.13 
2.5 ± 0.27 
0.73 
0.76 
0.70 
0.68 
0.83 
0.80 
0.74 
0.89 
13.31 20.1 2.1 ± 0.06 
3.2 ± 0.06 
2.9 ± 0.03 
2.7 ± 0.09 
1.9 ± 0.23 
1.9 ± 0.36 
2.7 ± 0.13 
2.6 ± 0.03 
1.7 ± 0.15 
1.9 ± 0.43 
2.1 ± 0.09 
1.9 ± 0.19 
1.7 ± 0.05 
1.5 ± 0.08 
1.2 ± 0.42 
1.5 ± 0.17 
0.81 
0.59 
0.72 
0.70 
0.89 
0.79 
0.44 
0.58 
Mean ± SE 
n = 8  
2.83 ± 0.14 2.45 ± 0.14 2.00 ± 0.08 1.81 ± 0.16 0.71 
±0.02 
0.75 ± 
0.06 
T-test 
P Value 
Paired     = 0.03 
Unpaired = 0.08 
Paired     = 0.22 
Unpaired = 0.32 
Paired     = 0.58 
Unpaired = 0.58 
T-test of Actin.Tm: Actin.Tm.Tn Paired= <.0001 
Unpaired=0.0002 
Paired= 0.005 
Unpaired= 0.001 
 
 
Table 4.2 Effect of Rabbit Skeletal Troponin on Filament 
Percentage Motility at Low Ca2+ (1nM Ca2+) 
Mouse Line % Motility Actin.Tm % Motility Actin.Tm.Tn 
(1nM Ca2+) 
Relative % Motility 
of Actin.Tm.Tn: 
Actin.Tm 
NTg E361G NTg E361G NTg E361G NT E361G 
20.1.19 20.1.15 83 ± 1.41 
78 ± 6.51 
65 ± 2.65 
87 ± 4.26 
80 ± 8.26 
75 ± 5.32 
63 ± 6.23 
86 ± 1.56 
12 ± 2.22 
19 ± 1.78 
6 ± 0.65 
16 ± 9.7 
16 ± 3.50 
14 ± 0.41 
5 ± 2.50 
17 ± 7.05 
0.14 
0.24 
0.09 
0.18 
0.20 
0.19 
0.08 
0.20 
13.31 20.1 89 ± 2.16 
75 ± 3.16 
75 ± 2.36 
85 ± 5.12 
85 ± 1.32 
77 ± 2.63 
61 ± 2.31 
81 ± 5.63 
5 ± 1.73 
12 ± 4.57 
14 ± 1.70 
5 ± 2.14 
13 ± 2.00 
6 ± 2.33 
5 ± 2.56 
6 ± 0.65 
0.06 
0.16 
0.19 
0.06 
0.15 
0.08 
0.08 
0.07 
Mean ± SE 
n = 8  
79.63 ± 
2.81 
76.00 ± 
3.32 
11.13 ± 
1.88 
10.25 ± 
1.85 
0.14± 
0.02 
0.13 ± 
0.02 
T-test 
P Value 
Paired     = 0.06 
Unpaired= 0.42 
Paired     = 0.67 
Unpaired= 0.74 
Paired= 0.73 
Unpaired= 0.78 
T-test of 
Actin.Tm: 
Actin.Tm.Tn 
 Paired= <.0001 
Unpaired=<.0001 
Paired=<.0001 
Unpaired= <.0001 
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Table 4.3 Effect of Rabbit Skeletal Troponin on Filament Sliding 
Speed at High Ca2+ (3.9µM Ca2+) 
 
Table 4.4 Effect of Rabbit Skeletal Troponin on Filament 
Percentage Motility at High Ca2+ (3.9µM Ca2+) 
 
Mouse Line Sliding Speed Actin.Tm Sliding Speed 
Actin.Tm.Tn 
(3.9µM Ca2+) 
Relative Sliding 
Speed of 
Actin.Tm.Tn: 
Actin.Tm 
NTg E361G NTg E361G NTg E361G NT E361G  
20.1.19 20.1.15 2.6 ± 0.02 
3.3 ± 0.05 
2.7 ± 0.28 
3.1 ± 0.12 
2.4 ± 0.04 
3.0 ± 0.14 
2.3 ± 0.06 
2.8 ± 0.11 
2.5 ± 0.06 
3.4 ± 0.27 
3.2 ± 0.03 
3.3 ± 0.04 
2.1 ± 0.08 
2.9 ± 0.14 
3.2 ± 0.26 
2.5 ± 0.08 
0.96 
1.03 
1.19 
1.06 
0.88 
1.03 
1.39 
0.89 
13.31 20.1 2.1 ± 0.06 
3.2 ± 0.06 
2.9 ± 0.03 
2.7 ± 0.09 
1.9 ± 0.23 
1.9 ± 0.36 
2.7 ± 0.13 
2.6 ± 0.03 
3.7 ± 0.09 
3.3 ± 0.12 
3.1 ± 0.06 
3.1 ± 0.08 
3.7 ± 0.03 
2.9 ± 0.07 
3.1 ± 0.07 
2.9 ± 0.11 
1.76 
1.03 
1.07 
1.15 
1.95 
1.53 
1.14 
1.12 
Mean ± SE 
n = 8  
2.83 ± 0.14 2.45 ± 0.14 3.20 ± 0.12 2.91 ± 0.17 1.16 ± 
0.09 
1.24 ± 
0.13 
T-test 
P Value 
Paired     = 0.03 
Unpaired = 0.08 
Paired     = 0.03 
Unpaired = 0.19 
Paired = 0.29 
Unpaired = 0.60 
T-test of Actin.Tm: Actin.Tm.Tn Paired= 0.08 
Unpaired= 0.06 
Paired= 0.12 
Unpaired= 
0.05 
 
Mouse Line % Motility Actin.Tm % Motility Actin.Tm.Tn 
(3.9µM Ca2+) 
Relative % 
Motility of 
Actin.Tm.Tn: 
Actin.Tm 
NTg E361G NTg E361G NTg E361G NTg E361G 
20.1.19 20.1.15 83 ± 1.41 
78 ± 6.51 
65 ± 2.65 
87 ± 4.26 
80 ± 8.26 
75 ± 5.32 
63 ± 6.23 
86 ± 1.56 
85 ± 3.30 
77 ± 8.33 
67 ± 5.68 
89 ± 7.5 
74 ± 3.81 
87 ± 11.5 
71 ± 3.83 
79 ± 6.13 
1.02 
0.99 
1.03 
1.02 
0.93 
1.16 
1.13 
0.92 
13.31 20.1 89 ± 2.16 
75 ± 3.16 
75 ± 2.36 
85 ± 5.12 
85 ± 1.32 
77 ± 2.63 
61 ± 2.31 
81 ± 5.63 
91 ± 1.58 
79 ± 3.93 
68 ± 1.00 
88 ± 2.74 
87 ± 2.02 
70 ± 1.31 
57 ± 8.0 
83 ± 1.32 
1.02 
1.05 
0.91 
1.04 
1.02 
0.91 
0.93 
1.02 
Mean ± SE 
n = 8  
79.63 ± 
2.81 
76.00 ± 3.32 80.50  
± 3.31 
76.00  
± 3.60 
1.01 ± 
0.02 
1.00± 
0.03 
T-test 
P Value 
Paired     = 0.06 
Unpaired = 0.42 
Paired     = 0.14 
Unpaired = 0.37 
Paired     = 0.85 
Unpaired = 0.85 
T-test of 
Actin.Tm: 
Actin.Tm.Tn 
 Paired = 0.50 
Unpaired = 0.84 
Paired = 1.0 
Unpaired = 1.0 
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4.1.1 Comparing Ca2+ Concentration Curves of Non-Transgenic 
and E361G Actin with Rabbit Skeletal Troponin 
Thin filaments were reconstituted with 10nM E361G or non-transgenic 
actin, 60nM human cardiac tropomyosin, and 20nM rabbit skeletal troponin. The 
Ca2+ sensitivity of sliding and the percentage motile of actin filaments were 
measured 3 times from 2 separate paired non-transgenic and E361G mouse 
hearts (Figure 4.2 A-C). No accurate fit was possible with the sliding speeds, 
and the points have simply been plotted.  
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Figure 4.2 Ca2+ Regulation of Thin Filaments containing Non-
Transgenic and E361G Thin Filament Actin with Skeletal 
Troponin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The percentage motility fits have had the following parameters fixed to obtain an accurate 
sigmoidal curve: Graph B ( Min and Max values fixed at 9% and 80%), Graph C (Min and Max 
values fixed at 8.75% and 66.25%) . 
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Table 4.5 Ca2+ Regulation of Thin Filaments containing Non-
Transgenic and E361G Actin with Skeletal Troponin 
 
 
When skeletal muscle troponin was incorporated into the thin filament in 
place of the cardiac troponin, E361G actin had a lower Ca2+ sensitivity 
compared to non-transgenic actin. The E361G actin EC50 was approximately 
4.6-fold higher (Table 4.5). The use of skeletal rabbit troponin therefore 
unmasked a functional difference between non-transgenic and E361G actin 
which was not detectable in the system that used human cardiac regulatory 
proteins. A similar functional effect was produced to previous studies that 
reconstituted unphosphorylated recombinant troponin into the thin filament 
(Robinson et al., 2002, Mirza et al., 2005). 
 One obvious difference between skeletal and cardiac troponin is the N-
terminal extension of cardiac troponin I which is phosphorylated by PKA. 
The phosphorylation status of the troponin used in the E361G thin filament 
therefore appeared to be potentially important. The effect of human cardiac 
troponin dephosphorylation on the Ca2+ regulation of motility was investigated to 
determine whether the E361G thin filaments were responsive to altered 
phosphorylation levels of cardiac troponin. 
 
 
Mouse Line EC50 Percentage Motility, µM EC50 NTg 
EC50 E361G 
Non-
Transgenic 
E361G Non-
Transgenic 
E361G  
20.1.19 20.1.15 0.090 ± 3.462 0.225 ± 0.099 0.40 
20.1.19 20.1.15 0.121 ± 0.049 0.798 ± 0.180 0.15 
13.31 20.1 0.034 ± 0.007  0.099 ± 0.087 0.34 
Mean: ± SE 0.082 ± 0.025 0.374 ± 0.215 0.297 ± 0.075 
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4.2 Effect of Cardiac Troponin Dephosphorylation on the Ca2+ 
dependence of E361G and Non-transgenic Actin Motility 
Dephosphorylation was achieved by using 1.4 units/ml acid phosphatase. 
Samples were analysed by SDS-PAGE and stained with Pro-Q Diamond. 
 
Figure 4.3 SDS-PAGE of Non-Failing Human Cardiac Troponin  
 
 
 
 
 
 
 
 
 
 
 
 
 
SDS-PAGE gel of 3 non-failing troponin pairs showing the effect of acid phosphatase on 
troponin T and I phosphorylation. Stained with (A) Pro-Q Diamond (for phosphoproteins) and 
(B) Coomassie Blue for total protein levels  
 
There were three types of experiments that reconstituted 
dephosphorylated non-failing troponin into the thin filament. (1) Control 
experiments used thin filaments reconstituted with non-transgenic actin in 
combination with either native or dephosphorylated non-failing human cardiac 
troponin (Figure 4.4). (2) Mutant E361G actin was reconstituted into thin 
filaments in combination with either native or dephosphorylated non-failing 
human cardiac troponin (Figure 4.5), and finally (3) non-transgenic and E361G 
actin was reconstituted with non-failing dephosphorylated troponin (Figure 4.6).  
Pair 1 Pair 2 Pair 3 
Pro-Q 
Diamond 
Coomassie 
Blue 
TnT 
TnI 
TnC 
30mg troponin 
per lane 
TnT 
TnI 
TnC 
30mg troponin 
per lane 
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The control experiments will first be described (Figure 4.4). The Ca2+ 
sensitivity of the sliding speed and the percentage motile of actin filaments were 
measured for 5 non-transgenic mouse hearts. The actin sliding speeds 
produced variable measurements across all Ca2+ concentrations. Only the 
percentage motility could be accurately fitted to the Hill Equation.  
 Dephosphorylation of the troponin shifted the percentage motility curve 
to the left and increased the Ca2+ sensitivity of non-transgenic actin filaments.  
The dephosphorylated troponin produced a 2.98-fold increase in Ca2+ 
sensitivity, and this difference was significant (p = 0.003) (Table 4.6).  
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Figure 4.4 Effect of Non-Transgenic Actin in Combination with 
Native or Dephosphorylated Troponin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Ca2+ curves have had the following maximum and minimum parameters fixed to 
accurately represent the fit: Graph A (min fixed at 15%, max fixed at 77%), Graph B (min fixed 
at 10%, max fixed at 76%). 
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Graph D (min fixed at 10.5%, max fixed at 75.25%), Graph E (min fixed at 7%, max fixed at 
74%) 
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Table 4.6 Ca2+ Sensitivity Data for Non-Transgenic Actin 
Incorporated with Native or Dephosphorylated Troponin 
 
Non-Transgenic 
Mouse Line 
EC50 Percentage Motility, µM 
 
EC50 NF 
EC50 NF.dp 
 Non-Failing Non-
Failing.dp 
 
20.1.19 0.325 ± 0.141 0.133 ± 0.088 2.44 
20.55.16 0.238 ± 0.099 0.094 ± 0.029 2.53 
20.1.16 0.059 ± 0.030 0.017 ± 0.010 3.47 
20.1.16 0.433 ± 0.331 0.109 ± 0.091 3.97 
20.1.20 0.128 ± 0.033 0.051 ± 0.013 2.51 
Mean: ± SE 
 
0.237 ± 0.067 0.081 ± 0.021 2.984 ± 0.3146 
T test (paired) p = 0.03 single group, p = 
0.003 (compared 
with 1) 
T test (Unpaired) p = 0.06 
 
The effect on the Ca2+ sensitivity of E361G actin filaments when 
reconstituted with dephosphorylated troponin was then investigated (Figure 
4.5). Incorporating E361G actin with either native or dephosphorylated troponin 
resulted in no Ca2+ sensitivity difference between the filaments (p = 0.61). The 
ratio of percentage motility EC50 values was not significantly different from 1 (p 
= 0.74) (Table 4.7). 
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Figure 4.5 Effect of Troponin Dephosphorylation on E361G 
Actin Motility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following Ca2+ curves had the maximum and minimum parameters fixed to accurately 
represent the fit: Graph A (min fixed at 9.5%, max fixed at 68.5%), Graph B (min fixed at 7.4%, 
max fixed at 62%). 
A 20.55.19 B 20.1.20.1 
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Graph C (min fixed at 7.5%, max fixed at 70%), Graph D (min fixed at 9.6%, max fixed at 60%). 
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Table 4.7 Ca2+ Sensitivity Data for E361G Actin Incorporated 
with Native or Dephosphorylated Troponin 
 
The final set of experiments used E361G and non-transgenic actin in 
combination with non-failing dephosphorylated troponin (Figure 4.6). 
Dephosphorylating the troponin shifted the non-transgenic actin percentage 
motility curve to the left. E361G actin had a 2-fold lower Ca2+ sensitivity than 
non-transgenic actin, and this difference was significant (p = 0.01). 
Mouse Line EC50 Percentage Motility, µM EC50 NF 
EC50 NF.dp 
 
 Non-Failing Non-
Failing.dp 
 
20.55.19 0.309 ± 0.091 0.331 ± 0.087 0.93 
20.1.20.1 0.604 ± 0.160 0.623 ± 0.073 0.97 
20.55.26 0.153 ± 0.046 0.120 ± 0.045 1.28 
20.55.26 0.335 ± 0.058 0.358 ± 0.058 0.94 
Mean: ± SE 0.350 ± 0.094 0.358 ± 0.103 1.03 ± 0.08 
T test (paired) p = 0.61 Single group, p = 
0.74 (compare with 1) 
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Figure 4.6 Effect of Troponin Dephosphorylation on Non-
Transgenic and E361G Actin Motility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ca2+ curve B had the maximum and minimum parameters fitted to accurately represent the fit: 
(min fixed at 7%, max fixed at 78%) 
 
 
 
 
 
 
 
 
A 20.1.14, 20.1.22 B 20.1.14, 20.1.22 
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Graph C (min fixed at 4.5%, max fixed at 79%), Graph D (min fixed at 4.5%, max fixed at 79%). 
 
 
 
 
 
 
 
 
C 20.1.16, 20.55.19 D 20.1.16, 20.55.19 
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Table 4.8 Ca2+ Sensitivity Data for Non-Transgenic and E361G 
Actin Incorporated with Dephosphorylated Troponin 
 
To summarise, E361G-transgenic and non-transgenic actins were 
compared using dephosphorylated and native non-failing human cardiac 
troponin in all possible combinations. The figure below shows the difference in 
EC50 values for the percentage motile of filaments.  Thin filaments containing 
E361G actin did not appear to respond to changes in troponin I 
phosphorylation.  
 
Figure 4.7 E361G and Non-transgenic Actin in combination with 
Phosphorylated and Dephosphorylated Troponin  
 
 
 
 
 
 
 
 
 
The average EC50 value differences (percentage motility) of E361G-transgenic and non-
transgenic actin. The larger of the two sided arrows denotes the direction of higher EC50 value. 
Starred values* denote a statistically significant difference.  
Mouse Line EC50 Percentage Motility, µM EC50 NTg 
EC50 E361G 
 Non-
Transgenic 
E361G  
20.1.14 20.1.22 0.569 ± 0.129 0.781 ± 0.108 0.73 
20.1.14 20.1.22 0.335 ± 0.164 0.807 ± 0.181 0.42 
20.1.16 20.55.19 0.073 ± 0.031 0.175 ± 0.030 0.42 
20.1.16 20.55.19 0.063 ± 0.020 0.219 ± 0.103 0.29 
Mean: ± SE 0.260 ± 0.121 0.496 ± 0.173 0.465 ± 0.09 
T test (paired)  p = 0.06 Single group, p = 
0.01 (compared to 1) T test (Unpaired) p = 0.31 
E361G  
Non-
transgenic  
E361G  
+ NF.dp Tn 
Non-
Transgenic  
+ NF.dp Tn 
1.03 ± 0.08  
2.15 ± 0.09 * 
Higher Ca2+ 
sensitivity 
Low Ca2+ 
sensitivity 
Low Ca2+ 
sensitivity 
Low Ca2+ 
sensitivity 
2.98 ± 0.32 * 
1.07 ± 0.11 
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A reported feature of acquired human heart failure is the substantial 
dephosphorylation of troponin I, which may contribute towards a blunted 
inotropic and lusitropic response (Messer et al., 2006). It was therefore 
important to evaluate the phosphorylation status of non-transgenic and E361G 
mouse troponin (Figure 4.8).  
 
Figure 4.8 Phosphorylation of Non-Transgenic and E361G-
Transgenic Mouse Troponin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Non- Transgenic Troponin  E361G Troponin  
 ProQ/Coomassie Mols Pi/mol 
TnI 
ProQ/Coomas
sie 
Mols Pi/mol 
TnI 
TnT 1.49 2.54 1.54 2.62 
TnI 2.12 3.60 2.07 3.52 
 
No difference was found in the phosphorylation of troponin I and troponin 
T of non-transgenic and E361G mouse troponin. Compared with human cardiac 
troponin, the mouse cardiac troponin T was less highly phosphorylated (2.5 
compared to 3.1 mols Pi/mol TnI), and the troponin I was more phosphorylated 
(3.6 compared to 2.1 mols Pi/mol TnT). However, the E361G mutation did not 
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affect this ratio. In addition to measuring the phosphorylation level of pure 
troponin, myofibrils from non-transgenic and E361G hearts were analysed 
(Figure 4.9). Myofibrils were separated by SDS-PAGE and the bands detected 
by the Pro-Q Diamond phosphoprotein gel stain were normalised to the total 
protein levels in each band (stained by SYPRO Ruby). E361G transgenic 
myofibrils showed a high level of phosphorylation for myosin binding protein-C 
(MyBP-C), troponin T (TnT), troponin I (TnI) and myosin light chain 2 (MLC-2) 
that was indistinguishable from non-transgenic myofibrils. 
  
Figure 4.9 SDS-PAGE and Ratios of E361G and Non-Transgenic 
Myofibrils 
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Table 4.9 Pro-Q/SYPRO ratios from 5 Myofibril Experiments 
 
4.3 Discussion 
Our strategy for investigating the E361G actin mutation expressed in 
transgenic mouse hearts, was to reconstitute thin filaments that were as similar 
as possible to the human cardiac system. Using human cardiac tropomyosin 
and troponin, the mutant thin filaments had a Ca2+ sensitivity indistinguishable 
from non-transgenic thin filaments. Bing et al. reported that altering the troponin 
that was incorporated into the thin filament allowed a functional difference to be 
exposed between mutant and wild type proteins that was not detectable in a 
fully native system (Bing et al., 2000). Indeed, experiments that used rabbit 
skeletal troponin unmasked a functional difference between non-transgenic and 
E361G actin that was not present when native human cardiac troponin was 
incorporated into the thin filament. The E361G actin had 4.5-fold lower Ca2+ 
sensitivity and 9% slower sliding speed at high Ca2+. The reduced maximum 
sliding speed was significant over 8 measurements (p = 0.03). This was the first 
evidence of a functional effect caused by the mutation and indicated that the 
phosphorylation state of the troponin incorporated into the E361G thin filament 
was a crucial part of the E361G phenotype.  
The E361G phenotype that was exposed when using rabbit skeletal 
troponin appeared similar to previously studied DCM mutations (Robinson et 
al., 2002, Mirza et al., 2005). Mirza et al. studied the five TnT mutants (R131W, 
R141W, R205L, D Lys-210, D270N), two α-tropomyosin mutants (E40K and 
E54K), and the single TnC mutation (G159D). There was a single decrease in 
the maximum sliding speed at high Ca2+ by approximately 10% (p<0.001 for 
Expt. No. MyBP-C MLC-2 TnT TnI 
  361 NTg 361 NTg 361 NTg 361 NTg 
1 0.411 0.400 0.331 0.355 0.190 0.178 0.209 0.199 
2 0.395 0.422 0.276 0.295 0.164 0.187 0.179 0.189 
3 0.468 0.472 0.299 0.276 0.219 0.230 0.177 0.160 
4 0.388 0.412 0.404 0.396 0.295 0.268 0.269 0.258 
5 0.332 0.340 0.416 0.431 0.306 0.289 0.209 0.192 
Mean ± SE 0.399 
± 
0.022 
0.409 ± 
0.021 
0.345 
± 
0.028 
0.351 ± 
0.029 
0.235 
± 
0.028 
0.230 ± 
0.022 
0.209 
± 
0.017 
0.200 ± 
0.016 
T-test 
(paired/ 
unpaired) 
p = 0.209 / 0.741, 
n=5 
p = 0.580 / 0.897, 
n=5 
p = 0.660 / 0.905, 
n=5 
p = 0.144 / 0.707, 
n=5 
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TnT R131W; p<0.01 for TnT R141W, TnT R205L, TnT D Lys-210, and TnC 
G159D; and p<0.05 for α-tropomyosin E40K), and a decrease in the Ca2+ 
sensitivity by 0.18 (TnT D270N) and 0.4 (TnT R205L) pCa units in 50:50 wild 
type: mutant mixtures (1.3-2 fold increase in EC50). This was accompanied by a 
decrease in the Hill co-efficient, which reflected a loss of cooperativity. The 
decrease in sliding speed and Ca2+ sensitivity was also observed in ATPase 
assays using the same 50: 50 mixtures of recombinant proteins.  
Rabbit skeletal troponin therefore appeared to produce the same 
phenotype as recombinant human cardiac troponin, but native human cardiac 
troponin did not. It is important to note that skeletal troponin does not have a 
phosphorylation site and that the recombinant human cardiac troponin was not 
phosphorylated, whereas native human cardiac troponin has 3.1 mols Pi /mol 
TnT and 2.1 mols Pi /mol TnI (Messer et al., 2006). When non-transgenic and 
E361G actin were tested with native human cardiac troponin dephosphorylated 
by acid phosphatase, the DCM phenotype previously observed by Mirza et al. 
and Robinson et al. was replicated. The E361G thin filaments had a lower Ca2+ 
sensitivity than non-transgenic thin filaments (1.9 increase in EC50). The sliding 
speed at 3.9µM Ca2+ was not different, however in this system the sliding speed 
appeared not to depend upon the Ca2+ concentration, unlike with skeletal 
troponin (E361G actin 9% slower, p = 0.03). 
Non-transgenic mouse actin in the presence of dephosphorylated troponin 
produced a high Ca2+ sensitivity compared to reconstitution with natively 
phosphorylated troponin (EC50 decreased by 2.9, p = 0.03). Similarly, a 2.5 
times higher Ca2+ sensitivity of dephosphorylated human cardiac troponin with 
rabbit skeletal actin was previously found by A.E Messer (PhD Thesis, 2007). 
In order to examine whether the mutant affected the contractility in a similar way 
when the troponin was dephosphorylated, E361G actin was reconstituted into a 
thin filament containing dephosphorylated non-failing human cardiac troponin. 
The increased Ca2+ sensitivity of non-transgenic actin in the presence of 
dephosphorylated troponin was significantly depressed (0.35 ± 0.09 vs 0.36 ± 
0.10, p = 0.61). We can therefore conclude that this actin DCM mutant 
significantly blunts the contractile response to troponin phosphorylation levels. 
These observations were made by direct comparisons of Ca2+ curves from 
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E361G or non-transgenic actin measured with phosphorylated or 
dephosphorylated troponin in the same cell.  
Changing the phosphorylation of troponin that is incorporated into the 
E361G thin filament has therefore elucidated a potential mechanism for familial 
DCM. E361G thin filaments are not responsive to altered phosphorylation levels 
and the cardiac contractile reserve could be reduced. It was shown that the 
actual levels of troponin I and troponin T phosphorylation in non-transgenic and 
E361G hearts are the same. Troponin T is phosphorylated at 2.54 mols Pi/mol 
TnT in non-transgenic hearts compared to 2.62 mols Pi/mol TnT in E361G 
hearts. Troponin I is phosphorylated at 3.6 mols Pi/mol TnI in non-transgenic 
hearts compared to 3.52 mols Pi/mol TnI in E361G hearts. Myosin light chain 
and myosin binding protein C are also unchanged. The levels of troponin 
phosphorylation thus appear normal in the E361G transgenic mouse heart but 
the myofilaments cannot respond to changes in phosphorylation. It is also 
interesting to make comparisons with the phosphorylation levels of human 
cardiac troponin. Messer et al. showed non-failing human cardiac troponin 
contained 2.1 mol Pi/mol TnI. This is 42% less than in mouse troponin, so it 
could be that PKA or PKC sites are more phosphorylated in mouse than in 
human troponin. Non-failing human cardiac troponin contained 3.1 mol Pi/mol 
TnT (22% more than in mouse troponin) (Messer et al., 2006).  
Mice carrying the ACTC E361G mutation have a normal lifespan and in 
vivo investigations using MRI have shown no overt failing heart phenotype 
exists. The cardiac morphology of six transgenic and six non-transgenic mice 
was investigated by Caroline Carr and Daniel Stuckey (Department of 
Physiology, University of Oxford). Dr. Weihua Song provided the data (Figure 
4.10). No differences were found between the E361G-transgenic and non-
transgenic mice in the left ventricular mass (E361G = 95.92mg ± 7.53, NTg = 
94.52mg ± 9.04, p=0.38), stroke volume (E361G = 39.32ul ± 4.81, NTg = 
38.02ul ± 5.0, p=0.32), or ejection fraction (E361G = 61.06% ± 8.46, NTg = 
58.25% ± 7.46, p=0.27). Cardiac output was slightly different in left ventricular 
function (E361G = 16.8ul/min ± 2.39, NTg = 14.35ul/min ± 2.66, p=0.06), 
although this was because of the slightly higher heart rates of the transgenic 
mice (E361G = 427.78 bpm ± 37.72, NTg = 376.65 bpm ± 38.07, p=0.02). The 
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higher heart rates were considered to be due to experimental variation rather 
than a systematic difference. 
 
Figure 4.10 MRI Scanning of E361G Transgenic Mouse Hearts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 4 chamber long axis, (B) Mid-papillary short axis, (C) Basal short axis, (D) apical short axis 
Subsequent investigations of unloaded cardiac myocyte contractility 
have shown that the E361G mutation does also not induce any difference in the 
basal contraction, response to Ca2+ changes, response to isoprenaline, or the 
response to frequency changes (Figure 4.11 - Figure 4.14).Data has been 
provided by Dr. Weihua Song.  
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Figure 4.11 Non-Transgenic and E361G Basal Contraction Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Non-Transgenic and E361G Isoprenaline Response 
Data 
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Figure 4.13 Non-Transgenic and E361G Ca2+ Response Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Non-Transgenic and E361G Frequency Response 
Data 
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The nature of the experimental system has proven to have a strong 
influence on the results obtained with the E361G thin filament. Although E361G 
is the only actin DCM associated mutant to be tested in combination with 
troponin phosphorylation, similar studies that have used a recombinant troponin 
C DCM mutant G159D have also revealed insensitivity to troponin 
phosphorylation (Biesiadecki et al., 2007, Preston et al., 2007a). There is 
therefore convincing evidence that this novel mechanism may contribute to the 
pathogenic effect of DCM. We have been fortunate enough to obtain a sample 
of human heart muscle containing the troponin C DCM-causing mutation 
G159D. Our results with this tissue are reported in the next chapter. 
 
 
   CHAPTER 5 
 
 175
5. FUNCTIONAL INVESTIGATION OF A DCM TROPONIN C 
MUTANT GLY159ASP 
The missense mutation Gly159Asp (G159D) in cardiac troponin C is 
associated with DCM. It was first identified by Mogensen et al. through a 
genetic case study of cardiac troponin C and troponin T in 235 consecutive 
patients with idiopathic DCM (Mogensen et al., 2004b). We have obtained a 
cardiac muscle sample from a patient belonging to the original family with the 
DCM troponin C G159D mutation. This chapter will describe the functional 
investigation of this mutant troponin using the in vitro motility assay. Our 
strategy has been to reconstitute human cardiac partner proteins into the thin 
filament to accurately replicate a human system. The human cardiac troponin 
isolated from the biopsy should have the physiological post-translational 
modifications and mutant to wild type ratios characteristic of this DCM 
phenotype. 
 
5.1 Patient History and Diagnosis 
The three-year old male patient was admitted to hospital with a 3-day 
history of vomiting and reduced urine output (Kaski et al., 2007). He had been 
unwell for the previous three months with lethargy, dyspnoea, and a cough. A 
presumptive diagnosis was made of cardiomyopathy, given his chest X-ray 
findings (increased cardiothoracic ratio, pulmonary oedema) and the strong 
family history of DCM (refer to (Mogensen et al., 2004b)). On the maternal side 
his mother has dilated cardiomyopathy, uncle has had a heart transplant aged 
21, aunt is awaiting a transplant and grandmother died at the age of 45. During 
admission he had a short lasting tachyarrhythmia (rate 210 bpm) detected on 
the monitor, but not captured on the 12-lead echocardiogram. The ECG 
demonstrated a normally connected heart, with 4-chamber dilatation, left 
ventricular end-diastolic dimensions of 54mm, with end-systolic dimension of 
50mm, poor biventricular systolic function, and the left ventricular ejection 
fraction being at 20%. Despite inotropic support, he developed respiratory 
distress and increasing agitation, which progressed to bradycardia and 
respiratory arrest. He was therefore intubated for extracorporeal membrane 
oxygenation support. An orthotopic heart transplantation followed and at the 7-
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month review after transplantation he remained well and active, with no 
episodes of rejection detected clinically or on endomyocardial biopsy.  
Histological analysis of the explanted heart showed non-specific patchy 
fibrosis, particularly in the subendocardium (Figure 5.1). There was no myocyte 
disarray or hypertrophy. Mutation analysis on the patient’s genomic DNA 
extracted from a peripheral blood sample confirmed the presence of the G159D 
mutation.  
 
Figure 5.1 Histological Analysis of Left Ventricular Myocardium 
 
A section of left ventricular myocardium from the explanted heart. A few elongated myofibres 
with enlarged nuclei are visible. There is no fibrosis, inflammation or necrosis. Obtained from 
(Kaski et al., 2007) 
 
5.2 Location of the TNNC1 G159D Mutation  
The representation in Figure 5.2 shows that the structure of human cardiac 
troponin is composed of two domains, (1) the regulatory head, and (2) the 
troponin I-troponin T arm. The G159D mutation is located within the C-terminal 
lobe of cardiac troponin C (Biesiadecki et al., 2007). This is considered a 
structural rather than a regulatory site  (reviewed in  (Kobayashi and Solaro, 
2005)). NMR analysis of troponin C-troponin I complexes have shown that the 
N-terminal domain of Troponin I makes contact with the C-terminal domain of 
troponin C, at a site close to the Troponin C residue G159D (Finley et al., 
1999).  
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Figure 5.2 Troponin C Gly159 in the Whole Troponin Complex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ribbon representation of the troponin complex, highlighting the position of Troponin C Gly159 
mutation in red. Troponin C and T are shown in blue and yellow respectively. Troponin I is 
shown in green. Black spheres show the Ca2+ ions. Molecular graphics were prepared with 
Chimera. 
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5.3 Isolation of Non-Failing and G159D Troponin  
Troponin was isolated from 150-200mg of non-failing and G159D heart 
tissue by affinity chromatography with the anti-troponin I monoclonal antibody 
16A11 (section 2.8). Figure 5.3 shows SDS-PAGE analysis of the affinity 
purification. Pure non-failing troponin has eluted in fractions E1 and E2. Pure 
G159D troponin has eluted in E2. The yield was normally 300-700µl of 5-7µM 
from 150mg of tissue. 
 
Figure 5.3 SDS-PAGE Showing Extraction of Troponin from 
Non-Failing and G159D Heart Tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XT – Extract, FT – Flow through, W – Wash, E – Elute fraction, MHC – Myosin heavy chain, 
MLC – Myosin light chain, Tm – Tropomyosin, Tn – Troponin. 
 
CHAPTER 5 
 179
5.4 Phosphorylation Measurements 
Levels of phosphorylation from native non-failing and G159D troponin 
were measured directly using SDS-PAGE with the Pro-Q Diamond 
phosphoprotein gel stain (Figure 5.4). 
 
Figure 5.4 SDS-PAGE of Non-Failing and G159D Troponin  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Phosphorylation levels were measured from 4 paired troponin isolations. 
G159D troponin had an 11% reduction in troponin T phosphorylation compared 
to non-failing troponin, and a 3% increase in troponin I phosphorylation. 
However, these differences were not significantly different from non-failing 
troponin, p = 0.45 and 0.92 respectively (Table 5.1, Figure 5.5). 
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Table 5.1 Phosphorylation Differences Between Non-Failing 
and G159D Troponin 
 
Figure 5.5 Average Phosphorylation Levels of Troponin T and 
Troponin I  
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 Pro-Q Diamond/Coomassie Ratio  
 Non-Failing G159D % Difference 
TnT 1.06 ± 0.07 0.94 ± 0014 - 11.3% 
t-test (n = 4) Paired = 0.45 
Unpaired = 0.47 
TnI 1.31 ± 0.19 1.36 ± 0.23 + 3.8% 
t-test (n = 4) Paired = 0.92 
Unpaired = 0.89 
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5.5 In Vitro Motility Analysis 
5.5.1 Effects of Human Cardiac Tropomyosin on Actin Filament 
Motility 
Over 19 separate measurements, skeletal rabbit actin moved an average 
of 2.9 ± 0.15 µm/sec with 78 ± 3.12 % motility. 20-60nM human cardiac 
tropomyosin was titrated against 10nM skeletal rabbit actin. This resulted in the 
actin sliding speed increasing by 12% to 3.12 ± 0.15 µm/sec, and the 
percentage of filaments motile to increase by 9% to 84 ± 2.01 %. A typical 
titration is shown in Figure 5.6. 
 
Figure 5.6 Effect of Human Cardiac Tropomyosin on Rabbit 
Actin Motility (from Expt. 1; Table 5.2 and Table 5.5) 
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5.5.2  Effects of Human Cardiac Troponin on Actin Filament 
Motility 
Thin filaments were assembled using rabbit skeletal muscle actin, human 
cardiac tropomyosin, and non-failing or G159D troponin. Troponin at increasing 
concentrations (20-40nM) was titrated with 10nM actin and 60nM human 
cardiac tropomyosin. Initial titrations at 1nM Ca2+ showed at which 
concentration troponin produced a maximum switch off. This was usually 
obtained with 40nM Troponin. With increasing troponin concentrations the 
filament sliding speed reached a maximum value and then levelled off.  
 
Figure 5.7 Effects of Non-failing and G159D Human Cardiac 
Troponin (40nM) on Actin Motility at 3.9µM Ca2+ and 1nM Ca2+  
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At 1nM Ca2+, the actin filament motility for both non-failing and G159D 
troponin was switched off by 40nM troponin with the percentage motility falling 
to approximately 5% and the sliding speed reduced by 38% for non-failing 
troponin and 35% for G159D troponin (Table 5.2 and Table 5.3). There was no 
significant difference between non-failing and G159D troponin in terms of the 
percentage motility (p = 0.53) or the sliding speed (p = 0.52). Both inhibited 
actin filament motility to a similar degree. The G159D mutation has previously 
been studied in our laboratory using the in vitro motility assay, and a similar 
result was obtained (Mirza et al., 2005). Troponin complexes were reconstituted 
from recombinant human cardiac troponin I, C, and T with wild type troponin C 
and G159D mutant troponin C. Under relaxing conditions of 1nM Ca2+, filament 
motility of thin filaments containing wild type and G159D mutant troponin C 
were indistinguishable. The percentage motility was switched off by troponin 
such that <10% of filaments were motile and the sliding speed was reduced by 
approximately 40%.  
 At 3.9µM Ca2+, 40nM of both non-failing and G159D troponin increased 
actin sliding speeds by 7% over actin-tropomyosin (Table 5.4). The increase in 
sliding speed with non-failing troponin can be contrasted with the larger 
increase of 26% reported by Messer et al. who similarly used human cardiac 
troponin and tropomyosin (Messer et al., 2006), and the 34% increase reported 
by Mirza et al. when using recombinant wild type troponin. Using recombinant 
G159D troponin with human cardiac tropomyosin, Mirza et al. found that G159D 
troponin conferred a significantly lower maximum sliding speed compared to 
non-failing troponin. The recombinant G159D troponin caused a 14% increase 
in sliding speed compared to the 34% increase with non-failing troponin.  
Our studies found the percentage motility at high Ca2+ was also not 
significantly different (p = 0.63) (Table 5.5). Non-failing troponin caused an 
increase of just 2% and G159D human cardiac troponin increased by 1%. 
Between 81-82% of actin filaments were motile at saturating concentrations of 
tropomyosin and non-failing and G159D troponin. Similarly, Mirza et al. found 
no significant difference between the percentage motility of non-failing and 
G159D troponin at high Ca2+ conditions (p = 0.9) (Mirza et al., 2005).  
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Table 5.2 Effect of Human Cardiac Troponin on Filament Sliding 
Speed at Low Ca2+ (1nM Ca2+) 
Exp. No. Sliding Speed, µm/sec Relative Sliding Speed of 
Actin.Tm.Tn: Actin.Tm 
 Actin-Tm NF G159D NF G159D 
1 3.3 ± 0.07 1.4 ± 0.03 2.0 ± 0.22 0.4 0.6 
2 3.0 ± 0.04 1.4 ± 0.11 1.4 ± 0.08 0.5 0.5 
3 2.3 ± 0.03 1.4 ± 0.01 2.0 ± 0.23 0.6 0.9 
4 2.3 ± 0.04 2.0 ± 0.06 1.5 ± 0.04 0.9 0.7 
5 2.0 ± 0.04 1.6 ± 0.07 1.6 ± 0.03 0.8 0.8 
6 2.5 ± 0.09 1.9 ± 0.09 2.0 ± 0.10 0.8 0.8 
7 2.5 ± 0.12 1.7 ± 0.03 1.6 ± 0.10 0.7 0.6 
Mean ± 
SE 
n = 7 
2.56 ± 0.17 1.63 ± 0.09 1.73 ± 0.10 0.67 ± 0.07 0.70 ± 0.05 
T-test 
P Value 
 Paired = 0.52 
Unpaired = 0.48 
Paired = 0.67 
Unpaired = 0.75 
 
Table 5.3 Effect of Human Cardiac Troponin on Filament 
Percentage Motility at Low Ca2+ (1nM Ca2+) 
Exp. No. Percentage Motile, % Relative % Motility of 
Actin.Tm.Tn: Actin.Tm 
 Actin-Tm NF G159D NF G159D 
1 89 ± 5.57 3 ± 2.63 3 ±5.62 0.03 0.03 
2 90 ± 2.61 7 ± 1.43 5 ± 3.28 0.08 0.06 
3 61 ± 1.63 3 ± 1.22 1 ± 1.00 0.05 0.02 
4 83 ± 1.64 2 ± 1.84 4 ± 2.63 0.02 0.05 
5 79 ± 3.92 6 ± 0.75 12 ± 2.89 0.08 0.15 
6 87 ±1.31 6 ± 2.96 8 ± 1.26 0.07 0.09 
7 75 ± 1.03 3 ± 1.64 2 ± 4.01 0.04 0.03 
Mean ± 
SE 
n = 7 
80.57 ± 3.85 4.28 ± 0.75 5.00 ± 1.45 0.05 ± 0.01 0.06 ± 0.02 
T-test 
P Value 
 Paired = 0.53 
Unpaired = 0.67 
Paired = 0.53 
Unpaired = 0.67 
 
CHAPTER 5 
 185
 
Table 5.4 Effect of Human Cardiac Troponin on Filament Sliding 
Speed at High Ca2+ (3.9µM Ca2+) 
Exp. 
No. 
Sliding Speed, µm/sec Relative Sliding Speed of 
Actin.Tm.Tn: Actin.Tm 
 Actin-Tm NF G159D NF G159D 
1 3.3 ± 0.07 2.8 ± 0.05 2.8 ± 0.02 0.9 0.9 
2 3.0 ± 0.04 3.1 ± 0.09 3.2 ± 0.03 1.0 1.1 
3 2.3 ± 0.03 2.8± 0.03 2.8 ± 0.01 1.2 1.2 
4 2.3 ± 0.04 2.5 ±0.36 2.5 ±0.02 1.1 1.1 
5 2.0 ± 0.04 2.9 ± 0.25 2.8 ± 0.24 1.5 1.4 
6 2.5 ± 0.09 2.5 ± 0.15 2.8 ± 0.11 1.0 1.1 
7 2.5 ± 0.12 2.5 ± 0.02 2.2 ± 0.05 1.0 0.9 
Mean ± 
SE 
n = 7 
2.56 ± 0.17 2.73 ± 0.09 2.73 ± 0.12 1.08 ± 0.07 1.08 ± 0.08 
T-test 
P Value 
 Paired  = 1.0 
Unpaired = 1.0 
Paired  = 0.92 
Unpaired = 0.98 
 
Table 5.5 Effect of Human Cardiac Troponin on Filament 
Percentage Motility at High Ca2+ (3.9µM Ca2+) 
Exp. 
No. 
Percentage Motile, % Relative % Motility of 
Actin.Tm.Tn: Actin.Tm 
 Actin-Tm NF G159D NF G159D 
1 89 ± 5.57 92 ± 2.65 89 ±3.62 1.0 1.0 
2 90 ± 2.61 81 ± 1.65 82 ± 2.05 0.9 0.9 
3 61 ± 1.63 73 ± 3.57 67 ± 3.76 1.2 1.1 
4 83 ± 1.64 86 ± 1.89 90 ± 5.62 1.0 1.1 
5 79 ± 3.92 65 ± 1.44 59 ± 4.48 0.8 0.8 
6 87 ±1.31 94 ± 1.84 99 ± 4.51 1.1 1.1 
7 75 ± 1.03 87 ± 1.33 86 ± 2.36 1.2 1.1 
Mean ± 
SE 
n = 7 
80.57 ± 3.85 82.57 ± 3.95 81.71 ± 5.28 1.03 ± 0.05 1.01 ± 0.05 
T-test 
P Value 
 Paired = 0.63 
Unpaired = 0.90 
Paired = 0.60 
Unpaired = 0.85 
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5.5.3 Comparing Ca2+ Sensitivity Curves of Non-Failing and 
G159D Cardiac Troponin  
Concentrations of troponin that gave maximal inhibition of filament 
activity at 1nM Ca2+ were used to measure the Ca2+ dependence of thin 
filament in vitro motility. The Ca2+ sensitivity of the sliding speed and the 
percentage motile of actin filaments were investigated for 3 paired non-failing 
and G159D heart muscle samples. Reconstituted thin filaments consisted of 
10nM skeletal rabbit actin, 60nM human cardiac tropomyosin, and 40nM non-
failing or G159D troponin. In these experiments, the human cardiac troponin 
was in its native phosphorylation state.  
The Ca2+ sensitivity curves for the sliding speed proved inaccurate when 
fitted to the Hill Equation since the overall increase in sliding speeds from 1nM 
Ca2+ to 3.9µM Ca2+ was small. The resulting fits are shown in Figure 5.8, 
however the sliding speeds did not change enough for the calculated EC50 
value to be accurate. The Ca2+ sensitivity curves for the percentage motility of 
thin filaments containing G159D mutant troponin C could be accurately fitted. 
The curves were shifted to the left and the calculated Ca2+ sensitivity was 
increased. The G159D mutation caused a 4.7 ± 1.87-fold decrease in 
percentage motility EC50 compared to non-failing troponin (Table 5.6). 
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Figure 5.8 Ca2+ Regulation of Thin Filaments containing Non-
failing or G159D Troponin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following data had the parameters set to obtain an accurate sigmoidal curve: 
Graph 1 (Min values set at 1.6µm/sec and 2%, max-min at 1.1µm/sec) 
Graph 2 (Min values set at 1.4µm/sec and 6%, max-min at 1.8µm/sec and 76%). 
 
 
1 
2 
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Graph 3 (Min values set at 1.3µm/sec and 9%, max-min at 1.3µm/sec and 53%). 
 
Table 5.6 Ca2+ Sensitivity Data for Non-Failing and G159D 
Troponin incorporated into the Native Thin Filament 
 
 
 
 
Expt. 
No. 
EC50 Sliding Speed, µM EC50 NF 
EC50 
G159D 
EC50 Percentage 
Motility, µM 
EC50 NF 
EC50 
G159D 
Non-Failing G159D  Non-
Failing 
G159D  
1 0.025 ± 
0.018 
0.005 ± 
0.005 
5.00 0.044 ± 
0.002 
0.010 ± 
0.013 
4.40 
2 0.066 ± 
0.018 
0.013 ± 
0.013 
5.08 0.201 ± 
0.080 
0.025 ± 
0.009 
8.04 
3 0.264 ± 
0.155 
0.024 ± 
0.065 
11.00 0.177 ± 
0.029 
0.112 ± 
0.019 
1.58 
Mean 
± SD 
0.118 ± 
0.07 
0.014 ± 
0.01 
7.03 ± 
1.99 
0.141 ± 
0.049 
0.049 ± 
0.032 
4.67 ± 1.87 
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These Ca2+ sensitivity results that used native troponin from a human 
G159D heart sample can be compared with those produced when wild type and 
G159D troponin C was expressed in Eschericia.coli and then substituted into 
recombinant troponin (Mirza et al., 2005). The recombinant G159D troponin 
produced an opposite phenotype in the in vitro motility assay. The Ca2+ 
sensitivity was decreased (increase in EC50 by 1.6-fold ± 0.01 and 1.5-fold ± 
0.03 for sliding speed and percentage motility respectively), and the Hill 
coefficient also decreased for both parameters. However, the recombinant 
troponin incorporated was not phosphorylated and our native human cardiac 
troponin was phosphorylated at 3.1 mol Pi/molTnT and 2.1mol Pi/mol TnI 
(Messer et al., 2006). The Ca2+ sensitivity of phosphorylated recombinant 
G159D troponin was never tested. The in vitro motility results from the DCM 
actin E361G mutation implicate insensitivity to troponin phosphorylation levels 
may be a critical causative factor in familial DCM. We therefore tested the 
troponin from the G159D biopsy in its native and dephosphorylated state.  
 
5.5.4 Effect of Troponin Dephosphorylation on the Ca2+-
Dependence of Motility 
Dephosphorylation was achieved by incubation of the troponin with 1.4 
units/ml acid phosphatase (Figure 5.9). Thin filaments were assembled from 
combinations of native and dephosphorylated non-failing and G159D troponin 
Figure 5.10 demonstrates the well-known impact of dephosphorylation on non-
failing troponin. There is a significant leftward shift of the sliding 
speed/percentage motility-Ca2+ relationship and a lower sliding speed at 3.9µM 
Ca2+. The Ca2+ sensitivity of the myofilaments increased 2.8-fold ± 0.66 for the 
sliding speed and 4.8-fold ± 2.05 for the percentage motility (Messer et al., 
2006).  
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Figure 5.9 SDS-PAGE of Non-Failing and G159D Human Cardiac 
Troponin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDS-PAGE gel of two non-failing and G159D troponin pairs, showing the effect of acid 
phosphatase on troponin T and I phosphorylation. Stained with (A) Pro-Q Diamond (for 
phosphoproteins) and (B) Sypro Ruby for total protein levels.  
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Figure 5.10 Effect of Dephosphorylation on Non-Failing 
Troponin  
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Figures obtained from A.E Messer PhD Thesis, 2007. 
 
 The impact of dephosphorylation on G159D filament Ca2+-sensitivity 
was investigated (Figure 5.11, Error! Reference source not found.). The 
characteristic increase in Ca2+ sensitivity that normally accompanies troponin I 
dephosphorylation was abolished. Native and dephosphorylated G159D 
troponins produced similar Ca2+ sensitivities (EC50 159/159.dp = 1.24 ± 0.17). 
The dephosphorylated G159D thin filaments were not responsive to the 
phosphorylation change shown by the non-failing troponin in Figure 5.10 and 
behaved as if phosphorylated at all times. 
CHAPTER 5 
 192
1 
2 
 
Figure 5.11 Effect of Dephosphorylation on the Regulation by 
G159D Troponin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The sliding speeds did not change enough for accurate EC50 values to be obtained. The points 
have simply been plotted. Graph B had the minimum percentage motility parameter values set 
at 1%, and maximum-minimum at 75.5%. 
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Graph C had the minimum values set at 11%, and maximum-minimum set at 55% to obtain 
accurate sigmoidal curves.  
 
Table 5.7 Ca2+ Sensitivity Data for Native and Dephosphorylated 
G159D Troponin 
 
 
Dephosphorylating both non-failing and G159D troponin and 
reconstituting them into the thin filament produced a slight leftward shift of 
G159D troponin (Figure 5.12). Over 2 separate measurements, G159D showed 
a 1.77 ±0.29 -fold higher Ca2+ sensitivity of the percentage motility (Table 5.8).  
Expt. 
No. 
EC50 Percentage Motility, µM EC50 G159D 
EC50 G159D.dp 
G159D G159D.dp 
1 0.036 ± 0.014 0.033 ± 0.009 1.09 
2 0.019 ± 0.005 0.018 ± 0.003 1.06 
3 0.033 ± 0.018 0.021 ± 0.010 1.57 
Mean 
± SD 
0.029 ± 0.005 0.024 ± 0.006 1.24 ± 0.17 
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Figure 5.12 Effect of Dephosphorylation of Non-Failing and 
G159D Troponin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 1 (Min values set at 14%, max-min at 75%),  Graph 2 (Min values set at 4.6%, max-min at 
75%). 
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Table 5.8 Ca2+ sensitivity Data for Dephosphorylated Non-
Failing and G159D Troponin  
 
 Our strategy has been to reconstitute a system that is as close as 
possible to the human myofilament. The regulatory properties of thin filaments 
depend upon all the components. This was illustrated by Bing et al., who 
reported that different effects of HCM mutations in tropomyosin occur when 
using either rabbit skeletal muscle troponin or human cardiac troponin (Bing et 
al., 2000). Two examples concerning the G159D mutation also confirm the 
importance of the nature of the experimental system. The previous in vitro 
motility results with wild type and G159D troponin expressed in Eschericia.coli 
and substituted into native troponin used human cardiac tropomyosin in the thin 
filament (Mirza et al., 2005). However, since this troponin was not 
phosphorylated, an unnatural thin filament was experimented upon. The 
opposite results found to ours of decreased Ca2+ sensitivity and a lower 
maximum sliding speed reflected this. The second example comes from 
previous in vitro motility studies in our laboratory that used troponin from the 
same G159D human heart muscle sample (Jacques, unpublished data 2007). 
In contrast to our findings however, a lower Ca2+ sensitivity and a lower 
maximum sliding speed was found. However, these experiments had AS-α-
tropomyosin reconstituted into the thin filament, producing another unnatural 
thin filament system. In order to clarify the situation, we have repeated these in 
vitro motility experiments on thin filaments assembled from AS-α-tropomyosin 
and native non-failing and G159D human cardiac troponin. Results of a similar 
direction and magnitude to those reported by Jacques were found in this 
system. The G159D troponin had a 2.6-fold lower Ca2+ sensitivity of percentage 
Expt. 
No. 
EC50 Percentage Motility, µM EC50 NF.dp 
EC50 G159D.dp 
NF.dp G159D.dp  
1 0.132 ± 0.041 0.064 ± 0.031 2.06 
2 0.105 ± 0.669 0.071 ± 3.006 1.48 
Mean ± 
SD 
0.119 ± 0.014 0.068 ± 0.004 1.77 ± 0.29 
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1 
2 
motility (EC50 NF/G159D = 0.39) and an 8% lower maximum sliding speed 
(Figure 5.13, Table 5.9, Table 5.10). 
 
Figure 5.13 Effect of Recombinant Tropomyosin incorporated 
into the Non-Failing and G159D Thin Filament 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 1 (Min values set at 2.6%, max-min at 79%), Graph 2 (Min values set at 2.8%, max-min 
at 65%). 
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Graph 3 (Min values set at 4%, max-min at 73%) 
 
Table 5.9 Ca2+ Sensitivity Data for Non-failing and G159D Thin 
Filaments Incorporated with AS-α-Tropomyosin  
 
Table 5.10 Non-Failing and G159D Thin Filament Sliding Speeds 
at 3.9µM Ca2+ 
 
Expt. No. EC50 Percentage Motility, µM EC50 NF 
EC50 G159D 
NF G159D  
1 0.127 ± 0.014 0.406 ± 0.026 0.31 
2 0.177 ± 0.024 0.321 ± 0.040 0.55 
3 0.008 ± 0.003 0.026 ± 0.010 0.31 
Mean ± SD 
(n = 3) 
0.104 ± 0.050 0.251 ± 0.115 0.39 ± 0.08 
 3.9µM Sliding Speeds µm/sec 
 
Expt No. Non-Failing 
 
G159D 
1 2.75 ± 0.11 2.52 ± 0.15 
2 2.70 ± 0.06 2.54 ± 0.06 
3 2.48 ± 0.02 2.22 ± 0.05 
Mean: ± SE 
(n = 3) 
2.64 ± 0.08 2.43 ± 0.10 
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5.6 Discussion 
The TNNC1 G159D mutation was first identified by Mogensen et al. in a 
genetic screen study of DCM families (Mogensen et al., 2004b). One family was 
affected, and we were fortunate enough to obtain a muscle sample from a 
three-year old child belonging to the original family that underwent an orthotopic 
heart transplant. To date this is the only known DCM tissue sample that has 
been genotyped. The aim was to isolate pure troponin (fully phosphorylated) 
from the patient with the G159D troponin C mutation and investigate the 
functional effects of the mutation in combination with troponin phosphorylation 
using the in vitro motility assay. Previous in vitro motility studies have been 
done on thin filaments assembled from combinations of recombinant and native 
troponin and tropomyosin subunits (Mirza et al., 2005). However, since we have 
had access to a muscle sample we have been able work with proteins that were 
all isolated from human cardiac muscle. Troponin was isolated from the human 
muscle sample via an affinity separation method that used an anti-cardiac 
troponin I monoclonal antibody conjugated to CNBr Sepharose CL-4B (section 
2.8.1). The yield was normally 600µl of 7µl from 100mg of tissue. Troponin was 
dephosphorylated by incubation with 1.4 U/ml acid phosphatase (section 
2.8.1.1). Staining of this troponin with a Pro-Q Diamond Phosphoprotein Gel 
Stain confirmed its full dephosphorylation (Figure 5.9). Thin filaments were 
reconstituted with skeletal rabbit actin (same amino acid sequence as human 
ACTA1), human cardiac troponin (from non-failing heart or the G159D heart 
muscle sample) and human cardiac α-tropomyosin. 
 When G159D troponin and non-failing troponin were incorporated into 
the thin filaments in their native phosphorylation states (with both troponin I and 
troponin T phosphorylated), the Ca2+ sensitivity of G159D troponin was 4.67 ± 
1.87 -fold higher than NF troponin in the percentage motility parameter. The 
sliding speed did not change enough for an accurate EC50 value to be 
determined. When dephosphorylated, G159D troponin had a Ca2+ sensitivity 
that was similar to G159D troponin in its native phosphorylated state, EC50 
159/159.dp = 1.24 ± 0.17. This can be directly compared with the 4.8 -fold ± 
2.05 increase in Ca2+ sensitivity of dephosphorylated non-failing troponin 
compared to native non-failing troponin. This lack of response to troponin I 
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phosphorylation levels was also found with the actin E361G DCM mutation. 
Comparisons of the G159D with non-failing troponin when both 
dephosphorylated showed the G159D troponin to have a slightly raised Ca2+ 
sensitivity compared to dephosphorylated non-failing troponin (percentage 
motility EC50 NF.dp/159.dp = 1.77 ± 0.29), although the difference is less than 
with the native troponin (percentage motility EC50 NF/159 = 4.67 ± 1.87). These 
findings are summarised in Figure 5.14. 
 
Figure 5.14 Comparison of Phosphorylated and 
Dephosphorylated Non-failing and G159D Troponin  
 
 
 
 
 
 
 
 
The average EC50 value differences (percentage motility) of non-failing and G159D troponin. 
The larger of the two sided arrows denotes the direction of higher EC50 value. 
 
The troponin isolated from the human muscle sample should have the 
mutant to wild type ratios characteristic of the DCM phenotype. Preliminary 
mass spectrometry data has been conducted to try and determine what this 
ratio is. Initial ESI-FTICR studies of a trial mixture of 1:1 wild type: G159D 
recombinant troponin C mixture conducted in Peter Derrick’s laboratory has 
shown the FTICR technique can clearly distinguish the mutant troponin C and 
quantify the amount present (Figure 5.15).  
 
 
 
Higher Ca2+ 
sensitivity 
Higher Ca2+ 
sensitivity 
 
Low Ca2+ 
Higher Ca2+ 
sensitivity 
G159D G159D.dp 
Non-Failing Non-Failing.dp 
1.24 ± 0.17 
4.8 ± 2.05 
4.7 ± 1.87 1.77 ± 0.29 
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Figure 5.15 ESI-FTICR of 1:1 Recombinant Troponin C and 
G159D Troponin C Mixture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two species with major bands are clearly resolved. Peak 1a corresponds to t roponin C 
(18,403Da from amino acid sequence), and peak 2a corresponds to troponin C G159D 
(+150Da). The satellite peaks 1b and 2b are +Mg,  and 1c and 2c are Ca2+. The proportion of 
each of the 3 bands is different for troponin C and G159D troponin C. Adding up the 3 bands on 
peak height gives 10.7 units for troponin C and 11.1 units for G159D troponin C. This equals the 
1:1 ratio of species actually present, thus G159D is 51% of cardiac troponin C. 
 
 Evidence for the presence of the G159D mutation in whole troponin 
isolated from our G159D human muscle biopsy has been confirmed by SELDI-
Mass Spectrometry carried out by Dr. Douglas Ward (CRC Cancer Studies at 
the University of Birmingham), and Dr. Clare Gallon (NHLI, Imperial College 
London). The whole troponin was purified using an NP20 SELDI Chip. Figure 
5.16 shows 100% recombinant wild type and G159D troponin C traces and 
mixtures of 25%, 50%, and 75% G159D troponin C. The wild type mass 
obtained of 18395Da was close to the theoretical value of 18403Da. The 
G159D mass obtained of 18462Da was close to the theoretical value of 
1a 1b 1c 
2a 
2b 2c 
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18461Da. The identity of the peak to the right of the wild type troponin C is 
unknown. 
Figure 5.17 shows two mass spectra obtained from the human muscle 
sample of cardiac G159D troponin. Sample 2 has a poor resolution, although 
both show 2 peaks corresponding to cardiac troponin C and G159D cardiac 
troponin C. The quantity of mutant to wild type troponin C in our human muscle 
biopsy seems to be between 50-75%. SELDI-MS of troponin is able to detect 
cardiac troponin C at a much lower resolution than FTICR. Further mass 
spectroscopy studies are being conducted on the G159D human muscle biopsy 
in Prof. Jeffery Walker’s laboratory at the University of Wisconsin.  
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Figure 5.16 SELDI-MS of Recombinant Troponin C Mixtures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17 SELDI-MS of G159D Whole Troponin  
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The findings from this G159D human muscle study can be directly 
compared with recently published studies that used pseudophosphorylated and 
unphosphorylated recombinant G159D and wild type troponin (Biesiadecki et 
al., 2007, Preston et al., 2007a). When Biesiadecki et al. incorporated 
recombinant wild type and G159D troponin (with no phosphorylation) into 
chemically skinned rat trabeculae, no differences were found between wild type 
and G159D troponin (WT-Tn EC50 = 2.34 ± 0.11, G159D-Tn EC50 = 2.29 ± 
0.14). However, when pseudophosphorylated troponin I was incorporated into 
the skinned rat trabeculae, the Ca2+ sensitivity of G159D troponin was 
increased 1.35-fold compared with exchange with wild type-
pseudophosphorylated troponin (G159D-Tn-DD EC50 = 2.51 ± 0.17, WT-Tn-DD 
EC50= 3.39 ± 0.18).  ATPase measurements also demonstrated ATPase 
hydrolysis was significantly enhanced 1.32-fold after exchange with the 
pseudophosphorylated G159D troponin compared with wild type 
pseudophosphorylated troponin (G159D-Tn-DD EC50 = 2.14 ± 0.15, WT-Tn-DD 
EC50 = 2.82 ± 0.2). These experiments are equivalent to the native G159D and 
non-failing troponin comparison described in this thesis, and a similar result was 
obtained. In comparison, Preston et al. reported that G159D troponin C in the 
presence of a PKA phosphomimic of troponin I (Ser23Asp, Ser24Asp) had an 
equal Ca2+ sensitivity to wild type troponin I PKA pseudophosphorylated 
troponin (exchanged into skinned rabbit psoas fibres) (Preston et al., 2007a).  
Both Biesiadecki et al. and Preston et al. reported that the Ca2+ 
sensitivity of G159D troponin was insensitive to troponin 
pseudophosphorylation. Biesiadecki et al. reported no differences in the 
ATPase and tension of G159D containing a PKA pseudophosphorylated 
Troponin I exchanged into trabeculae compared to those containing 
unphosphorylated Troponin I (G159D-Troponin-DD EC50 = 2.51 ± 0.17, G159D-
Troponin EC50 = 2.29 ± 0.14). Preston et al. showed that the G159D mutation 
abolished the significant increase in maximal force (but not the decrease in Ca2+ 
sensitivity) that resulted from the incorporation of the troponin I phosphomimic 
in the presence of wild type Troponin C. The mutation blunted the reduction in 
Ca2+ sensitivity caused by a mimic of PKC troponin T phosphorylation 
(Thr203Glu). These findings showing the blunted response of G159D troponin 
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to phosphorylation correlate with the in vitro motility assay results reported in 
this study. 
It is a widely established finding that a lower Ca2+ sensitivity is obtained 
when troponin is phosphorylated and this is associated with a decrease in Ca2+ 
binding affinity to the troponin complex. Measurements of Ca2+ binding by 
troponin I-C complexes in vitro have shown that the dependence of Ca2+ 
binding affinity on troponin I phosphorylation was lost due to the G159D 
mutation (Biesiadecki et al., 2007, Dong et al., 2007). Biesiadecki et al. has 
shown that the presence of the G159D mutation did not alter Ca2+ binding 
affinity when unphosphorylated (EC50 WT-Troponin/G159D-Troponin = 1.03). 
However when phosphorylated, the decrease in Ca2+ binding shown with wild 
type troponin was prevented with G159D troponin. Dong et al. reported using 
förster resonance energy transfer (FRET) combined with equilibrium Ca2+ 
titration and stopped-flow kinetic measurements, that the kinetics of the Ca2+ 
induced opening or closing of the N-domain was altered by G159D and when 
troponin I was phosphorylated by PKA, the G159D mutation completely 
abolished the effect of phosphorylation on the kinetics of troponin C N-domain 
opening and closing. The Ca2+ binding affinity results of Biesiadecki et al. and 
Dong et al. are in direct correlation with our in vitro motility studies on G159D, 
and are summarised in Figure 5.18. In contrast to Biesiadecki et al. and Dong et 
al., Robinson et al. have found no difference in Ca2+ binding when troponin I 
was unphosphorylated. They showed using an IAANS fluorescent probe 
attached to Cys34 of troponin C followed by reconstitution into regulated thin 
filaments, that a 50: 50 mixture of unphosphorylated G159D troponin had a 2.6-
fold decrease in the Ca2+ binding affinity (EC50 WT-troponin = 0.61 ± 0.02, 
EC50G159D-troponin = 1.58 ± 0.02) (Robinson et al., 2007). However, the Ca2+ 
binding affinity of G159D troponin C in combination with troponin I 
phosphorylation was not investigated. 
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Figure 5.18 Comparison of Pseudophosphorylated and 
Unphosphorylated Non-failing and G159D Recombinant 
Troponin 
 
 
 
 
 
 
 
 
 
 
The average differences of pseudophosphorylated and unphosphorylated non-failing and 
G159D troponin from Biesiadecki et al. and Dong et al. experiments are shown above. 
Biesiadecki (Isometric Force measurements), Biesiadecki (Ca2+ binding measurements), Dong 
(Ca2+ binding measurements). The larger of the two sided arrows denotes the direction of 
higher EC50 value. 
 
A reduced response to troponin I phosphorylation levels and a higher 
Ca2+ sensitivity were two of the main effects produced by the G159D mutation 
described in this thesis. The results of Biesiadecki et al., Preston et al. and 
Dong et al. are in agreement with our in vitro motility data (Biesiadecki et al., 
2007, Preston et al., 2007a, Dong et al., 2007). The reduced response of 
mutant thin filaments to troponin phosphorylation levels also corresponds with 
the E361G ACTC mutation, and could on its own cause a DCM phenotype. 
However, the higher Ca2+ sensitivity does not correspond with either the E361G 
mutation or with previous studies on G159D (Jacques, unpublished data 2007) 
(Mirza et al., 2005). 
Previous in vitro motility studies have been done on troponin extracted 
from this same G159D human biopsy sample in our laboratory (Jacques, 
unpublished data 2007). In contrast to our results however, the native G159D 
troponin showed a lower Ca2+ sensitivity (EC50 increased by 1.63) and a 17% 
lower maximum sliding speed than native non-failing troponin. It is important to 
note however, that these results were obtained when Ala-Ser α-tropomyosin 
G159D G159D.dp 
Non-Failing Non-Failing.dp 
x 1.10 
x 1.30 
x 1.10 
x 1.45 
x 2.61 
x 1.48 
x 1.35 
x 2.08 
x 1.86  
x 1.02 
x 1.03 
x 1.38  
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(AS-α-Tm) was reconstituted into the non-failing and G159D thin filaments. 
Results reported in this chapter of an increased Ca2+ sensitivity of native G159D 
troponin and insensitivity to troponin I phosphorylation, were produced when 
human cardiac tropomyosin was incorporated into the thin filament. We have 
been able to reproduce this AS-α-Tm result and a similar decrease in Ca2+ 
sensitivity was found (EC50 increased by 2.4). The G159D mutation has 
therefore been shown to cause a lower or higher Ca2+ sensitivity compared to 
non-failing troponin depending on the incorporation of either native human 
cardiac tropomyosin or AS-α-Tm into the thin filament. Recombinant AS-α-Tm 
differs from native human cardiac tropomyosin in its N-terminal Ala-Ser 
extension, which mimics acetylation. Studies on the cooperative allosteric 
regulation of tropomyosin isoforms have shown AS-α-Tm to have a significantly 
lower cooperative unit size of 6.5 compared to a cooperative unit size of 10 
produced with native N-acetylated α-tropomyosin (Mirza et al., 2007). 
Cooperative control of the thin filament is dependent upon the end-to-end 
interactions that occur between tropomyosin dimers at the N-terminus, and the 
N-terminal Ala-Ser extension of AS-α-Tm could explain the change in G159D 
troponin function that was produced in this study.  
 The higher Ca2+ sensitivity of the native G159D troponin found in our 
study is also in contrast to results produced from a 50:50 mixture of wild type: 
recombinant G159D troponin, which showed that G159D troponin had a 14% 
lower sliding speed at 3.9µM Ca2+ and a lower Ca2+ sensitivity in the in vitro 
motility assay (EC50 increased by 1.54) (Mirza et al., 2005). This phenotype was 
found by all 8 DCM mutations studied in cardiac troponin T, troponin C, and α-
tropomyosin using the in vitro motility and ATPase assays by Mirza et al., and 
was the same direction and magnitude to results produced by A. Jacques using 
the human G159D biopsy. However, both these studies used a mixture of 
recombinant and human cardiac proteins in the thin filaments and did not 
therefore produce an entirely physiological system. In contrast, the results 
described in this chapter used troponin from a human G159D biopsy which 
should have the post-translational modifications and mutant: wild type ratios 
characteristic of the DCM phenotype. Incorporation of this troponin with human 
cardiac tropomyosin should represent the conditions of an actual human 
system. 
CHAPTER 5 
 207
In conclusion, our results demonstrate that cardiac thin filaments 
regulated by G159D troponin have a higher Ca2+ sensitivity and lack the Ca2+ 
desensitisation that normally results when Troponin I is phosphorylated by PKA. 
It is important to determine what may be physiological and what may cause the 
DCM phenotype. The blunting of response to troponin I phosphorylation has 
been found in all native systems for G159D, as well as for the actin E361G 
mutation and could occur for other DCM tropomyosin and troponin T mutations. 
This may indeed be enough to cause the DCM phenotype. In comparison, the 
higher Ca2+ sensitivity of G159D troponin is different from all other DCM 
mutations that have been previously studied, although these previous studies 
were in non-physiological systems so it could just be an artefact of this system.  
To date, these are the first set of measurements from human DCM tissue 
tested in combination with troponin phosphorylation, and the natively modified 
partner proteins used this study are more likely to mimic the real in vivo 
situation than previous systems. 
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6. FUNCTIONAL INVESTIGATION OF HCM ACTIN MUTANT 
GLU99LYS 
6.1 Introduction 
To date, there are 7 mutations in the human alpha-cardiac actin gene 
(ACTC) known to cause HCM. In this study, a transgenic mouse model has 
been developed that over expresses the HCM actin mutation Glu99Lys (E99K) 
in their hearts. The E99K mutation has been identified in numerous genetic 
screening studies (Arad et al., 2005a, Olson et al., 2000, Monserrat et al., 
2007). Many affected families show an uncommon apical form of HCM. The 
mutation is also associated with atrial septal defects. Using the in vitro motility 
assay, this chapter will describe the functional investigation of E99K actin when 
reconstituted into a regulated thin filament.  
 
6.2 Location of E99K in the Actin Molecule 
The E99K mutation is located in a surface loop in subdomain 1 of the actin 
molecule (Figure 6.1A). This is one of the secondary binding sites for the 
myosin head on each actin monomer. The E99K region is thought to interact 
with the positively charged cluster located in the lower 50-kDa domain of the 
myosin motor domain. The E99K mutant, caused by a single charge reversion, 
is likely to have an impact on actomyosin interactions (Bookwalter and Trybus, 
2006).  
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Figure 6.1 Location of the E99K Mutation in Actin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[A] A ribbon representation of actin with E99K shown in black (produced using Chimera). [B] S1 
docking onto actin. S1 interacts with 2 actins (shown in green and red). E99K is on the red actin 
subunit and is part of the secondary binding site that interacts with residue Lys-571 of S1. A 
close up is shown in [C]. Two other nearby Lys residues (Lys-573 (green) and Lys-576(cyan) 
are also indicated. Obtained from (Bookwalter and Trybus, 2006). 
S1 
Actin  
E99K 
B C 
A 
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6.3 E99K Transgenic Mouse Phenotype 
The E99K transgenic mice have not shown any cardiac hypertrophy and 
no septal defects have been observed. The mice appear healthy and breed 
normally. However, the mice show a high rate of sudden death. Prior to death, 
there is no weight loss and post-mortem mice have the same weight as their 
non-transgenic littermates. Assuming all sudden deaths are in transgenic 
individuals, the females exhibiting early death die in the range of 28-45 days 
(mean 35 days). The males are very similar, with sudden death ranging from 
31-49 days (mean 40 days) (Figure 6.2). As a percentage of the total of 
genotyped transgenics, 71% of the females die at this time, and 34% of the 
males. After this period, there is low sporadic mortality that is more prominent in 
females than males and is higher than normal for this genetic background. 
However, there was no obvious pre-mortem clinical signs or post-mortem 
abnormalities.  
 
Figure 6.2 Age of Death in Male and Female E99K Transgenic 
Mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was no difference between males and females in terms of breeding. The higher numbers 
of male mice was due to fewer genotyped females.  
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6.4 Screening of E99K Transgenic Lines 
The charge change of glutamic acid to lysine (+2) allowed the mutant to 
be identified and quantified by 2-D Electrophoresis. Four E99K transgenic lines 
were generated (Table 6.1). Just one line (N11) successfully incorporated the 
transgene and expressed E99K mutant cardiac actin in their hearts. This 
expression amounted to approximately 55% of the total actin. 
 
Table 6.1 Screening of E99K Transgenic Lines 
 Sample Heart 
Weight (g) 
PCR 
Result 
2-DE % E99K 
actin 
Line 16 16.5 0.10 +  
 
0 % 
 16.6 0.11 -  
 
0 % 
 16.7 0.12 +  
 
0 % 
Line N2 3 +  +  
 
0 % 
Line N5 9 +  +  
 
0 % 
Line N11 17 +  +  56 % 
 16 + 
 
 +  45% 
 
6.5 Isolation of F-Actin from E99K Transgenic Mouse Hearts 
Actin was isolated directly from native thin filaments using the method 
described in section 2.5. This successfully preserved the 50% expression of the 
E99K mutation in the F-actin. 
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Figure 6.3 SDS-PAGE of (A) E99K and (B) Non-Transgenic Actin 
Isolation Fractions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1) Whole muscle homogenate,  (2) first wash s/n, (3) last wash s/n, (4) S/n after 2 extractions in 
thin filament extraction buffer, (5) S/n after 50K spin, (6) Pellet after 50K spin, (7) S/n after 100K 
spin, (8) Resuspended pel let of 100K spin before dialysis, (9) S/n after dialysis, (10) KCl s/n + 
150nM phalloidin, (11) KCl s/n – 150nM phalloidin, (12) f-actin (+ phalloidin), (13) f-actin (- 
phalloidin).  
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The whole thin filaments were pelleted after the 100K spin of the thin 
filament extract supernatants (fraction 8). The pellet was resuspended in an 
ATP buffer and dialysed for 3 hours. After dialysis (fraction 9), the thin filaments 
were mixed with 0.8M KCl, with and without phalloidin (fraction 10 and 11), and 
the F-actin was pelleted (fraction 12 and 13). No differences were detected 
during the isolation of non-transgenic and E99K actin. The final F-actin pellet 
was pure for both non-transgenic and E99K actin.  
 
Figure 6.4 Western Blot of Actin Isolation Fractions 
 
 
 
 
(1) E99K whole homogenate, (2) E99K supernatant after 100K spin, (3) E99K KCl supernatant 
+ 150nM TRITC-phalloidin, (4) E99K F-actin pellet + TRITC-phalloidin, (5) NTg whole 
homogenate, (6) NTg supernatant after 100K spin, (7) NTg KCl supernatant + 150nM TRITC-
phalloidin, (8) NTg F-actin pellet + TRITC-phalloidin,  (9) 0.02µg actin marker, (10) 0.05µg 
marker. 
  
Western blotting analysis was used to determine the final concentration 
and overall yield of E99K F-actin, which was found to be the same as the non-
transgenic F-actin. The concentration of both E99K and non-transgenic actin 
was approximately 0.4 mg/ml and the yield of actin approximately 1mg per 1mg 
of tissue.  
10 1 2 3 4 5 6 7 8 9 
Non-transgenic E99K 
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2-D Electrophoresis was carried out on the whole muscle homogenate 
and f-actin from 2 separate actin preparations. Extracting actin from whole thin 
filaments preserved the expression at approximately 50% in the final f-actin 
(Figure 6.5).  
 
Figure 6.5 Preservation of E99K Expression 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
6.6 Measurement of Phosphorylation Levels 
Myofibrils from non-transgenic and E99K hearts were analysed to 
determine the phosphorylation level of all proteins. Myofibrils were separated by 
SDS-PAGE, and bands detected by the Pro-Q Diamond phosphoprotein gel 
stain were normalised to the total protein levels in each band (stained by 
SYPRO Ruby) (Figure 6.6). No difference was found between the 
phosphorylation of myosin binding protein C, troponin T, troponin I, and myosin 
light chain 2 in non-transgenic and E99K heart myofibrils.  
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Figure 6.6 SDS-PAGE of E361G and Non-Transgenic Myofibrils 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2 Pro-Q/SYPRO ratios from 5 Myofibril Experiments 
 
 
 
Expt. No. MyBP-C MLC-2 TnT TnI 
  E99K NTg E99K NTg E99K NTg E99K NTg 
1 0.334 0.361 0.321 0.342 0.175 0.192 0.284 0.275 
2 0.422 0.393 0.243 0.275 0.188 0.204 0.261 0.232 
3 0.278 0.263 0.290 0.298 0.181 0.169 0.185 0.207 
4 0.256 0.244 0.339 0.375 0.275 0.266 0.176 0.207 
5 0.376 0.350 0.393 0.372 0.164 0.170 0.210 0.220 
Mean ± 
SE 
0.333 
±0.031 
0.322 
±0.029 
0.317 
±0.025 
0.333 
±0.020 
0.197 
±0.020 
0.200 
±0.018 
0.223± 
0.021 
0.228 ± 
0.013 
T-test 
(paired/ 
unpaired) 
p = 0.327 / 
0.799, n=5 
p = 0.210 / 
0.648, n=5 
p = 0.611 / 0.901, 
n=5 
p = 0.693 / 0.854, 
n=5 
E99K NTg E99K NTg 
Pro-Q 
Diamond 
SYPRO  
Ruby 
MyBP-C 
TnT 
TnI 
MLC-2 
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6.7 Length Distribution of E99K and Non-Transgenic Actin 
Non-transgenic and E99K actin filaments were of similar appearance 
when labelled with TRITC-phalloidin (Figure 6.7). Filaments were short and 
bright and present in high yield relative to the concentration at a 1/1000 dilution. 
Measurements using the DIAS 3.2 programme showed non-transgenic and 
E99K actin had similar filament length distributions (Figure 6.8). The mean 
length of non-transgenic actin was 7.4µm ± 0.46 (n = 6) and E99K actin was 
7.8µm ± 0.4 (n = 6). 
 
Figure 6.7 Non-Transgenic and E99K Actin Filaments Labelled 
with TRITC-phalloidin 
 
 
 
 
 
 
 
 
 
Figure 6.8 Length Distribution of Non-Transgenic and E99K 
Actin 
 
 
 
 
 
 
 
 
 
Non-Transgenic E99K 
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6.8 In Vitro Motility Assay 
6.8.1 Non-Transgenic and E99K Actin Filament Motility 
14 separate measurements were taken using 6 pairs of hearts and the 
averages are shown in Table 6.3. The sliding speed of E99K actin was 
consistently lower than non-transgenic actin. This difference was 8%, which 
was significant in the paired t-test (p = 0.004). E99K actin also had a 4% lower 
percentage motile of filaments than non-transgenic actin, although this was not 
significant (paired t-test, p = 0.22). 
 
Table 6.3 Comparison of Non-Transgenic and E99K Actin 
 
The significantly slower sliding speed of E99K actin compared to non-
transgenic actin correlates with findings by Bookwalter et al. on E99K actin 
expressed and purified from the baculovirus/insect cell expression (Bookwalter 
and Trybus, 2006). They found E99K actin had a reduced velocity of between 
13-21% relative to wild type actin.  
 
 
Transgenic Line Actin Sliding Speed 
(mm/sec) 
Actin Percentage Motile 
 
NTg E99K NTg E99K NTg E99K 
N2.4 N11.17 3.3 ± 0.03 
2.7 ± 0.06 
3.0 ± 0.05 
3.1 ± 0.11 
2.9 ± 0.04 
2.7 ± 0.08 
2.5 ± 0.14 
3.0 ± 0.11 
89 ± 1.80 
75 ± 2.93 
80 ± 2.86 
85 ± 4.42 
58 ± 1.80 
82 ± 1.73 
74 ± 3.62 
88 ± 3.40 
N2.3 N11.17 3.4 ± 0.09 
3.3 ± 0.05 
3.0 ± 0.12 
3.0 ± 0.18 
3.3 ± 0.23 
3.3 ± 0.09 
2.2 ± 0.04 
2.6 ± 0.17 
97 ± 0.71 
92 ± 3.19 
80 ± 0.41 
71 ± 6.77 
90 ± 4.94 
96 ± 1.78 
71 ± 4.01 
74 ± 2.40 
N11.30.
9 
N11.16 2.6 ± 0.06 
3.0 ± 0.07 
2.4 ± 0.08 
2.5 ± 0.10 
66 ± 0.50 
76 ± 5.37 
73 ± 4.10 
71 ± 1.93 
N.16.30 N11.30.1
6 
2.3 ± 0.05 2.3 ± 0.12 72 ± 3.23 67 ± 1.78 
N5.3 N11.30.1
2 
2.1 ± 0.07 2.1 ± 0.07 57 ± 3.50 51 ± 2.33 
N5.9 N11.30.1
0 
2.3 ± 0.11 
2.7 ± 0.08 
2.3 ± 0.10 
2.4 ±0.03 
76 ± 4.15 
75 ± 4.27 
79 ± 4.57 
70 ± 5.02 
Mean ± SE 
n = 14  
2.84 ± 0.11 2.61 ± 0.10 78 ± 2.80 75 ± 3.22 
T Test 
P Value 
Paired     = 0.004 
Unpaired = 0.13 
Paired     = 0.22 
Unpaired = 0.44 
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6.8.2 Effects of Human Cardiac Tropomyosin on Actin Filament 
Motility 
20-60nM tropomyosin was titrated with 10nM non-transgenic and E99K 
actin. 10 measurements were taken from 6 paired non-transgenic and E99K 
hearts, and the averages are shown in Table 6.4 and Table 6.5. 
 
Figure 6.9 Effect of Tropomyosin on Sliding Speed (A) and 
Percentage Motility (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 An optimal increase in non-transgenic and E99K actin sliding speeds and 
percentage motility was seen upon titration with 40nM human cardiac 
tropomyosin (Table 6.4). The sliding speed of non-transgenic actin increased by 
6.5%, which was significant in the paired t-test (p = 0.007). E99K actin 
increased by 10% (p = 0.06). Overall, E99K actin.tropomyosin had a 4% slower 
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sliding speed compared to non-transgenic actin.tropomyosin, although the 
difference was not significant in the paired t-test (p = 0.30).  
  
Table 6.4 Effect of 40nM Human Cardiac Tropomyosin on Non-
Transgenic and E99K Actin Sliding Speeds  
Filament Sliding Speed(mm/sec) 
Transgenic Line Actin Actin.Tm 
NTg E99K NTg E99K NTg E99K 
N2.4 N11.17 3.3 ± 0.03 
2.7 ± 0.06 
2.9 ± 0.04 
2.7 ± 0.08 
3.2 ± 0.15 
2.9 ± 0.11 
2.6 ± 0.08 
2.8 ± 0.15 
N2.3 N11.17 3.4 ± 0.09 
3.3 ± 0.05 
3.0 ± 0.12 
3.3 ± 0.23 
3.3 ± 0.09 
2.2 ± 0.04 
3.5 ± 0.05 
3.7 ± 0.14 
3.3 ± 0.28 
3.6 ± 0.07 
3.8 ± 0.07 
3.0 ± 0.27 
N11.30.9 N11.16 2.6 ± 0.06 2.4 ± 0.08 2.8 ± 0.07 2.6 ± 0.11 
N.16.30 N11.30.1
6 
2.3 ± 0.05 2.3 ± 0.12 2.4 ± 0.02 2.4 ± 0.03 
N5.3 N11.30.1
2 
2.1 ± 0.07 2.1 ± 0.07 2.5 ± 0.07 2.0 ± 0.16 
N5.9 N11.30.1
0 
2.3 ± 0.11 
2.7 ± 0.08 
2.3 ± 0.10 
2.4 ± 0.03 
2.5 ± 0.11 
2.7 ± 0.03 
2.4 ± 0.12 
3.2 ± 0.10 
Mean ± SE 
n = 10 
2.77 ± 0.15 2.59 ± 0.14 2.95 ± 0.14 2.84 ± 0.18 
T Test 
P Value 
Paired = 0.06 
Unpaired = 0.39 
Paired     = 0.30 
Unpaired = 0.64 
T-test of Actin: Actin.Tm Paired = 
0.007 
Unpaired = 
0.39 
Paired = 0.06 
Unpaired = 0.28 
 
The percentage motility of non-transgenic actin actually decreased by 
3% upon titration with human cardiac tropomyosin (Table 6.5). E99K actin 
increased by 10%, which was significant in the paired t-test (p = 0.03). At 40nM 
tropomyosin, E99K actin had a 5.5% higher percentage motility, however this 
was not significantly different from the non-transgenic actin (p = 0.16). 
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Table 6.5 Effect of 40nM Human Cardiac Tropomyosin on Non-
Transgenic and E99K Actin Percentage Motility 
Filaments Percentage Motile 
Transgenic Line Actin Actin.Tm 
NTg E99K NTg E99K NTg E99K 
N2.4 N11.17 89 ± 1.80 
75 ± 2.93 
58 ± 1.80 
82 ± 1.73 
80 ± 5.75 
81 ± 1.11 
85 ± 4.04 
87 ± 1.41 
N2.3 N11.17 97 ± 0.71 
92 ± 3.19 
80 ± 0.41 
90 ± 4.94 
96 ± 1.78 
71 ± 4.01 
95 ± 1.70 
94 ± 2.69 
58 ± 8.00 
95 ± 3.44 
95 ± 2.40 
92 ± 1.00 
N11.30.9 N11.16 75 ± 4.27 70 ± 5.02 77 ± 2.40 78 ± 4.40 
N.16.30 N11.30.16 72 ± 3.23 67 ± 1.78 55 ± 1.20 65 ± 1.55 
N5.3 N11.30.12 57 ± 3.50 51 ± 2.33 73 ± 4.61 62 ± 8.37 
N5.9 N11.30.10 76 ± 4.15 
66 ± 0.50 
79 ± 4.57 
73 ± 4.10 
75 ± 6.70 
70 ± 0.63 
80 ± 3.50 
74 ± 3.17 
Mean ± SE 77.9 ± 3.84 73.7 ± 4.33 75.8 ± 4.13 81.3 ± 3.71 
T Test 
P Value 
Paired = 0.27 
Unpaired = 0.48 
Paired     = 0.16 
Unpaired = 0.34 
T-test of Actin: Actin.Tm Paired = 0.57 
Unpaired = 
0.71 
Paired = 0.03 
Unpaired = 
0.20 
 
6.8.3 Effects of Non-Failing Human Cardiac Troponin on Non-
Transgenic and E99K Actin at High and Low Ca2+ 
20-60nM human cardiac troponin was titrated with 10nM actin and 40nM 
human cardiac tropomyosin at 3.9µM and 1nM Ca2+. An optimal effect was 
usually seen upon titration with 40nM troponin. 7 measurements were taken 
from 6 separate paired non-transgenic and E99K mouse hearts.  
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Figure 6.10 Effects of Non-Failing Human Cardiac Troponin on 
Actin Motility at 3.9µM Ca2+ and 1nM Ca2+ 
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Under relaxing conditions of 1nM Ca2+, non-transgenic and E99K actin 
motility was indistinguishable. The percentage motility was switched off by 
40nM non-failing troponin, such that approximately 10% of both non-transgenic 
and E99K actin filaments were moving (p = 0.53) (Table 6.7). This was a 
reduction of approximately 67% from the actin.tropomyosin percentage motility. 
No significant differences were also found in the speed of non-transgenic and 
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E99K actin (p = 0.65) (Table 6.6). Sliding speeds were reduced from 
actin.tropomyosin speeds by 35% for non-transgenic actin and 34% for E99K 
actin, such that speeds at 1nM Ca2+ were similar. 
 At 3.9µM Ca2+, non-transgenic and E99K actin actually decreased in 
both their sliding speed and percentage motility. Reductions were of a similar 
magnitude for both actins (Table 6.8 and Table 6.9). Sliding speeds were 
reduced by 3% and the percentage motile of filaments reduced by 7%. This lack 
of a switch on in high Ca2+ conditions could be due to the quality of the human 
cardiac troponin or tropomyosin incorporated into the thin filaments, or was a 
characteristic of the mouse actin isolated via the whole thin filament method. 
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Table 6.6 Effect of 40nM Human Cardiac Troponin on Actin  
Sliding Speed at 1nM Ca2+ 
 
Table 6.7 Effect of Human Cardiac Troponin on Actin  
Percentage Motility at 1nM Ca2+ 
Transgenic 
Line 
Sliding Speed 
Actin.Tm 
Sliding Speed 
Actin.Tm.Tn (1 nM Ca2+) 
Relative Sliding 
Speed of 
Actin.Tm.Tn:Actin.
Tm 
NTg E99K NTg E99K NTg E99K NTg E99K 
N2.4 N11.17 2.9 ± 0.11 
3.2 ± 0.15 
2.8 ± 0.15 
2.6 ± 0.08 
2.3 ± 0.07 
2.1 ± 0.19 
2.1 ± 0.16 
2.0 ± 0.07 
0.79 
0.66 
0.75 
0.77 
N2.3 N11.17 3.5 ± 0.05 3.6 ± 0.07 1.8 ± 0.21 1.8 ± 0.14 0.51 0.50 
N11.3
0.9 
N11.16 2.8 ± 0.07 2.6 ± 0.11 1.6 ± 0.28 1.2 ± 0.05 0.57 0.46 
N.16.3
0 
N11.30.
16 
2.5 ± 0.07 2.0 ± 0.16 1.8 ± 0.07 1.7 ± 0.41 0.72 0.85 
N5.3 N11.30.
12 
2.5 ± 0.11 2.4 ± 0.12 1.6 ± 0.03 1.8 ± 0.21 0.64 0.75 
N5.9 N11.30.
10 
2.7 ± 0.03 3.2 ± 0.10 1.8 ± 0.08 2.1 ± 0.06 0.67 0.66 
Mean ± SE 
n = 7 
2.87 ± 0.14 2.74 ± 
0.20 
1.86 ± 0.10 1.81 ± 0.12 0.65 ± 
0.03 
0.68 ± 
0.06 
T Test 
P Value 
 
Paired = 0.39 
Unpaired = 0.61 
Paired = 0.65 
Unpaired = 0.78 
Paired = 0.50 
Unpaired = 0.71 
T-test of Actin.Tm: Actin.Tm.Tn Paired = 
0.0003 
Unpaired = 
<.0001 
Paired = 0.004 
Unpaired = 0.002 
 
Transgenic 
Line 
% Motile Actin.Tm % Motile at 1 nM Ca2+ Relative % Motility 
of 
Actin.Tm.Tn:Actin.
Tm 
NTg E99K NTg E99K NTg E99K NTg E99K 
N2.4 N11.17 80 ± 5.75 
81 ± 1.11 
85 ± 4.04 
87 ± 1.41 
30 ± 2.35 
2 ± 1.73 
26 ± 5.09 
11 ± 4.7 
0.37 
0.025 
0.31 
0.13 
N2.3 N11.17 73 ± 4.61  62 ± 8.37 8 ± 0.41 5 ± 1.71 0.11 0.081 
N11.3
0.9 
N11.16 70 ± 0.63 74 ± 3.17 1 ± 0.25 1 ± 0 0.014 0.014 
N.16.
30 
N11.30.
16 
95 ± 1.70 95 ± 3.44 13 ± 0.5 14 ± 2.72 0.14 0.15 
N5.3 N11.30.
12 
75 ± 6.70 80 ± 3.50 12 ± 0.67 10 ± 3.06 0.16 0.13 
N5.9 N11.30.
10 
77 ± 2.40 78 ± 4.40 25 ± 1.00 13 ± 4.95 0.32 0.17 
Mean ± SE 
n = 7 
78.7 ± 3.13 80.1 ± 
3.97 
13.0 ± 4.15 11.43 ± 3.04 0.16 0.14 
T Test 
P Value 
Paired = 0.55 
Unpaired = 0.78 
Paired = 0.53 
Unpaired = 0.76 
Paired = 0.42 
Unpaired = 0.69 
T-test of Actin.Tm: Actin.Tm.Tn Paired = <.0001 
Unpaired = <.0001 
Paired = <.0001 
Unpaired = 
<.0001 
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Table 6.8 Effect of 40nM Human Cardiac Troponin on Actin 
Sliding Speed at 3.9µM Ca2+ 
Transgenic 
Line 
Sliding Speed 
Actin.Tm 
Sliding Speed at 3.9 µM 
Ca2+ 
Relative Sliding Speed 
of Actin.Tm.Tn: 
Actin.Tm 
NTg E99
K 
NTg E99K NTg E99K NTg E99K 
N2.4 N11.1
7 
2.9 ± 0.11 
3.2 ± 0.15 
2.8 ± 0.15 
2.6 ± 0.08 
3.0 ± 0.07 
3.5 ± 0.14 
2.8 ± 0.09 
3.1 ± 0.18 
1 
1.1 
1 
1.2 
N2.3 N11.1
7 
3.5 ± 0.05 3.6 ± 0.07 3.2 ± 0.09 3.4 ± 0.09 0.91 0.94 
N11.3
0.9 
N11.1
6 
2.8 ± 0.07 2.6 ± 0.11 2.5 ± 0.07 2.4 ± 0.22 0.89 0.92 
N.16.
30 
N11.3
0.16 
2.5 ± 0.07 2.0 ± 0.16 2.2 ± 0.05 2.1 ± 0.04 0.88 1 
N5.3 N11.3
0.12 
2.5 ± 0.11 2.4 ± 0.12 2.4 ± 0.10 2.7 ± 0.08 0.96 1.1 
N5.9 N11.3
0.10 
2.7 ± 0.03 3.2 ± 0.10 2.2± 0.04 2.4 ± 0.04 0.81 0.75 
Mean ± SE 
n = 7 
2.87 ± 
0.14 
2.74 ± 
0.20 
2.71 ± 0.20 2.70 ± 0.17 0.94 ± 
0.04 
0.99 ± 
0.05 
T Test 
P Value 
Paired = 0.39 
Unpaired = 0.61 
Paired = 0.89 
Unpaired = 0.96 
Paired = 0.16 
Unpaired = 0.41 
T-test of Actin.Tm: Actin.Tm.Tn Paired = 0.18 
Unpaired = 
0.53 
Paired = 0.80 
Unpaired = 0.87 
 
 
Table 6.9 Effect of Human Cardiac Troponin on Actin 
Percentage Motility at 3.9µM Ca2+ 
 
Transgenic 
Line 
% Motile Actin.Tm % Motile at 3.9 µM Ca2+ Relative % Motility of 
Actin.Tm.Tn:Actin.Tm 
NTg E99
K 
NTg E99K NTg E99K NTg E99K 
N2.4 N11.1
7 
80 ± 5.75 
81 ± 1.11 
85 ± 4.04 
87 ± 1.41 
90 ± 0.87 
81 ± 3.84 
76 ± 4.02 
67 ± 4.73 
1.1 
1 
0.89 
0.77 
N2.3 N11.1
7 
73 ± 4.61  62 ± 8.37 66 ± 3.12 69 ± 3.40 0.9 1.1 
N11.3
0.9 
N11.1
6 
70 ± 0.63 74 ± 3.17 76 ± 1.73 75 ± 11.1 1.1 1 
N.16.
30 
N11.3
0.16 
95 ± 1.70 95 ± 3.44 76 ± 3.39 81 ± 4.10 0.8 0.85 
N5.3 N11.3
0.12 
75 ± 6.70 80 ± 3.50 61 ± 2.52 72 ± 3.47 0.81 0.9 
N5.9 N11.3
0.10 
77 ± 2.40 78 ± 4.40 60 ± 3.69 70 ± 0.91 0.78 0.9 
Mean ± SE 
n = 7 
78.7 ± 
3.13 
80.1 ± 
3.97 
72.9 ± 4.18 72.9 ± 1.82 0.93 0.92 
T Test 
P Value 
Paired = 0.55 
Unpaired = 0.78 
Paired = 1.0 
Unpaired = 1.0 
Paired =0.89 
Unpaired = 0.89 
T-test of Actin.Tm: Actin.Tm.Tn Paired = 0.23 
Unpaired = 0.28 
Paired = 0.07 
Unpaired = 0.12 
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6.8.4 Comparing Ca2+ Concentration Curves of Non-Failing and 
E99K Actin 
Initial Ca2+ sensitivity measurements were done with thin filaments that 
were reconstituted with 10nM E99K or non-transgenic actin, 40nM human 
cardiac tropomyosin, and 40nM cardiac troponin that was purified from non-
failing human heart muscle (troponin I phosphorylation 2.1 mols/mol). The Ca2+ 
sensitivity of sliding and the percentage motile of thin filament actin were 
measured with actin from 5 paired non-transgenic and E99K mouse hearts 
Figure 6.11 A-E). The individual mouse heart sample numbers for non-
transgenic and mutant actin are highlighted in blue and red respectively.  
Mouse actin produced a large variability in the sliding speed across all 
Ca2+ concentrations. No accurate fits have been possible and the points have 
simply been plotted. There is no significant difference in the sliding speeds of 
non-transgenic and E99K actin at 3.9µM Ca2+ (Table 6.10). For the percentage 
motility parameter, thin filaments reconstituted with mutant E99K actin had a 
higher Ca2+ sensitivity than thin filaments reconstituted with non-transgenic 
actin. The shift in Ca2+ sensitivity corresponds to a 2.5-fold decrease in EC50 of 
the percentage motility parameter (p = 0.07). Table 6.11 shows all the 
percentage motile EC50 values for 5 pairs of non-transgenic and E99K hearts.  
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Figure 6.11 Ca2+ Regulation of Thin Filaments Containing Non-
Transgenic and E99K Actin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following percentage motility curves have had parameters fixed to obtain an accurate 
sigmoidal curve:Graph B (Min value fixed at 1%), Graph C (Min and Max values fixed at 7% and 
60%). 
 
(A
) N
2.
3,
 N
11
.1
7 
(B
) N
11
.3
0.
9,
 N
11
.1
6 
(C
) N
2.
16
.3
0,
 N
11
.3
0.
16
 
CHAPTER 6 
 227
0
1
2
3
4
5
0.001 0.01 0.1 1 10
E99K
NTg
Sl
id
in
g 
Sp
ee
d 
µm
/s
ec
[Ca2+], µM
0
20
40
60
80
100
0.001 0.01 0.1 1 10
E99K
NTg
Pe
rc
en
ta
ge
 M
ot
ile
[Ca2+], µM
ErrorValue
0.375241.1298Hill Co-efficient
0.0691830.211700EC50
ErrorValue
0.199120.90901Hill Co-efficient
0.12740.5934EC50
0
1
2
3
4
5
0.001 0.01 0.1 1 10
E99K
NTg
Sl
id
in
g 
Sp
ee
d 
µm
/s
ec
[Ca2+], µM
0
20
40
60
80
100
0.001 0.01 0.1 1 10
E99K
NTg
Pe
rc
en
ta
ge
 M
ot
ile
[Ca2+], µM
ErrorValue
0.159080.99729Hill Co-efficient
0.0273540.17019EC50
ErrorValue
0.0981780.62076Hill Co-efficient
0.064460.33995EC50
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Graph D (Min and Max values fixed at 11% and 55%), Graph E (Min and Max values fixed at 
19% and 46%). 
 
 
(D) N5.3, N11.30.12 (E) N5.9, N11.30.10 
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Table 6.10 Non-Transgenic and E99K Actin Sliding Speeds at 
3.9µM Ca2+ 
 3.9µM Sliding Speeds µm/sec 
 
Mouse Line Non-Transgenic 
 
E99K 
N2.3 3.9 ± 0.13 4.1 ± 0.08 
N11.30.9 2.5 ± 0.07 2.4 ± 0.22 
N2.16.30 2.4 ± 0.02 2.1 ± 0.08 
N5.3 2.5 ± 0.43 2.7 ± 0.08 
N5.9 2.2 ± 0.04 2.4 ± 0.04 
Mean: ± SE 
(n = 5) 
2.70 ± 0.30 2.74 ± 0.35 
Student’s t-test (paired) p = 0.72 
(Unpaired) p = 0.93 
Table 6.10 shows the actual EC50 values and the difference in EC50 values expressed as a ratio 
of Non-Transgenic to E99K actin for the percentage motility parameter. 
 
Table 6.11 Ca2+-Sensitivity data for all Non-Transgenic and 
E99K Actin in a Non-Failing Thin Filament 
 
6.8.5 Effect of Troponin Dephosphorylation on the Ca2+ 
Dependence of Motility 
E99K and non-transgenic thin filaments were assembled from a 
combination of native (2.1 mol Pi/mol TnI) or dephosphorylated troponin and 
human cardiac tropomyosin. Troponin was dephosphorylated with 1.4 units/ml 
acid phosphatase (Figure 4.3). Using non-transgenic mouse actin, Figure 4.4 
illustrated the well-known impact of dephosphorylation on non-failing troponin. 
Mouse Line EC50 Percentage Motility, µM EC50 NTg 
EC50 E99K 
Non-
Transgenic 
E99K Non-Transgenic E99K  
N2.3 N11.17 0.047 ± 0.002 0.035 ± 0.010 1.34 
N11.30.9 N11.16 0.289 ± 0.114 0.059 ± 0.008 4.90 
N2.16.30 N11.30.16 0.492 ± 0.162 0.292 ± 0.084 1.68 
N5.3 N11.30.12 0.340 ± 0.064 0.170 ± 0.027 2.00 
N5.9 N11.30.10 0.593 ± 0.127 0.212 ± 0.069 2.80 
Mean: ± SE 
(n = 5) 
0.352 ± 0.09 0.154 ± 0.05 2.54 ± 0.64 
Student’s t-test (paired)  p = 0.03 single group,  
p = 0.07 
(compared with 1) 
(Unpaired) p = 0.10 
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Dephosphorylation of the troponin produced a leftward shift in the percentage 
motility-Ca2+ relationship and an increase in Ca2+ sensitivity, which 
corresponded to a 2.98 ± 0.31-fold decrease in the EC50 value.  
Figure 6.12 and Table 6.12 illustrate the Ca2+ response of E99K actin 
when incorporated into the thin filament with either native or dephosphorylated 
troponin. The higher Ca2+ sensitivity produced with non-transgenic actin 
incorporated with dephosphorylated troponin was not seen with the E99K actin 
and there was no difference in the Ca2+ sensitivity of the filaments (p = 0.16). 
The ratio of percentage motility EC50 values was not significantly different from 1 
(p = 0.12). E99K actin therefore shows insensitivity to troponin I phosphorylation 
levels.  
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Figure 6.12 Effect of Troponin Dephosphorylation on E99K 
Actin Motility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The percentage motility curves have had the f ollowing parameters fixed: Graph A (Min and Max 
values fixed at 6.6% and 76%), Graph B (Min and Max values fixed at 6% and 60%). 
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Graph C (Min and Max values fixed at 3% and 78%), Graph D (Min and Max values fixed at 9% 
and 68%). 
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Table 6.12 Ca2+ Sensitivity Data for E99K Actin Incorporated 
with Native or Dephosphorylated Troponin 
 
The final Ca2+ sensitivity measurements used E99K and non-transgenic 
actin incorporated with non-failing dephosphorylated troponin. A single 
experiment was performed. The percentage motility curve in Figure 6.13 had 
the minimum parameter fixed at 3% and the maximum at 83%. When the 
troponin was dephosphorylated, the E99K thin filaments had a 1.2-fold higher 
Ca2+ sensitivity of motility compared to non-transgenic thin filaments. However, 
this was not statistically significant. 
Mouse Line EC50 Percentage Motility, µM EC50 NF 
EC50 NF.dp 
 
 Non-Failing 
Troponin  
Non-Failing 
Troponin. dp 
 
N11.30.16 0.310 ± 0.068 0.269 ± 0.07 1.15 
N11.30.16 0.148 ± 0.050 0.154 ± 0.052 0.96 
N11.30.12 0.090 ± 0.028 0.076 ± 0.027 1.18 
N11.30.12 0.414 ± 0.126 0.332 ± 0.091 1.25 
Mean ± SE 
(n = 4) 
0.234 ± 0.072 0.187 ± 0.054 1.14 ± 0.06 
Student’s t-test (paired)  p = 0.16 Single group, p = 0.12 
(compared with 1) (Unpaired) p = 0.62 
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Figure 6.13 Effect of Troponin Dephosphorylation on Non-
Transgenic and E99K Actin Motility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.8.6 Competitive Binding Assay of Fluorescent and Non-
Fluorescent Actin to α-Actinin 
The α-actinin binding assay described in section 2.12 was used to 
establish that E99K actin has the same affinity for α-actinin as non-transgenic 
actin. This assay was repeated twice and the results are shown in Figure 6.14 A 
and B. Fitting the number of filaments to the α-actinin binding equation 
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produces the graph on the right. The average K value for E99K actin was 0.14 ± 
0.02 and for non-transgenic actin was 0.16 ± 0.01. Since the K values were less 
than 1, both E99K and non-transgenic mouse actins had an affinity for α-actinin 
that was less than rabbit actin.  
 
Figure 6.14 α-Actinin Competitive Binding Assay of E99K Actin 
and Non-Transgenic Actin Filaments 
 
 
 
 
 
 
 
 
 
 
E99K actin has a k value of 0.16 ± 0.04, and non-transgenic actin has a k value of 0.17 ± 0.02 
(k E99K/NTg = 0.94).  
 
 
 
 
 
 
 
 
 
 
 
E99K actin has a k value of 0.12 ± 0.02, and non-transgenic actin has a k value of 0.15 ± 0.03 
(k E99K/NTg = 0.8).  
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 These results were similar to those reported by Bookwalter et al. using 
E99K and wild type actin expressed and purified from the baculovirus/insect cell 
expression system (Bookwalter and Trybus, 2006). A control pelleting assay 
showed that E99K actin had the same affinity for α -actinin as wild type actin. 
However, using α-actinin as a load in the in vitro motility assay to measure 
relative isometric force, they showed that E99K actin supported a lower average 
force than wild type actin. Approximately 30% less α -actinin was needed to 
stop the movement of E99K actin compared to wild type.  
 
6.9 Discussion 
This study has focused on the apical HCM-causing actin mutation E99K, 
which is located in a surface loop in subdomain 1 of actin. Apical HCM is an 
uncommon hypertrophic morphology in which non-obstructive hypertrophy is 
localised to the cardiac apex. Individuals present with a later onset of the 
disease and display a variable degree of hypertrophy (Olson et al., 2000). 
Several clinical studies have reported the prevalence of the E99K mutation in 
patients with apical hypertrophy (Arad et al., 2005b, Olson et al., 2000, 
Monserrat et al., 2007). Arad et al. reported that the E99K mutation was unique 
in producing apical HCM in all clinically affected members from two distantly 
related families. This genotype has also been reported in another small family 
with apical HCM (Olson et al., 2000). Haplotype data has indicated that this 
family was genetically unrelated to the two families reported by Arad et al., 
which consolidates a primary relationship between this genotype and apical 
hypertrophy. A further study by Monserrat et al. screened specifically for the 
E99K mutation in 247 individuals with phenotypes of HCM, DCM, or left 
ventricular non-compaction (LVNC). It was reported that the E99K mutation was 
found in 42 individuals. In addition to being associated with apical HCM, it could 
also cause LVNC and produce a high incidence of septal defects. The mutation 
was found in one family with LVNC and four with HCM. The penetrance of the 
mutation was also high, as the mutant carriers all had pathological 
manifestations.  
To understand the functional effects produced by the E99K actin 
mutation in the development of these cardiac diseases, transgenic mice were 
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generated to express the E99K mutant actin in their hearts. Transgenic mice 
that carried the E99K transgene showed a high rate of sudden death. 
Approximately 70% of females and 34% of males died between 35-40 days, 
although no abnormal clinical features were present upon post-mortem. No 
inotropic stimulation was applied. Although several of the PCR pos itive lines did 
not contain the transgene, one line (N11) transmitted successfully at 55% in 
whole tissue and F-actin. In vitro motility studies were carried out on this line. 
 
6.9.1 Defects of Transgenic E99K Actin  
 F-actin was extracted from E99K mutant hearts via the thin filament 
method to produce the same yield as non-transgenic hearts. The in vitro motility 
results suggested that one of the primary defects the E99K actin produced was 
a slower motility over HMM (8% lower sliding speed, p = 0.004, 4% lower 
percentage motility, p = 0.22). In the presence of 40nM human cardiac 
tropomyosin, E99K actin exhibited a greater increase in sliding speed (10%, p = 
0.06) compared to non-transgenic actin (6.5%, p = 0.007), and reduced the 
difference in sliding speed to 4%. The average sliding speeds at optimum 
tropomyosin concentrations were not significantly different from each other (p = 
0.30), however E99K actin had a 7% higher percentage motility (p = 0.16) at 
optimum tropomyosin concentrations.  
Reconstitution with 40nM human cardiac tropomyosin and 40nM human 
cardiac troponin removed the slower sliding speed exhibited by E99K actin so 
that both were the same at 3.9µM Ca2+ (p = 0.89). Both E99K and non-
transgenic actin had a percentage motility that was reduced at 3.9µM Ca2+ by 3-
7%, which was possibly due to the other contractile proteins in the thin filament. 
At 1nM Ca2+, both were fully switched off. These results are summarised in 
Figure 6.15 and Figure 6.16. 
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Figure 6.15 In vitro Motility Assay Summary of Sliding Speed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16 In vitro Motility Assay Summary of Percentage 
Motile  
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Across a range of Ca2+ concentrations, the mutant thin filaments had a 
higher Ca2+ sensitivity of percentage motility (EC50 NTg/E99K = 2.54 ± 0.64, p = 
0.07) compared to non-transgenic actin. The sliding speeds could not be fitted 
to the Hill Equation as the net increase in actin filament sliding speed from 1nM 
Ca2+ to 3.9µM Ca2+ was small. E99K actin had a 1.5% faster sliding speed at 
3.9µM Ca2+ than non-transgenic actin, although this was not a significant 
difference (p = 0.72). When reconstituted with dephosphorylated non-failing 
human cardiac troponin, non-transgenic mouse actin exhibited a 2.98 ± 0.31-
fold increase in Ca2+-sensitivity (Figure 4.4). This characteristic response with 
non-transgenic actin can be compared with the much blunted Ca2+ sensitivity 
response produced when E99K actin was incorporated with dephosphorylated 
troponin (EC50 E99K/E99K+Tn.dp = 1.14 ± 0.06, p = 0.12). In a single 
experiment, E99K actin still exhibited a slightly higher Ca2+ sensitivity than non-
transgenic actin when both were incorporated with dephosphorylated troponin 
(EC50 NTg/E99K = 1.2), although this was not a statistically significant 
difference. The presence of the E99K mutation therefore appeared to blunt the 
Ca2+ sensitivity decrease caused by troponin I PKA phosphorylation (Figure 
6.17). 
 
Figure 6.17 Comparison of E99K and Non-Transgenic Actin 
Incorporated into Native or Dephosphorylated Thin Filaments 
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6.9.2 Comparison with Another E99K Mutation Study 
 Comparisons of our E99K actin in vitro motility results can be made with 
similar functional studies reported by Bookwalter and Trybus, who were 
successful in expressing high yields of E99K and wild type actin in the 
baculovirus/insect cell expression system (Bookwalter and Trybus, 2006). 
Consistent with the in vitro motility results reported in our study, Bookwalter and 
Trybus showed that E99K actin had a reduced velocity, although the effect was 
greater at between 13-21% relative to wild type actin over a range of KCl 
concentrations (p = <0.01). It is important to note though that they had 100% 
mutant expression compared to the 55% expression in our study which would 
account for the greater effect reported. Also consistent with our data was the 
similar affinity of E99K actin for α-actinin compared to the affinity showed by 
wild type actin. In addition though, they reported that E99K actin supported a 
30% lower force than wild type actin when the α-actinin was used as a load in 
the in vitro motility assay. The relative isometric force of E99K actin was not 
measured in our study.  
 Bookwalter and Trybus proposed that the slower motility, reduced 
average force, and a weakened interaction with myosin in the presence of ATP 
might be sufficient to trigger the HCM phenotype by the E99K mutation. 
However, this phenotype is opposite to most HCM molecular phenotypes, and 
in our study the effects of the mutation disappeared when tropomyosin and 
troponin were added. It is important to note that unlike our transgenic mouse 
study, the baculovirus/insect cell expression system that was used did not 
closely mimic the in vivo situation since no other thin filament proteins were 
reconstituted into the system with the mutant actin. It is also important to note 
that the expression of human cardiac wild type and E99K actin in the Sf9 cells 
was not entirely pure. Although western blotting with antibodies specific for 
cardiac muscle actins recognised the recombinant cardiac actin but not 
endogenous Sf9 cell actin, probing with a monoclonal antibody specific to b-
cytoplasmic actin showed a small carryover of endogenous Sf9 cell actin.  
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6.9.3 Comparisons with Other HCM-Associated Mutations 
Most HCM-associated mutations have been reported to produce a 
common hypercontractile response. One of the main goals of this study was to 
determine if the actin E99K mutant produces the same or different properties as 
other HCM mutations in the regulation of muscle contraction. The troponin T 
HCM mutation R92Q has previously been studied by in vitro motility assay and 
by ATPase measurements (Robinson et al., 2002). In contrast with our study, 
Robinson et al. used mutant and wild type recombinant troponin that was 
unphosphorylated at troponin I and troponin T. Our experimental system used 
the native phosphorylation state of the non-failing troponin. Therefore, 
comparisons can only be made with the system in our study that used 
dephosphorylated troponin. Similarly to E99K actin however, the R92Q troponin 
increased thin filament sliding speed with a higher Ca2+ sensitivity. R92Q also 
produced less inhibition of filament motility than wild type at 1nM Ca2+. These 
results were similar to the actomyosin ATPase assay, in which R92Q had a 1.7-
fold enhanced activation (EC50 WT = 0.33 ± 0.02, EC50 R92Q = 0.19 ± 0.03). In 
addition, at 1nM Ca2+ thin filaments containing R92Q troponin T gave less 
inhibition of ATPase (79% compared with 90% with wild type troponin).  
The results of Robinson et al. are in agreement with other R92Q studies 
in other systems. Morimoto et al. investigated the mechanical properties of 
R92Q expressed in Escherichia coli and exchanged into skinned rabbit 
trabeculae that had native phosphorylation levels (Morimoto et al., 1998). R92Q 
had a 1.5-fold higher Ca2+ sensitivity compared to wild type (EC50 WT = 1.78 ± 
0.03, EC50 R92Q = 1.20 ± 0.02). Similarly, using porcine fibres Szczesna et al. 
reported a 1.5-fold increased Ca2+ sensitivity of force production (EC50 WT = 
3.31 ± 0.01, EC50 R92Q = 2.19 ± 0.02) (Szczesna et al., 2000), and Yanaga et 
al. showed a 1.4-fold increase in Ca2+ sensitivity when measuring ATPase in 
reconstituted rabbit cardiac myofibrils (EC50 WT = 0.98 ± 0.04, EC50 R92Q = 
0.69 ± 0.08) (Yanaga et al., 1999). 
Previously in Prof. Marston’s laboratory, several other mutations that 
cause HCM have been investigated by the in vitro motility assay. Of these 
mutations, two were in α-tropomyosin (Asp175Asn and Glu180Gly) (Bing et al., 
2000), one was in troponin I (Arg145Gly) (Burton et al., 2002) and one was a 
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truncated mutation in troponin T (Redwood et al., 2000). Collectively, these 
previous functional studies of HCM mutants all show one or more of the 
following changes: (1) an increase in Ca2+ sensitivity, (2) a faster sliding 
speed/ATPase activity at 3.9µM Ca2+, and (3) failure of inhibition at 1nM Ca2+. 
When E99K actin was reconstituted with dephosphorylated non-failing troponin, 
there was a 1.2-fold increase in Ca2+ sensitivity, but no difference was seen in 
motility at 3.9µM Ca2+ or 1nM Ca2+ compared to non-transgenic actin. The 
change in Ca2+ sensitivity of E99K thin filament motility was of a similar direction 
to all previously studied HCM mutations. The magnitude of the change was 
however less than previous studies, including measurements from the R92Q 
troponin T mutation, which reported a 1.7-fold increase in Ca2+ sensitivity of 
R92Q troponin. These experiments were done with recombinant troponin that 
was not phosphorylated before reconstitution into the thin filament, so it may be 
possible that if these experiments were repeated using pseudophosphorylated 
R92Q and wild type troponin, the changes in Ca2+ sensitivity may be larger, like 
our E99K studies found with native non-failing troponin. This suggests that the 
effect of HCM mutations can be increased or decreased depending on the type 
of partner protein reconstituted into the thin filament (either native or 
recombinant). Our studies have shown that it is important to closely mimic the in 
vivo situation by using native human contractile proteins. 
Several transgenic animal studies have enabled the functional 
consequences of HCM mutations to be studied in real in vivo conditions 
(Knollmann et al., 2001, Miller et al., 2001). Miller et al. investigated skinned 
fibres dissected from transgenic mice with the HCM troponin T mutation 179N 
and found, similarly to E99K actin, an increased the Ca2+ sensitivity of 
myofilaments. Subsequent studies by Knollman et al. on the cardiac function of 
179N isolated hearts showed at baseline conditions the increased Ca2+ 
sensitivity is followed by an increase in contractility. The systolic function was 
higher than non-transgenic mice, with little effect on diastolic function. 
Echocardiography and Doppler measurements confirmed that baseline systolic 
function was higher in 179N mice. Interestingly, during inotropic stimulation with 
high extracellular Ca2+ or with isoproterenol, the diastolic function was impaired 
with increased end-diastolic pressure and time to 90% relaxation. Although 
chronic swimming exercise had no effect on mortality, the isoproterenol caused 
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significant mortality in the 179N mice. This may be due to the lower maximal 
force with high Ca2+ decreasing the contractile reserve available to increase 
cardiac output in response to isoproterenol. This HCM troponin T 179N study is 
therefore evidence that the effect of a mutation can be largely dependent upon 
the inotropic state of the heart, an effect that has also been reported by Deng et 
al. using ATPase and in vitro motility studies on the HCM cardiac troponin I 
mutation K206Q (Deng et al., 2003). Upon phosphorylation of the troponin I, 
this mutation had a 1.6-fold increase in the Ca2+ sensitivity of acto S1-ATPase 
activity (EC50 WT = 0.93 ± 0.02, EC50 K206Q = 0.59 ± 0.03) and also showed 
the same increase in maximum unloaded sliding speed in the in vitro motility 
assay compared to wild type cardiac troponin I (EC50 WT = 0.4 ± 0.02, EC50 
K206Q = 0.25 ± 0.04). However, the characteristic increase in Ca2+ sensitivity 
with unphosphorylated wild type cardiac troponin I (EC50 
WT.bisphosphorylated/WT = 1.6) was abolished by the K206Q mutation (EC50 
K206Q.bisphosphorylated/K206Q = 1). 
Similar to these previous HCM studies, a dependency on the inotropic 
state of the heart has been shown with the E99K mutation in the in vitro motility 
assay. The E99K HCM phenotype of an enhanced Ca2+ sensitivity therefore 
appears to correlate with all previous HCM phenotypes, but interestingly both 
the enhanced Ca2+ sensitivity and the blunted response to troponin I 
phosphorylation in the E99K native thin filament is similar to the G159D DCM 
phenotype.  
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7. GENERAL DISCUSSION 
 
7.1 Rationale for this Study 
The overall aim of this study was to investigate the role that contractile 
protein mutations have in determining the phenotype of HCM and DCM. It has 
been the first study that has used cardiac muscle with defined disease-causing 
mutations in actin and troponin C. Results with these samples can be compared 
with previous experiments that have used recombinant proteins in synthetic 
systems (Tobacman et al., 1999, Redwood et al., 2000, Knollmann and Potter, 
2001, Robinson et al., 2002, Mirza et al., 2005, Chang et al., 2005). 
I have chosen to study mutations in actin because it is the only contractile 
protein that is identical in man and mouse. Additionally, by expressing actin 
mutations in transgenic mice, the protein will have native post-translational 
modifications. It was therefore possible to accurately replicate and experiment 
upon a virtually perfect native human thin filament, when the mouse actin was 
reconstituted with human cardiac troponin (natively phosphorylated) and 
tropomyosin. This assay also made it possible to express actin without any 
adducts.  Since the ACTC mutations (E361G and E99K) induce a charge 
change, it was possible to determine by 2-D Electrophoresis that the tissue 
content of mutant actin was approximately 50% of the total actin. This is a level 
similar to that predicted for a DCM/HCM pat ient with a dominant mutation. In 
previous experiments, levels of mutant expression were 50% or less (Cuda et 
al., 1997, Bottinelli et al., 1998, Nier et al., 1999).  
I have also studied a unique human heart sample from a patient with DCM 
requiring heart transplantation. The G159D troponin C mutation was identified 
in this family member with familial DCM (Mogensen et al., 2003b) and the heart 
muscle sample was available for functional analysis. The troponin extracted 
from this sample therefore had the post-translational modifications and native 
molecular ratios of mutant: wild type characteristic of this DCM phenotype. 
Moreover, this ratio was measurable by mass spectroscopy at approximately 
50% of troponin C. This is the only study in which both the structural properties 
(expression level, phosphorylation levels) and functional properties of the 
G159D mutation has been investigated. This sample has yielded unexpected 
CHAPTER 7 
 244
results that emphasise the importance of being able to study native contractile 
proteins rather than synthetic systems.   
Both the transgenic mouse models and the human muscle sample have 
allowed the conditions in muscle of HCM and DCM patients to be closely 
replicated.  
 
7.2 Limitations of the Study 
There was a major difference between the way I prepared actin from mouse 
hearts compared to all previous experimentation. The inability of the mouse 
actin to polymerise lead to the mutant actin being lost when isolated via the 
usual acetone powder method (Straub, 1942). This presumably was because 
the mutation destabilised the G-actin. Actin polymerisation was stabilised upon 
incubation with TRITC-phalloidin but this lead to only 25-40% of the mutant 
actin being incorporated. Full mutant expression was retained in the F-actin 
upon extraction from native thin filaments, however this actin exhibited different 
behaviour in the in vitro motility assay compared with the actin extracted from 
an acetone powder. The lack of an increase in the thin filament sliding speed 
with mouse actin across the entire range of Ca2+ concentrations from 3.9µM to 
1nM limited the information that could be obtained from the in vitro motility 
assay. Thin filaments reconstituted with acetone powder actin show a 2-3 fold 
Ca2+ dependent increase (Bing et al., 1998, Purcell et al., 1999, Bing et al., 
2000). Results were therefore based entirely on the percentage motility 
parameter. However, it has been repeatedly shown that changes in the velocity 
and percentage motility parameters of Ca2+ sensitivity correlate with each other 
(Mirza et al., 2005, Messer et al., 2006). 
 
7.3 The in vitro Motility Assay 
As a functional technique, the in vitro motility assay was essential for 
investigating the effects of the mutations associated with HCM and DCM. 
Comparative experiments were run in split motility cells where the only variable 
was the mutated protein. The technique enabled small differences to be 
detected that were highly reproducible. It also allowed the proteins of the thin 
filaments to be manipulated, in particular the levels of phosphorylation. This has 
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been the first study to test the effect of cardiac muscle with defined disease-
causing mutations in combination with altered phosphorylation.  
This thesis has investigated transgenic mice at the molecular level primarily 
using the in vitro motility assay, but the mouse models will also be suitable for 
investigating the whole heart and whole animal physiological consequences of 
these mutations.  
 
7.4 Contractile Abnormalities caused by DCM Mutations  
Previous work in our laboratory has shown there are features common to 
all DCM mutations investigated by the in vitro motility assay. These features are 
independent of both the location of the mutation and the contractile protein 
bearing the mutation (Mirza et al., 2005). They include a decrease in the Ca2+ 
sensitivity of 50: 50 mixtures, a significant decrease in the maximum sliding 
speed at high Ca2+ (except E54K), and a decrease in the Hill coefficient 
reflecting a loss of cooperativity in several cases. The decrease in sliding speed 
and Ca2+ sensitivity correlates with ATPase measurements (Robinson et al., 
2002, Mirza et al., 2005). It is also in agreement with the reduction in the Ca2+ 
sensitivity caused by the troponin T mutations DLys210, Arg141Trp and 
Arg205Leu in partially substituted rabbit skeletal muscle fibres (Morimoto et al., 
2002, Mirza et al., 2005) and in fully substituted pig heart fibres using 
recombinant troponin subunits (Venkatraman et al., 2003). 
These in vitro studies suggest that DCM mutations will produce 
myofilaments that are less responsive to Ca2+ and will cause a decrease in 
force across a range of Ca2+ concentrations. This was considered sufficient to 
be a cause of DCM. My results with native-sequence thin filaments containing 
the E361G mutation were completely different from the previous results, since 
E361G transgenic and non-transgenic thin filaments were indistinguishable. 
However, dephosphorylation of both troponin I and troponin T (or substitution 
with skeletal muscle troponin) uncovered a difference between E361G 
transgenic and non-transgenic, where the E361G thin filaments reduced the 
Ca2+ sensitivity in common with previous experiments.  
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7.4.1 E361G: Blunted Response to Troponin I Phosphorylation  
When E361G actin was reconstituted into the thin filament in combination 
with natively phosphorylated human cardiac troponin, it had a low Ca2+ 
sensitivity and was indistinguishable from non-transgenic actin. But when 
E361G troponin was dephosphorylated the Ca2+ sensitivity remained low, 
whereas it increased 3-fold in the non-transgenic. Thus, the mutant thin 
filaments were not responsive to a change in the troponin phosphorylation. In 
our E361G DCM mouse, the level of phosphorylation of all contractile proteins, 
including troponin I and troponin T, were the same as non-transgenic. This was 
also the case for the TNNC1 G159D muscle sample. Therefore the abnormality 
is in the Ca2+ sensitivity of the dephosphorylated troponin. It is unlikely that the 
reduced Ca2+ sensitivity with unphosphorylated troponin is relevant for the 
development of DCM. It is more likely that the critical factor is the associated 
lack of response to changes in the level of phosphorylation. This provides a 
novel mechanism for DCM. 
It is well established that troponin I phosphorylation plays a major role in 
the normal response to adrenergic stimulation. For instance, transgenic mouse 
studies have shown that phosphorylation by PKA at troponin I Ser23/24, along 
with the phosphorylation of the membrane proteins involved in Ca2+ 
homeostasis, are essential to increase cardiac relaxation which is needed to 
maintain adequate diastolic ventricular filling with increased heart rate (Wolska 
et al., 2002). The E361G mutation may therefore impair myocardial relaxation 
and trigger maladaptive cardiac remodelling leading to the DCM phenotype. In 
the normal heart, phosphorylation by PKA at troponin I Ser23/24 causes a 
decreased Ca2+ sensitivity and an increase cross-bridge cycling rate (Kentish et 
al., 2001, Hunlich et al., 2005). Such modifications result in an increase in 
power output in both the myocyte and the whole heart. Our results indicate that 
the E361G mutation suppresses the b-adrenergic stimulation of systolic 
function. It could be predicted that this would lead to a reduced cardiac output 
and the development of heart failure under stress. This mechanism is quite 
compatible with all the previously published work on DCM mutations since the 
effect of changing the phosphorylation levels were not tested.  
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7.4.2 Reduced α-actinin Binding  
In addition to the reduced response to troponin I phosphorylation, the 
E361G mutation also significantly reduces the binding of actin affinity to α -
actinin. This could lead to impaired cardiac muscle function through the 
defective transmission of force and could be enough alone to cause the DCM 
phenotype. It is worth noting however that it is unlikely that this happens with 
DCM mutations in troponin subunits since they do not interact with α-actinin. 
Data from our laboratory (Mirza 2005, unpublished) found no differences in α -
actinin force measurements with skeletal troponin T and two tropomyosin 
mutants.  
 
7.4.3 The DCM Transgenic Mouse Phenotype 
The mice exhibited no overt phenotype at rest and have a normal lifespan. 
Single cell contractility measurements and MRI analysis detected no functional 
abnormalities. This does not necessarily indicate that the mutation has no effect 
in vivo, since transgenic models are often compensated. Indeed, the TNNT 
DLys210 DCM transgenic mouse showed a similar lack of phenotype at the 
whole cell level whilst the contractile apparatus was clearly abnormal (Morimoto 
et al., 2006). This suggests the systolic function was fully compensated. Du et 
al. showed a lower Ca2+ sensitivity of force generation but no difference in the 
maximum isometric force produced by intact DLys210 cardiac muscle fibres, 
indicating an increase in the intracellular Ca2+ transient. It seems likely that it is 
necessary to subject the mice to stress in order to reveal the phenotype 
(Geisterfer-Lowrance et al., 1996). These physiological experiments are 
planned.  
 
7.4.4 The G159D Phenotype 
The G159D mutation has been found in a single family with a history of 
heart failure and sudden death over 5 generations and with a 100% association 
of the mutation with heart disease (penetrance). The individual whose heart we 
studied was on life-support at the age of 3 years, indicating that this is a 
particularly severe mutation (Kaski et al., 2007). 
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Previous studies have investigated recombinant troponin with several 
troponin T and tropomyosin mutations, as well as the single TNNC1 mutation 
G159D (Mirza et al., 2005). Mirza et al. showed the G159D mutation produced 
a lower Ca2+ sensitivity and cross-bridge turnover rate in common with the other 
DCM mutations. Despite this, our investigation of the troponin extracted from 
the human muscle sample with this mutation produced a strikingly different 
result, with the mutation producing a higher Ca2+ sensitivity both with natural 
phosphorylation levels and with dephosphorylated troponin. A similar result was 
obtained in the experiments of Biesiadecki et al. (Biesiadecki et al., 2007). What 
the G159D troponin did share with the ACTC E361G DCM mutation was a lack 
of response to changes in troponin phosphorylation. Interestingly, the report 
from Preston et al. indicates that troponin T phosphorylation is critical for this 
effect to be observed (Preston et al., 2007b).  
An initial conclusion from our observations is that the common feature of 
all DCM mutations may be insensitivity to changes in troponin phosphorylation, 
with accompanying blunting of the response to adrenergic stimulation. The 
DCM phenotype does not seem to correlate with the altered Ca2+ sensitivity 
since both increased and decreased sensitivity has been observed in DCM 
phenotypes. Nor does the phenotype correlate with the reduced cross-bridge 
turnover rate, since this was not observed with the G159D mutation. The 
increased Ca2+ sensitivity in G159D is characteristic of HCM, but in this case it 
would seem not to result in any HCM-like phenotype. It may however contribute 
to the unusually high penetrance and severity of this mutation (Mogensen et al., 
2004b, Kaski et al., 2007), perhaps by a mechanism similar to restrictive 
cardiomyopathy. Restrictive cardiomyopathy has been shown to have a 
molecular phenotype similar to, but more extreme than HCM (Mogensen et al., 
2003a).  
 This is the first study of a DCM mutation using the troponin extracted 
from the muscle of a patient. It illustrates in an extreme way the principle that 
we were already aware of, namely that the behaviour of any mutation is 
dependent upon the nature of the partner proteins. This has been shown 
previously for the truncated troponin T HCM mutation (Redwood et al., 2000), 
and the D175N and E180G TPM1 HCM mutations (Bing et al., 2000). Here, we 
find that G159D reverts to the ‘classical’ in vitro phenotype when either the 
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troponin T and troponin I are not native (Mirza et al., 2005), or the α-
tropomyosin is not native (reported in this thesis). The tropomyosin result is 
remarkable, since the only known difference is the substitution of the N terminal 
acetyl group for Ala-Ser, which does not alter any function except cooperativity 
(Monteiro et al., 1994, Bing et al., 2000, Mirza et al., 2007). The implication is 
that there may be additional post-translational modifications in native 
tropomyosin that we are not aware of. 
 
7.5 Contractile Abnormalities caused by HCM Mutations  
The E99K HCM mice produce a strikingly different pattern of results to 
DCM mutations of an increase in the Ca2+ sensitivity, irrespective of the level of 
troponin phosphorylation. This HCM phenotype correlates well with the 
common mechanism when a dephosphorylated system is used. Previous in 
vitro motility studies and ATPase assays of the HCM mutation R92Q showed an 
increase in maximum filament sliding speed and an increase in the Ca2+ 
sensitivity (Mirza et al., 2005). This also correlates with in vitro motility data of 
the tropomyosin mutations (Asp175Asn, Glu180Gly), and a truncated troponin T 
mutation (Bing et al., 2000, Redwood et al., 2000). In addition, a transgenic 
mouse model of the troponin I mutation R145E showed an increase in the Ca2+ 
sensitivity of skinned muscle fibres and at the whole organ level there was 
hypercontractility with diastolic dysfunction (James et al., 2000). 
The hypothesis has previously been put forward of HCM mutations 
causing a hypercontractile response, and they do so by affecting the Ca2+ 
sensitivity and cross-bridge cycling rate. However, this has been the first study 
to test the effect of a HCM mutation in combination with altering the 
phosphorylation of the troponin in the thin filament, and the E99K mutation also 
seems to produce a reduced but not completely suppressed response to 
troponin I phosphorylation. This seems to be at odds with the conclusion that 
the lack of response to troponin phosphorylation is a key feature of the DCM 
phenotype. In reality it may be a matter of degree, such that the same response 
is enough to avoid the DCM phenotype. 
A feature of these transgenic mice is the substantial HCM-like sudden 
death (30% in males, 75% in females), which occurs between 30-45 days of 
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age. At the protein level, E99K transgenic mouse muscle had high levels of 
phosphorylation similar to non-transgenic muscle. This can be compared with 
the low level of phosphorylation seen in hypertrophic obstructive 
cardiomyopathy (HOCM) muscle obtained from septal myectomy operations. 
Myectomy muscle shows substantial reductions in the phosphorylation of 
myosin binding protein C (45%), troponin T (12%), troponin I (90%), and myosin 
light chain-2 (45%) (Gallon et al., 2007). However, the phosphorylation changes 
in myectomy muscle seem to be secondary to the hypercontractile response 
caused by HCM mutations and the hypertrophy that is caused. In the mouse 
muscle, no secondary changes of post translational modifications were 
reported. This may have been due to the size of the mouse heart, the higher 
heart rates of the mice, or the short lifespan. Whatever the reason, it appears 
that the mouse model may reproduce the initial stages of HCM but  not the later 
stages observed in patients undergoing myectomy.  
The HCM phenotype caused by the E99K mutation is in great contrast to 
those caused by the DCM mutations that have been studied in this thesis. DCM 
is a chronic progressive disorder of the heart muscle characterised by a poor 
functioning and dilated ventricle. In the patient genotyped with the G159D 
mutation the clinical diagnosis of DCM was made, but at the molecular level 
G159D shows characteristics of being both HCM and DCM-like. The paradox of 
the HCM-like higher Ca2+ sensitivity of G159D may just reflect the fact that there 
are multiple pathways for a mutation to cause DCM. In contrast to DCM, HCM is  
characterised by the thickening of the ventricles which causes obstruction of the 
outflow tract and heart failure in some cases. A hypercontractile response has 
been commonly reported for HCM mutations and was indeed shown for the 
E99K mutation. This study of defined disease-causing mutations using the in 
vitro motility assay has revealed the importance of the nature of the 
experimental system in establishing the real in vivo effect of HCM and DCM and 
has opened up many questions.  
 
7.6 Future Work 
The altered response of myofilaments to changes in troponin I 
phosphorylation provides a novel mechanism for DCM, and there is indirect 
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evidence that this mechanism may also occur with several other DCM 
mutations studied in the past but in synthetic thin filament systems. All known 
DCM mutations should therefore be re-investigated in experimental systems 
that are close as possible to native human cardiac thin filaments. These should 
contain native post-translational modifications and human cardiac sequences. 
In the case of troponin I and troponin T, this can be done by exchange. It will be 
interesting to determine whether the blocking of the Ca2+-desensitisation effect 
of troponin I phosphorylation is common to all DCM mutations, or whether there 
are multiple pathways for mutations to cause the disease.  
The phenotype caused by the ACTC E361G mutation was exposed by 
altering the phosphorylation and by changing the partner proteins within the thin 
filament, and the G159D phenotype was completely different in native and 
synthetic systems. To determine whether the tropomyosin or troponin T is 
responsible for the two different phenotypes reported for this one mutation, it 
will be necessary to exchange the mutant troponin C or troponin T into human 
cardiac troponin with native phosphorylation levels.  
HCM investigated in human heart muscle appears to be caused by a 
different and more complex mechanism than DCM. It is evident that the E99K 
mutation induces a clear phenotype in vitro under basal conditions but further 
functional studies are required. Mouse cardiac myofibrillar force measurements 
could be investigated, allowing the kinetics of Ca2+ activation and relaxation to 
be studied. These measurements should involve manipulation of protein 
phosphorylation levels within the myofibril.  
This study has successfully combined human and mouse studies to 
investigate the molecular phenotype of genetic HCM and DCM. To further our 
understanding it will be necessary to study the disease mechanisms at the level 
of the intact heart and whole animal through physiological measurements (PV 
loop, MRI, 3D echo), allowing the development of HCM and DCM to be tracked. 
It will also be necessary to induce stress upon the E361G mice to perhaps 
uncover a phenotype. This could be done using drugs (dobutamine), exercise, 
or through surgery (aortic constriction).  
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